https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bct197-interaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bct197-part-a-acute-kidney-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bct197-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bgs649-hypogonadotropic-hypogonadism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bgs649-pelvic-pain-associated-with-refractory-endometri 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bps804-20mg-kg-osteopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bps804-chronic-kidney-disease-stage-5d-on-stable-hemodi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bps804-hypophosphatasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/bps804-osteogenesis-imperfecta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/brontictuzumab-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/demcizumab-locally-advanced-or-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/demcizumab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/demcizumab-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/demcizumab-primary-peritoneal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/docetaxel-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/etigilimab-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/investigational-new-drug-company-code-bgs649-obese-hypogonadotropic-hypogonadism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/mph966-hematologic-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/nivolumab-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-131r10-advanced-relapsed-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-21m18-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-305b83-advanced-solid-tumor-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-305b83-cancer-ovaries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-305b83-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-313m32-locally-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-336b11-locally-advanced-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-52m51-relapsed-or-refractory-lymphoid-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-52m51-relapsed-or-refractory-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-54f28-nab-paclitaxel-and-gemcitabine-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-54f28-paclitaxel-and-carboplatin-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-54f28-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-54f28-with-sorafenib-hepatocellular-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-59r5-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-59r5-stage-iv-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-59r5-stage-iv-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/pemetrexed-nonsquamous-nonsmall-cell-neoplasm-of-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/placebo-oral-tablet-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/setrusumab-osteogenesis-imperfecta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/setrusumab-osteogenesis-imperfecta-type-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/vantictumab-combined-with-paclitaxel-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/vantictumab-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/ascape-based-follow-up-strategy-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/forecyte-breast-aspirator-breast-cancer-preneoplastic-conditions-brca 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/fulvestrant-female-breast-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/provox-vega-voice-prosthesis-22-5-fr-total-laryngectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/provox-voice-prosthesis-total-laryngectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/provox-xtra-hme-total-laryngectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/topical-endoxifen-mammographic-breast-density 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/z-endoxifen-breast-density 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/atossa-therapeutics-inc/projects/z-endoxifen-breast-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mira-pharmaceuticals-inc/projects/toujeo-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/131i-apamistamab-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/vtp-1000-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/131i-apamistmab-sickling-disorder-due-to-hemoglobin-s 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/actinium-225-labeled-humanized-anti-cd33-monoclo-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/cytarabine-phase-1-only-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/iomab-b-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/iomab-b-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/lintuzumab-ac-225-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actinium-pharmaceuticals/projects/lintuzumab-ac225-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tvardi-therapeutics/projects/control-group-squamous-cell-carcinoma-of-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tvardi-therapeutics/projects/tti-101-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tvardi-therapeutics/projects/tti-101-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tvardi-therapeutics/projects/tti-101-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tvardi-therapeutics/projects/tti-101-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tvardi-therapeutics/projects/tti-101-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-000184-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-000184-chronic-hepatitis-b-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-010133-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/briacell-therapeutics/projects/bc1-cell-line-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-020572-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-055009-healthy-volunteer-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-055009-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-055009-nash-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-097558-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/alg-125755-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iae0972-methotrexate-npc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/atorvastatin-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/carbamazepine-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/pevifoscorvir-sodium-alg-000184-chronic-hepaititis-b-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aligos-therapeutics/projects/pevifoscorvir-sodium-alg-000184-chronic-hepatitis-b-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/apolipoprotein-apoe-detection-senile-plaques 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/benralizumab-asthma-eosinophilic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/bupivacaine-fentanyl-depression-postpartum 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/capre-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/capre-tm-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/clearsight-hpi-monitoring-system-anesthesia-epidural 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/clonidine-pregnancy-related 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/control-standard-treatment-moisture-associated-skin-damage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/desvenlafaxine-succinate-vascular-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/eat-well-live-well-nutrition-program-diabetes-or-diabetes-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/ff-umec-vi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/fospropofol-lusedra-6-5-interstitial-cystitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/gs-100-ngly1-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/gtx-101-postherpetic-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/gtx-102-medium-dose-fast-period-1-and-period-2-ataxia-telangiectasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/gtx-104-aneurysmal-subarachnoid-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/gtx-104-aneurysmal-subarachnoid-hemorrhage-asah 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/hydromorphone-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/ketamine-ketalar-dose-level-1-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/ketamine-ketalar-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/ketamine-obstetric-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/lipid-lowering-medication-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/lung-ultrasound-lus-community-acquired-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/progastrin-colon-cancer-screening 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/qvm149-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/rapid-test-for-diagnosis-orientation-flu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/tirzepatide-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/grace-therapeutics/projects/zinc-gluconate-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/outlook-therapeutics/projects/bevacizumab-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/outlook-therapeutics/projects/bevacizumab-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/senti-biosciences-holdings/projects/senti-202-aml-mds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/senti-biosciences-holdings/projects/sn301a-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/bxcl501-80-micrograms-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/bxcl501-agitation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/bxcl501-agitation-psychomotor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/bxcl501-sublingual-film-bipolar-i-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/bxcl701-metastatic-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/bxcl701-plus-pembrolizumab-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/dexmedetomidine-dex-for-sublingual-sl-administra-alcohol-use-disorder-aud 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/dexmedetomidine-opioid-withdrawal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/dexmedetomidine-schizophrenia-agitation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/dexmedetomidine-sublingual-film-delirium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/placebo-alcohol-use-disorder-aud 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/sublingual-film-containing-bxcl501-dexmedetomidi-agitation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/sublingual-film-containing-dexmedetomidine-agitation-psychomotor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/sublingual-film-containing-dexmedetomidine-bxcl5-agitation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/sublingual-film-containing-dexmedetomidine-bxcl5-agitation-associated-with-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/sublingual-film-containing-igalmi-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bioxcel-therapeutics/projects/talabostat-mesylate-cancer-of-pancreas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurosense-therapeutics/projects/fixed-dose-combination-ciprofloxacin-celecoxib-als-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurosense-therapeutics/projects/fixed-dose-combination-ciprofloxacin-celecoxib-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurosense-therapeutics/projects/primec-748-mg-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurosense-therapeutics/projects/primec-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurosense-therapeutics/projects/primec-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurosense-therapeutics/projects/primec-er-748-mg-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/auto-cd34-cells-chronic-myocardial-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/autologous-dendritic-cell-tumor-cell-immunothera-stage-iv-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/biological-vaccine-therapeutic-autologous-dendri-kidney-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/cend-1-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/certepetide-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/certepetide-pancreas-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mscs-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/clbs03-low-dose-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/clbs12-critical-limb-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/clbs14-low-dose-myocardial-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/clbs16-coronary-microvascular-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/clbs201-chronic-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/lymphokine-activated-killer-cells-brain-and-central-nervous-system-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/nbs10-st-segment-elevation-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/therapeutic-autologous-dendritic-cells-melanoma-skin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/ph-10-0-001-rose-bengal-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/ph-10-0-002-rose-bengal-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/ph-10-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/ph-10-rose-bengal-disodium-0-001-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/pv-10-10-rose-bengal-disodium-cancer-metastatic-to-the-liver 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/pv-10-10-rose-bengal-disodium-cutaneous-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/pv-10-10-rose-bengal-disodium-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/pv-10-rose-bengal-disodium-10-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/pv-10-rose-bengal-disodium-10-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/rose-bengal-disodium-neuroendocrine-tumors-metastatic-to-the-liver 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/provectus-biopharmaceuticals-inc/projects/topical-rose-bengal-0-005-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/chadox1-hbv-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/chadox1-hbv-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/chadox1-hpv-hpv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/chadox1-mva-5t4-vaccine-intermediate-risk-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/chadox1-pcaq-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/mva-np-m1-human-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/mva-np-m1-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/barinthus-biotherapeutics-plc/projects/seasonal-influenza-vaccine-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/briacell-therapeutics/projects/sv-br-1-gm-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/briacell-therapeutics/projects/sv-br-1-gm-breastcancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tempest-therapeutics/projects/part-1-tpst-1120-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tempest-therapeutics/projects/tpst-1120-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tempest-therapeutics/projects/tpst-1495-twice-daily-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/serina-therapeutics/projects/ser-214-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/serina-therapeutics/projects/ser-252-peoz-apomorphine-parkinson-disease-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/clr-131-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/clr-131-high-grade-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/clr-131-pediatric-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/i-124-clr1404-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/i-131-clr1404-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/i-131-clr1404-injection-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/i-131-clr1404-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/i-131-clr1404-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/i124-nm404-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/iopofosine-i-131-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/iopofosine-i-131-single-dose-waldenstrom-macroglobulinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/nov-002-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/nov-205-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/paclitaxel-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/av-101-drug-drug-interaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/av-101-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/av-101-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/fasedienol-nasal-spray-placebo-nasal-spray-social-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/fasedienol-nasal-spray-social-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/salvianolic-acid-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/fasedienol-nasal-spray-social-anxiety-disorder-sad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/ph94b-adjustment-disorder-with-anxious-mood 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/ph94b-nasal-spray-social-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/ph94b-social-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vistagen-therapeutics/projects/placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oncotelic-therapeutics/projects/atezolizumab-metastatic-lung-non-small-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oncotelic-therapeutics/projects/ot-101-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oncotelic-therapeutics/projects/ot-101-malignant-pleural-mesothelioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oncotelic-therapeutics/projects/ot-101-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/briquilimab-allergic-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/briquilimab-chronic-inducible-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/briquilimab-chronic-spontaneous-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/briquilimab-urticaria-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/humanized-anti-cd117-monoclonal-antibody-jsp191-myelodysplastic-syndrome-mds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/humanized-anti-cd117-monoclonal-antibody-jsp191-scid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/jsp191-lower-risk-myelodysplastic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/nelfinavir-and-omeprazole-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jasper-therapeutics/projects/nicotine-patch-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/therapeuticsmd/projects/estradiol-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/therapeuticsmd/projects/estradiol-vulvovaginal-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/therapeuticsmd/projects/oral-estradiol-1-0-mg-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/therapeuticsmd/projects/progesterone-secondary-amenorrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/therapeuticsmd/projects/segesterone-acetate-and-ethinyl-estradiol-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/therapeuticsmd/projects/segesterone-acetate-and-ethinyl-estradiol-women 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sensei-biotherapeutics/projects/sns-301-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sensei-biotherapeutics/projects/sns-301-squamous-cell-carcinoma-of-the-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/blood-sampling-colorectal-cancer-screening 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/blood-sampling-screening-for-colon-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/fr-peptide-plus-adjuvant-gm-csf-platinum-sensitive-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/her-2-neu-peptide-vaccine-her2-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/low-dose-fr-vaccine-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/mail-in-urine-test-for-edcs-endocrine-disrupting-chemicals 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/mt-401-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/mt-401-ots-acute-myeloid-leukemia-in-relapse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/mt-601-dose-200-million-cells-pancreas-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/mt-601-non-hodgkin-lymphoma-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/tpiv200-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/urinary-edc-metabolite-testing-environmental-exposure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/marker-therapeutics/projects/urinary-edc-metabolite-testing-obesity-amp-amp-amp-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aytu-biopharma-inc/projects/adzenys-xr-odt-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aytu-biopharma-inc/projects/antioxidant-compare-the-sorp-rate-in-sperm-samples-obtained 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aytu-biopharma-inc/projects/enzastaurin-vascular-ehlers-danlos-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allarity-therapeutics/projects/2x-121-advanced-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allarity-therapeutics/projects/2x-121-and-dovitinib-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allarity-therapeutics/projects/apo010-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allarity-therapeutics/projects/irofulven-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allarity-therapeutics/projects/ixabepilone-injection-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allarity-therapeutics/projects/liplacis-phase-1-advanced-or-refractory-solid-tumours 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allarity-therapeutics/projects/parp-inhibitor-2x-121-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/5-mg-serlopitant-tablets-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/5-mg-serlopitant-tablets-refractory-chronic-cough 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/5mg-serlopitant-tablets-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/ark-e021-5-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/comparator-mk0594-5-mg-day-alcohol-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fcd105-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fdx104-4-doxycycline-rash-due-to-epidermal-growth-factor-receptor-inh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx-101-4-minocycline-foam-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx-101-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx101-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx101-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx101-minocycline-4-foam-acne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx101-vehicle-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx103-1-5-papulopustular-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx103-minocycline-foam-1-5-facial-papulopustular-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/fmx114-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/isotretinoin-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/mk0594-urinary-incontinence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/permethrin-foam-4-scabies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/serlopitant-high-dose-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/serlopitant-prurigo-nodularis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/serlopitant-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/serlopitant-tablet-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/topical-minocycline-foam-fxfm244-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/topical-minocycline-foam-fxfm244-impetigo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/topical-minocycline-foam-fxfm244-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/vpd-737-chronic-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/vpd-737-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vyne-therapeutics/projects/vyn201-gel-non-segmental-vitiligo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/abp-450-cervical-dystonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/abp-450-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/autologous-et1402l1-cart-cells-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/et1402l1-artemis-t-cells-iv-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/mitomycin-c-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/ologen-collagen-matrix-congenital-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tpo-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/provisc-steroid-induced-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/use-of-mitomycin-c-in-trabeculectomy-open-angle-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/werewolf-therapeutics/projects/wtx-124-metastatic-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/werewolf-therapeutics/projects/wtx-330-advanced-or-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/dex-21-p-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/dexamethasone-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/inxn-1001-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/dexamethasone-nervous-system-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/dexamethasone-sodium-phosphate-ataxia-telangiectasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/dsp-loaded-rbc-using-erydex-system-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/erydex-dexamethasone-sodium-phosphate-encapsulat-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/erydex-low-dose-dsp-nervous-system-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quince-therapeutics/projects/erydex-system-ataxia-telangiectasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pasithea-therapeutics/projects/pas-004-capsules-ras-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pasithea-therapeutics/projects/pas-004-tablets-nf1-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apimeds-pharmaceuticals-us/projects/apitox-pure-honeybee-toxin-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apimeds-pharmaceuticals-us/projects/apitox-purified-honeybee-toxin-lyophilized-in-sa-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apimeds-pharmaceuticals-us/projects/honeybee-venom-apitoxin-korea-apitox-usa-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/dextromethorphan-hbr-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/drug-gc4419-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/drug-gc4711-sbrt 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4419-90mg-oral-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4419-avasopasem-manganese-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4419-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4419-iv-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4419-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4419-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4419-squamous-cell-carcinoma-of-the-oral-cavity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4702-dry-powder-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4711-30-mg-iv-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4711-30mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/gc4711-oral-capsule-g-101-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galera-therapeutics/projects/low-dose-gc4419-30mg-day-radiation-induced-oral-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomed-therapeutics-ltd/projects/adoptive-cell-transfer-of-nkg2dl-targetting-chim-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomed-therapeutics-ltd/projects/allogeneic-nkg2dl-targeting-chimeric-antigen-rec-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomed-therapeutics-ltd/projects/human-mesenchymal-stem-cell-msc-infusion-therapy-aging-well 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomed-therapeutics-ltd/projects/human-umbilical-cord-derived-mscs-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/cesium-131-brachytherapy-recurrent-brain-metastases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/gtb-3550-trike-phase-i-high-risk-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/gtb-5550-tri-specific-killer-engager 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/semaglutide-obesity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/stereotactic-radiation-therapy-brain-metastases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/stereotactic-radiation-therapy-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/surgical-tumor-resection-gammatile-radiation-the-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/gt-biopharma/projects/temozolomide-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibitor-therapeutics/projects/small-rna-sequencing-fertility 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibitor-therapeutics/projects/window-of-implantation-ivf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/14c-olinciguat-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/14c-praliciguat-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/iw-1701-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/iw-1701-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/iw-1973-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/iw-1973-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/matching-placebo-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/olinciguat-achalasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cyclerion-therapeutics/projects/olinciguat-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phio-pharmaceuticals/projects/dp-cd8-til-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phio-pharmaceuticals/projects/ph-762-squamous-cell-carcinoma-of-the-skin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/intensity-therapeutics-inc/projects/int230-6-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/intensity-therapeutics-inc/projects/int230-6-sarcoma-soft-tissue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/intensity-therapeutics-inc/projects/jin-a02-egfr-mutant-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/intensity-therapeutics-inc/projects/mpt0b640-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/intensity-therapeutics-inc/projects/mpt0b640-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moleculin-biotech/projects/liposomal-annamycin-l-annamycin-sarcoma-soft-tissue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moleculin-biotech/projects/liposomal-annamycin-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moleculin-biotech/projects/mol4239-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/inxn-2001-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moleculin-biotech/projects/placebo-in-combination-with-cytarabine-injection-acute-myeloid-leukaemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moleculin-biotech/projects/stat3-inhibitor-wp1066-glioblastoma-idh-wildtype 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moleculin-biotech/projects/wp1122-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moleculin-biotech/projects/wp1220-cutaneous-t-cell-lymphoma-mycosis-fungoides 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/chemomab-therapeutics/projects/10-mg-kg-cm-101-systemic-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/chemomab-therapeutics/projects/5-mg-kg-cm-101-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/chemomab-therapeutics/projects/anti-human-ccl24-monoclonal-antibody-cm-101-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/chemomab-therapeutics/projects/anti-human-ccl24-monoclonal-antibody-cm-101-part-nonalcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/chemomab-therapeutics/projects/anti-human-ccl24-monoclonal-antibody-cm-101-primary-sclerosing-cholangitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/chemomab-therapeutics/projects/cm-101-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiora-pharmaceuticals-inc/projects/100-g-kio-301-retinitis-pigmentosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiora-pharmaceuticals-inc/projects/kio-104-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiora-pharmaceuticals-inc/projects/kio-201-a-crosslinked-thiolated-carboxymethyl-hy-persistent-corneal-epithelial-defect 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiora-pharmaceuticals-inc/projects/kio-301-retinitis-pigmentosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hoth-therapeutics/projects/biolexa-cohort-1-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hoth-therapeutics/projects/ht-001-2-topical-gel-acneiform-eruption-due-to-chemical 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakewood-amedex-biotherapeutics/projects/5-bisphosphocin-topical-gel-chronic-diabetic-foot-ulcers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakewood-amedex-biotherapeutics/projects/5-nu-3-gel-diabetic-foot-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakewood-amedex-biotherapeutics/projects/antimicrobial-agent-diabetic-foot-ulcers-dfus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakewood-amedex-biotherapeutics/projects/bisphosphocin-nu-3-diabetic-foot-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-1051-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-acute-myeloid-leukemia-or-myelodysplastic-syndro 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-azacitidine-mds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-eprenetapopt-acalabrutinib-in-cll-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-eprenetapopt-pembrolizumab-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-hematologic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-high-grade-serous-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-myelodysplastic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-myelodysplastic-syndrome-with-gene-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-myeloid-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-246-platinum-sensitive-recurrent-high-grade-serous-o 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/apr-548-azacitidine-mds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/atrn-119-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aprea-therapeutics/projects/atrn-119-hpv-positive-oropharyngeal-squamous-cell-carcino 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quoin-pharmaceuticals/projects/qrx003-2-lotion-netherton-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quoin-pharmaceuticals/projects/qrx003-4-lotion-netherton-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/quoin-pharmaceuticals/projects/qrx003-netherton-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bolt-biotherapeutics/projects/bdc-1001-her2-positive-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bolt-biotherapeutics/projects/bdc-1001-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/urapidil-aging 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bolt-biotherapeutics/projects/bdc-3042-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bolt-biotherapeutics/projects/bdc-4182-gastric-cancer-adenocarcinoma-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/addex-therapeutics/projects/adx10059-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/addex-therapeutics/projects/adx10059-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/addex-therapeutics/projects/adx48621-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/addex-therapeutics/projects/adx48621-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/addex-therapeutics/projects/dipraglurant-blepharospasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/addex-therapeutics/projects/dipraglurant-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aspire-biopharma-holdings/projects/adreview-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acurx-pharmaceuticals/projects/ibezapolstat-clostridium-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acurx-pharmaceuticals/projects/ibezapolstat-clostridium-difficile-infection-recurrence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/brainstorm-cell-therapeutics-inc/projects/debamestrocel-msc-ntf-nurown-amyotrophic-lateral-sclerosis-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/brainstorm-cell-therapeutics-inc/projects/msc-ntf-cells-transplantation-by-multiple-intram-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/brainstorm-cell-therapeutics-inc/projects/msc-ntf-cells-transplantation-im-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/brainstorm-cell-therapeutics-inc/projects/nurown-msc-ntf-cells-amyotrophic-lateral-sclerosis-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/brainstorm-cell-therapeutics-inc/projects/nurown-msc-ntf-cells-multiple-sclerosis-chronic-progressive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aspire-biopharma-holdings/projects/act-20-msc-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aspire-biopharma-holdings/projects/beet-it-sport-shot-blood-pressure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aspire-biopharma-holdings/projects/myocardial-perfusion-imaging-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aspire-biopharma-holdings/projects/nutritional-supplement-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aspire-biopharma-holdings/projects/pulse-sequence-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aspire-biopharma-holdings/projects/regadenoson-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf-102-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-1-mg-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-1mg-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-2mg-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-keratoconjunctivitis-sicca 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-ocular-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf101-uveitis-posterior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf102-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/cf102-non-alcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/18f-f-arag-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/namodenoson-25mg-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/namodenoson-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/namodenoson-nash-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/piclidenoson-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/piclidenoson-lowe-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/can-fite-biopharma/projects/piclidenoson-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/ht-100-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/pcs12852-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/pcs499-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/pcs499-necrobiosis-lipoidica 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/pcs6422-and-capecitabine-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/pcs6422-and-capecitabine-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/rx-3117-metastatic-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/processa-pharmaceuticals/projects/rx-3117-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/0-01-concentration-atropine-drops-acupressure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/0-1-bromfenac-ophthalmic-solution-cataract 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/0-2mg-group-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss55-safety-issues 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/0-3-ropivacaine-and-50-g-dexmedetomidine-free-flap-reconstruction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/0-9-sodium-chloride-injection-unstable-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/1-23-fluoride-foam-application-dental-caries-in-children 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/1-g-ml-esat6-cfp10-and-tuberculin-purified-prote-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/100mg-aspirin-recurrent-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/100mg-diclofenac-post-ercp-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/11-valent-recombinant-human-papilloma-virus-vacc-hpv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/16mg-kb-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/18f-psma-1007-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/1mg-khk7580-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/20-g-recombinant-hepatitis-b-vaccine-at-months-0-hepatitis-b-vaccine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/23-valent-pneumococcal-polysaccharide-vaccine-vaccination 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/2l-peg-bowel-preparation-scale 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/2mg-baricitinib-acute-ichemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/30-oxygen-atelectasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/30-oxygen-atelectasis-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/5-cysteamine-cream-melasma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/5-fu-epirubicin-ctx-following-docetaxel-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/5-g-ml-esat6-cfp10-in-left-arm-and-tb-ppd-in-rig-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/5-g-ml-esat6-cfp10-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/5-lidocaine-patch-herpes-zoster-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/60-g-dose-hepatitis-b-vaccine-hepatitis-b-vaccination 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/60-g-dose-hepatitis-b-vaccine-hepatitis-b-vaccine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/68ga-nodaga-sna006-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/68ga-psma-11-biochemical-recurrence-of-malignant-neoplasm-of 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/75-mg-acetylsalicylic-acid-preeclampsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/80-oxygen-oxygenation-index 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/99mtc-4boh-spect-myocardial-perfusion-imaging-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/a-compound-glutamine-capsule-a-compound-glutamin-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/a-compound-glutamine-capsule-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/a-ha-tm-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/a-patient-self-reporting-applet-cancer-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/abatacept-dermatomyositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/abemaciclib-liver-metastases-from-colorectal-cancer-mcrc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/abiraterone-acetate-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/acei-arb-finerenone-henoch-sch-nlein-purpura-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/acetohydroxamic-acid-multidrug-resistant-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ad-hgf-ischemic-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/adebrelimab-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/adebrelimab-pd-l1-inhibitor-pancreatic-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/adefovir-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ademetionine-1-4-butanedisulfonate-obstructive-hypertrophic-cardiomyopathy-ohcm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/adjuvant-chemotherapy-total-neoadjuvant-treatment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/adjuvant-immunotherapy-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/administering-rasi-the-trade-name-or-universal-n-carotid-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/adsc01-connective-tissue-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/aim-chd-mobile-health-intervention-secondary-prevention-of-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ak104-resectable-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ak117-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/akkermansia-probiotics-colo-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/albumin-bound-paclitaxel-gastric-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/albumin-paclitaxel-neutrophil-drug-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/albumin-paclitaxel-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/albumin-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/alectinib-bone-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/alendronate-osteogenesis-imperfecta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/parabilis-medicines/projects/fog-001-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/allogeneic-cd19-bcma-targeted-car-t-cell-injecti-refractory-relapsed-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/allogeneic-msc-allomsc-refractory-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/almonertinib-lung-cancer-non-small-cell-stage-iv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/almonertinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/almonertinib-non-small-cell-lung-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/alpha-receptor-antagonist-prostatic-hypertrophy-benign 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/amino-acid-derived-lipids-radiation-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/amlodipine-essential-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/amway-herbal-drink-skin-laxity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anerning-particle-community-acquired-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anlotinib-combined-docetaxel-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anlotinib-sarcoma-soft-tissue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anrotinib-plus-tirelizumab-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anshen-buxin-liuwei-pill-cardiac-neurosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anterior-capsulotomy-obsessive-compulsive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-bcma-and-cd19-cart-cells-will-be-injected-i-autoimmune-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-bcma-car-t-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-bcma-car-t-plasma-cell-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-bcma-car-transduced-t-cells-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-bcma-cd3-bispecific-antibody-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cd19-allo-car-t-cells-relapsed-adult-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cd19-car-t-cells-and-anti-cd20-car-t-cells-lymphoma-large-b-cell-diffuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cd19-universal-car-t-cells-injection-relapsed-or-refractory-b-cell-acute-lymphoblasti 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cd20-car-transduced-t-cells-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cd30-car-t-cells-adult-t-cell-lymphoma-leukaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cd30-car-transduced-t-cells-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cd38-antibody-injection-antiphospholipid-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cdh17-car-t-cells-infusion-cdh17-positive-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-cll1-cart-cells-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-gprc5d-car-t-cells-infusion-multiple-myeloma-in-relapse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-her2-car-t-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-infective-therapy-bronchiectasis-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-ley-car-transduced-t-cells-myeloid-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-pd-1-antibody-drug-named-serplulimab-locally-advanced-rectal-cancer-larc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-pd-1-antibody-drug-named-sintilimab-stage-iv-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-pd-1-antibody-gastric-or-gastroesophageal-junction-adenocarcin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-pd-1-pd-l1-monoclonal-antibody-and-chemothe-effect-increased 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-platelet-drugs-unstable-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/anti-thyroid-drugs-graves-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/antibiotic-selection-based-on-the-antibiotic-sus-gastritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/antihistamine-low-dose-chlorpheniramine-dexchlor-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/apatinib-breast-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/apatinib-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/apatinib-mesylate-tablet-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/apatinib-metastatic-gastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/arbidol-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/artificial-intelligence-assisted-chest-x-ray-in-tuberculosis-tb 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/asc30-tablets-t2dm-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/asc30-weight-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/asc47-chronic-weight-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/asct-cd7-cart-cd7-positive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/aspirin-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/aspirin-clopidogrel-rivaroxaban-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/astragalus-membranaceus-aneurysmal-subarachnoid-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/atezolizumab-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/atlg-hematopoietic-stem-cell-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/atomoxetine-80mg-combined-with-oxybutynin-5mg-obstructive-sleep-apnea-of-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/atorvastatin-atherosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/atra-arsenic-acute-promyelocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/atropine-sulfate-eye-drops-0-01-myopia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/aumolertinib-oral-tablet-lung-cancer-stage-iv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/autologous-bcma-targeting-car-t-cells-multiple-myeloma-in-relapse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/autologous-decidual-like-nk-cells-abortion-habitual 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/autologous-differentiated-myocyte-transplantatio-metabolic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/autologous-hematopoietic-stem-cell-infusion-prolonged-cytopenia-following-car-t-therapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/autologous-t-cells-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/autologous-tumor-infiltrating-lymphocyte-cells-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/auy922-gastrointestinal-stromal-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/avapritinib-azacitidine-venetoclax-aml-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/avatrombopag-20-mg-oral-tablet-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/avatrombopag-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/avatrombopag-refractory-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/avatrombopag-severe-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/avatrombopag-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/azacytidine-cytarabine-aclacinomycin-chidamide-v-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/azacytidine-cytarabine-aclacinomycin-chidamide-v-relapsed-refractory-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/azithromycin-bronchiectasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/azvudine-sars-cov-2-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/baricitinib-2-mg-olumiant-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bc006-advanced-solid-tumors-including-gctts 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bcma-car-t-multiple-myeloma-plasma-cell-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bcma-cart-ultra-high-risk-mm-uhr-mm-18-70-years-old-suitab 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bcma-cd3-bispecific-antibody-cm336-solitary-bone-plasmacytoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/becotatug-vedotin-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/becotatug-vedotin-penile-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bedaquiline-b-tuberculosis-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/befotertinib-combined-bevacizumab-egfr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/befotertinib-nsclc-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/behavior-intervention-and-male-circumcision-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/benazepril-renal-insufficiency-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/benmelstobart-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/benmelstobart-sclc-extensive-stage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/berberine-plus-lifestyle-intervention-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bevacizumab-disease-free-survival 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bi-754091-plus-afatinib-esophageal-squamous-cell-carcinoma-escc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bicalutamide-breast-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bilateral-nucleus-accumbens-dbs-suzhou-sceneray-obsessive-compulsive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/biobran-supplementation-breast-cancer-stages-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/biologics-treatment-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bisoprolol-fumarate-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bisoprolol-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bispecific-antibody-based-combined-with-car-t-ce-b-cell-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bitter-melon-peptides-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bleomycin-lymphatic-malformation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/blinatumomab-b-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bmsc-transplantation-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bortezomib-dexamethasone-acquired-pure-red-cell-aplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bortezomib-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adial-pharmaceuticals-inc/projects/rhbmp-2-placement-tooth-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bortezomib-pirarubicin-dexamethasone-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bortezomib-plasma-cell-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bortezomib-waldenstr-m-macroglobulinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bosentan-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bovine-lactoferrin-nosocomial-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bozitinib-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/brentuximab-vedotin-for-injection-classical-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/brivudine-herpes-zoster 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bromocriptin-2-5mg-2-3-times-a-day-pituitary-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bronchial-basal-cells-bronchiectasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bronchial-basal-cells-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/brucea-javanica-oil-emulsion-injection-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bu-yang-huan-wu-tang-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/budesonide-formoterol-cough-variant-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/budesonide-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/budesonide-surfactant-premature-infants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bufei-recipe-preserved-ratio-impaired-spirometry 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bundle-group-1-with-nutrilite-lifestyle-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/buprenorphine-transdermal-system-disease-or-disorder-intervertebral-disc-with-mye 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/butorphanol-visceral-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/butylphthalide-restenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/buyang-huanwu-decoction-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bxd-treatment-ibd-inflammatory-bowel-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/bz019-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/c-car088-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cabozantinib-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cadonilimab-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camrelizumab-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cadonilimab-combined-paclitaxel-albumin-bound-gastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/caffr-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camel-milk-containing-bifidobacterium-animalis-a-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camrelizumab-adrenal-cortical-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camrelizumab-and-sbrt-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camrelizumab-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camrelizumab-chemotherapy-thalidomide-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camrelizumab-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/camrelizumab-plus-apatinib-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/canagliflozin-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/capecitabine-cisplatin-stomach-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/capecitabine-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/capox-chemotherapy-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/car-t-cells-chimenric-antigen-receptor-t-cells-b-cell-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/car-t-cells-chimeric-antigen-receptor-t-cells-relapsed-refractory-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/car-t-cells-chimeric-antigenreceptor-cells-relapsed-refractory-b-cell-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/car-t-cells-philadelphia-positive-acute-lymphoblastic-leukem 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/carbohydrates-insulin-resistance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/carbon-nanoparticle-iron-suspension-for-injectio-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/carbon-nanoparticle-suspension-injection-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cardioblate-surgical-ablation-system-rheumatic-valve-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cart-tdf-azt-3tc-lpv-r-acute-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/caudal-dexmedetomidine-inguinal-hernia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd-001-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd123-cll-1-dual-target-car-t-cells-sequential-i-aml-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd19-bcma-in-vivo-car-t-autoimmune-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd19-cd20-dual-car-t-cells-b-cell-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd19-cd20-dual-car-t-cells-b-cell-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd19-cd22-car-t-cells-relapsed-or-refractory-b-cell-acute-lymphoblasti 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd19-or-cd20-car-t-cells-briging-hsct-lymphoma-large-b-cell-diffuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd19-star-t-cells-b-cell-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd19x-car-t-large-b-cell-lymphoma-lbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd22-cd19-car-t-and-auto-hsct-sandwich-strategy-b-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd25-antibody-combined-glucocorticoid-as-first-l-acute-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cd7-ucar-t-cells-t-cell-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cefditoren-pivoxil-tablets-medication-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/celebrex-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/celecoxib-400mg-peutz-jeghers-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/celecoxib-oral-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cell-sheet-pellets-and-cell-sheet-fragment-chronic-periodontitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cell-therapy-periodontal-pocket 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cell-therapy-primary-ovarian-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cetuximab-erbitux-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chemotherapy-and-shr-1316-adebrelimab-comnined-w-limited-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chemotherapy-pd-1-inhibitor-8gy-x-3f-hr-her2-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chemotherapy-plus-tcm-1-icis-plustcm2-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chemotherapy-ts-1-leucovorin-and-gemcitabine-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chickenpox-vaccines-chickenpox-vaccines 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chidamide-tablets-pd-l1-inhibitor-as-per-chosen-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chidamide-tislelizumab-chemotherapy-capeox-colon-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chinese-herb-astragalus-membranaceus-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chinese-herb-huang-chi-wu-wu-tang-intracranial-arterial-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chinese-herbal-therapy-urinary-incontinence-stress 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chinese-herbs-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chinese-herbs-i-mycobacterium-abscessus-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chinese-medicine-acute-mountain-sickness-ams 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chinese-tea-flavor-liquor-alcohols 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chloroprocaine-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chop-selinexor-5-azacitidine-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cinacalcet-hcl-hyperparathyroidism-secondary-renal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cipher-prescription-1-percutaneous-coronary-artery-intervention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ciprofol-sedation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/circulating-tumor-cells-test-thyroid-nodule 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cisatracurium-ards 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cisplatin-albumin-bound-paclitaxel-1-cycle-and-p-uterine-cervical-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cisplatin-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cisplatin-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cisplatin-i-p-epithelial-carcinoma-ovarian 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cisplatin-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cisplatin-oral-cavity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/citalopram-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/citalopram-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/citrate-anticoagulation-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/clarithromycin-chronic-rhinosinusitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cll1-and-cd38-dual-target-car-t-cell-injection-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/clopidogrel-and-aspirin-atherosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/clopidogrel-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cm-336-bcma-cd3-bispecific-antibody-al-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cm-ma-hsing-kan-shih-tang-in-combination-with-li-childhood-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cm313-injection-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cm336-bcma-cd3-bispecific-antibody-relapsed-refractory-multiple-myeloma-rrmm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cm336-plus-isatuximab-multiple-myeloma-mm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cmgv-recurrent-adult-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cmv-tcr-t-cells-cmv-infection-or-reactivation-after-allogenic-hs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cnct19-car-t-cell-therapy-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cnct19-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/coenzyme-q10-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/colchicine-0-5mg-cerebral-amyloid-angiopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/colchicine-in-stent-restenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/colchicine-transcatheter-aortic-valve-replacement 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/colla-corii-asini-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/colquhounia-root-tablet-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/combination-of-bortezomib-fludarabine-and-cyclop-mantle-cell-lymphoma-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/combined-use-of-tpo-ras-with-low-dose-anti-cd20-immune-thrombocytopenia-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/compound-norethisterone-enanthate-injection-contraception-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/compound-realgar-indigo-naturalis-formula-plus-r-acute-promyelocytic-leukaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/concentrated-growth-factor-bone-substitute-concentrated-growth-factor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/conservative-treatment-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/convention-therapy-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/conventional-therapy-plus-low-dose-huc-mscs-trea-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/conventional-therapy-s-ketamine-s-ketamine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/conventional-treatment-copd-exacerbation-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cordyceps-cicadae-extract-myopia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cordyceps-cicadae-visual-acuity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/coronary-artery-bypass-graft-with-the-use-of-cpb-the-efficacy-and-safety-of-off-pump-cabg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/coronary-computed-tomography-angiography-cardiovascular-primary-prevention-strategy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/coronary-computed-tomography-angiography-major-adverse-cardiovascular-events-mace 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/coronary-computed-tomography-angiography-statin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/coronary-cta-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/corticosteroid-heart-valve-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/corticosteroids-acute-severe-colitis-asc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/corticosteroids-combined-with-immunoglobulin-and-primary-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/covax-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/covid-19-vaccine-0-1-4-schedule-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/covid-convalescent-plasma-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cow-s-milk-acute-respiratory-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/crb4101-healthy-adult-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/crizotinib-systemic-anaplastic-large-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ct-colonoscopy-normal-dose-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ct-three-dimensional-reconstruction-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sa55-injection-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cy-219-car-t-relapsed-refractory-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cyclophosphamide-pemetrexed-5-fluorouracil-locally-advanced-thyroid-gland-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cytarabine-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/cytokine-induced-killer-cells-folfox4-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/da-jian-zhong-tang-zanthoxylum-ginger-ginseng-ma-eras 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/daaoi-p-parkinson-s-disease-with-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/daclatasvir-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/danggui-buxue-tang-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/danlou-tablet-coronary-artery-disease-cad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dapagliflozin-acute-kidney-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dapagliflozin-standard-treatment-for-12-weeks-wa-pediatric-hereditary-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/daratumumab-and-corticosteroid-treatment-acquired-hemophilia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/daratumumab-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/daratumumab-injection-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dasatinib-relapsed-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/daunorubicin-idarubicin-aml-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dc-cik-combined-with-regorafenib-iparomlimab-and-dc-cik-treatment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dc-tc-gm-csf-primary-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/de-escalated-dual-antiplatelet-therapy-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/deb-tace-haic-hepatocellular-carcinoma-non-resectable 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/decitabine-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/decitabine-myelodysplastic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/deferoxamine-intracerebral-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dendritic-cell-recurrent-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/denosumab-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/desflurane-delirium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/desiccated-thyroid-extract-dte-levothyroxine-l-t-intermediate-to-high-risk-differentiated-thyroid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexamethasone-acute-respiratory-distress-syndrome-ards 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexamethasone-and-n-acetylcysteine-nac-carbon-monoxide-poisoning 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexamethasone-combined-with-romiplostim-n01-primary-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexamethasone-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-bronchoscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-cardiac-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-chronic-post-surgical-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-group-colonoscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-group-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-injectable-solution-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-injection-nasal-spray-propofol-i-dexmedetomidine-induced-sedation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-lower-limb-fracture 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-sleep-quality-of-patients-undergoing-turp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-supplemented-morphine-analgesia-elderly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dexmedetomidine-thoracic-paravertebral-blocks 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/diclofenac-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/diet-management-strategy-for-encephalopathy-hepatic-encephalopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/digaoxin-amiodarone-receptor-antagonist-calcium-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/diphtheria-tetanus-and-acellular-pertussis-three-whooping-cough 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dobutamine-patients-with-septic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/docetaxel-cisplatin-and-fluorouracil-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/docetaxel-cisplatin-fluorouracil-locally-advanced-head-and-neck-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/docetaxel-lobaplatin-lobaplatin-and-gemcitabine-in-combination-second 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/docetaxol-cisplatin-capecitabine-advanced-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/donepezil-cognitive-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dose-attenuated-ist-and-hetrombopag-sever-aplastic-anaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/dose-escalation-poor-graft-function 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/drug-ixazomib-drug-pomalidomide-drug-dexamethaso-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/drug-treatment-prolactinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eadm-carcinoma-hepatocellular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/early-enteral-nutrition-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/early-nutrition-intervention-nutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ebv-immunological-agent-malignant-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ebv-tcr-t-yt-e001-cells-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/echocardiographic-guidance-aortic-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eculizumab-kidney-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/edaravone-dexborneol-chemo-brain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/edoxaban-non-valvular-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/efbemalenograstim-alfa-injection-primary-secondary-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/egfr-tk-inhibitor-nonsmall-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eldecalcitol-osteoporosis-in-postmenopausal-women 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/elective-nodal-irradiation-eni-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/electroacupuncture-group-urinary-stress-incontinence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eltrombopag-chemotherapy-induced-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eltrombopag-thrombocytopenia-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/empagliflozin-10-mg-pre-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/endostar-nasopharyngeal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/engineered-mitochondrial-vaccine-advanced-solid-tumor-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/engineered-mitochondrial-vaccine-imp3-mito-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/enhanced-dermatologic-management-nsclc-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/enoxaparin-pregnancy-related 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/enrolled-patients-with-blast-phase-chronic-myelo-cml-blast-phase 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ensartinib-group-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ensartinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/entecavir-adefovir-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/entecavir-fuzheng-huayu-tcm-granule-hepatitis-b-virus-related-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/enteral-immunonutrition-locally-advanced-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/enzalutamide-metastatic-hormone-sensitive-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/epirubicin-carcinoma-hepatocellular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/epirubicin-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/epo-premature-infant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/erlotinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/erythropoietin-premature-infants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/esat6-cfp10-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/escitalopram-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/escitalopram-major-depressive-disorder-mdd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/escitalopram-mild-to-moderate-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/favipiravir-influenza-human 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/escitalopram-oral-antidepressant-depression-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/esketamine-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss67-injection-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/esketamine-lidocaine-group-postoperative-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/et-01-transfusion-dependent-beta-thalassaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eth-155008-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eth-155008-nhl-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/etomidate-anesthesia-general-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/etomidate-postoperative-complications 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/etoposide-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/etoposide-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cero-therapeutics-holdings-inc/projects/cer-1236-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/eus-guided-pancreatic-pseudocyst-drainage-pancreatic-pseudocyst 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ev71-vaccine-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/everolimus-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/evm16-advanced-or-recurrent-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/evm18001-injection-system-lupus-erythematosus-sle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ex-vivo-expanded-allogeneic-t-cells-aml-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ex-vivo-expanded-allogeneic-t-cells-non-hodgkin-s-lymphoma-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/exclusive-enteral-nutrition-therapy-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/exenatide-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/experimental-vaccine-1-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/exposure-to-sporting-events-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/famitinib-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fast-dual-car-t-injection-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fast-technique-st-segment-elevation-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fecal-microbiota-transplantation-fmt-slow-transit-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fecal-microbiota-transplantation-fmt-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fecal-microbiota-transplantation-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ferric-derisomaltose-heart-failure-with-preserved-ejection-fraction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ferric-derisomaltose-heart-failure-with-reduced-ejection-fraction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fespixon-cream-diabetic-foot-ulcer-dfu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fgfr-inhibitor-idh1-inhibitor-her2-inhibitor-par-biliary-tract-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/first-line-scheme-compound-kushen-injection-advanced-colorectal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fludarabine-flu-aplastic-anemia-idiopathic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fluoxetine-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fluticasone-formoterol-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fluzoparib-breast-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fmt-capsules-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/folfox-folfiri-unresectable-or-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/folfoxiri-based-haic-fuquinitinib-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/folfoxiri-colon-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/folic-acid-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/folic-acid-neural-tube-defects-spina-bifida-and-anencephaly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fosinopril-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fospropofol-disodium-drug-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/freeze-dried-capsulized-fmt-slow-transit-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fruquintinib-fruquintinib 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fruquintinib-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fuke-qianjin-capsules-chronic-endometritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/furmonertinib-in-combination-with-anrotinib-and-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/furmonertinib-lung-adenocarcinoma-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fuzheng-1-acquired-immune-deficiency-syndrome-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/fuzheng-3-acquired-immune-deficiency-syndrome-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/g-csf-intrauterine-adhesion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gabapentin-tramadol-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gastrogra-n-fecal-impaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gastrografin-cre-induced-sbo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gc012f-injection-infusion-idiopathic-inflammatory-myopathy-iim 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gecacitinib-cgvhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gefitinib-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gefitinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-1000-mg-phase-ii-open-label-parallel-2-arm-multi-center 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-5fu-leucovorin-biliary-tract-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-and-cisplatin-docetaxel-cisplatin-an-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-and-cisplatin-induction-chemotherapy-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-and-cisplatin-nasopharyngeal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-cisplatin-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-docetaxel-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-nimotuzumab-toripalimab-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-oxaliplatin-5fu-and-leucovorin-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gemcitabine-plus-cisplatin-biliary-tract-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gene-detection-of-therapeutic-drugs-for-chronic-hypertension-essential 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/genotype-detected-through-genseizer-high-through-non-tuberculosis-mycobacteria-lung-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/genotype-guided-dosingtaiwan-algorithm-for-warfa-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/glofitamab-relapsed-or-refractory-aggressive-b-cell-lymphom 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/glp-1-receptor-agonists-short-bowel-syndrome-sbs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/glutamine-combined-with-thalidomide-mucositis-oral 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/glutamine-rheumatic-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/glycopyrronium-postoperative-nausea-and-vomiting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/glyt-1-inhibitor-1-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gnp-in-combination-with-ivonescimab-and-sbrt-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gnrha-hcg-hmg-azoospermia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/golidocitinib-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gpc3-car-t-cells-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/granulocyte-colony-stimulating-factor-g-csf-myelodysplastic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/green-tea-polyphenols-egcg-ecg-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/group-a-clinical-guideline-machine-learning-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/group-a-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/group-a-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/group-a-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/group-a-the-standard-2hrze-4hr-regimen-pulmonary-tuberculosis-tb-in-sputum-microscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gspe-atherosclerosis-of-arteries-of-the-extremities-u 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gt719-injection-hematological-malignancy-leukemia-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/guilingji-capsule-oligospermia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/guli-capsule-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gv20-0251-hcc-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/gvm-r-regimen-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/haecs-premature-ovarian-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/haic-tislelizumab-lenvatinib-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/handwashing-communicable-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/haploid-allogeneic-nk-cell-therapy-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hbv-mrna-vaccine-liver-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hcq-cq-and-cab-combined-treatment-resistance-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hemodialysis-with-polymethylmethacrylate-artific-uremia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/heparin-thromboprophylaxis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/herbal-medicine-c-117-occlusion-and-stenosis-of-unspecified-cerebral-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/herombopag-chemotherapy-induced-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/herombopag-non-severe-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hetrombopag-hematological-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/high-dose-ggql-decoction-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/high-fat-diet-group-ad16-20mg-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/high-protein-life-quality 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hipec-with-neoadjuvant-chemotherapy-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hn2301-injection-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hn2302-injection-autoimmune-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/house-dust-mite-allergic-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/insulin-pancreatitis-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/houyanqing-oral-liquid-nasopharyngeal-cancinoma-npc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hrt-dhea-and-herb-irregular-menses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hs-sw01-cells-injection-ankylosing-spondylitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hs-sw01-cells-injection-primary-ovarian-insufficiency-poi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/huangjing-yangji-formula-granules-sarcopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hucb-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-amniotic-epithelial-stem-cells-haescs-acute-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-amniotic-epithelial-stem-cells-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-anti-pd-l1-monoclonal-antibody-injection-l-advanced-malignant-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-covid-19-immunoglobulin-ph4-for-intravenou-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-norovirus-bivalent-g-1-g-4-vaccine-recombi-norovirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-umbilical-cord-mesenchymal-stem-cells-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-umbilical-cord-mesenchymal-stem-cells-pneumoconiosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/human-urinary-kallidinogenase-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hydrogel-of-spirulina-derived-exosomes-radiation-induced-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hydrogen-peroxide-3-topical-solution-warts 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hydroxyethl-starch-cesarean-section 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hypofraction-radiation-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hypofractionated-radiation-chemotherapy-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hypofractionated-radiotherapy-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iah0968-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iap0971-advanced-malignant-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iap0971-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iaso104-relapsed-refractory-multiple-myeloma-rrmm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iaso206-injection-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iaso206-injection-relapsed-refractory-multiple-myeloma-rrmm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ibb0979-advanced-malignant-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ibb0979-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ibd0333-mtd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ibi363-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/icg-cisplatin-nanoprobe-nir-ii-nanom-liver-cancer-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ics-laba-bronchiectasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iguratimod-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/il-22bp-mrna-vaccine-injection-refractory-malignant-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iloprost-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/imatinib-solid-tumor-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/imipenem-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/immediate-ceus-liver-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/immunohistochemistry-or-genetic-test-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/immunonutrition-su-yusu-gastrointestinal-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/immunosuppressive-therapy-in-stent-restenosis-lesion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/imp3-sarna-ymn-136-vaccine-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/inactivated-covid-19-vaccine-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/inactivated-polio-vaccine-vaccination 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/inactivated-poliomyelitis-vaccine-sabin-strains-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/inactivated-sars-cov-2-vaccine-coadministered-wi-sars-cov-2-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/indigo-naturalis-ointment-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/individualized-elective-neck-irradiation-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/indomethacin-and-ibuprofen-ductus-arteriosus-patent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/induction-therapy-of-gp-pomalidomide-obinutuzuma-indolent-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/induction-therapy-splenic-b-cell-lymphoma-leukaemia-with-prominent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/infloran-enterocolitis-necrotizing 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/inhaled-placebo-ventilator-associated-pneumonia-vap 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/injection-of-iah0968-gemcitabine-cisplatin-her2-gene-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/innovative-dietary-formulation-patent-id-cn11025-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/inotuzumab-ozogamicin-acute-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/insulin-aspart-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intensity-modulated-radiation-therapy-imrt-in-co-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intensity-modulated-radiotherapy-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intensive-bp-treatment-group-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intensive-statin-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intermittent-pd-1-pd-l1-ici-vegfr-tki-renal-cell-carcinoma-rcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/internal-mammary-nodal-irradiation-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intervention-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intestinal-microbiota-transplant-imt-capsules-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intra-arterial-thrombolysis-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intranasal-corticosteroids-incs-combined-with-or-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intranasal-oxytocin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intranasal-oxytocin-learning-disabilities 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intranasal-oxytocin-ot-24-iu-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-dexmedetomidine-aneurysm-cerebral 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-nicardipine-hydrochloride-intracerebral-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-rhtnk-tpa-stroke-acute-ischemic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-stem-cell-transplantation-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-sufentanil-analgesia-patient-controlled 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-thrombolysis-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-thrombolysis-plus-tirofiban-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravenous-tramadol-catheter-site-discomfort 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intraventricular-pemetrexed-leptomeningeal-metastasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/intravitreal-injection-of-kh902-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/investigator-selected-standard-pd-1-pd-l1-inhibi-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iodine-containg-spareribs-soup-iodine-bioavailability 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iparomlimab-and-tuvonralimab-injection-ql1706-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/irinotecan-hydrochloride-liposome-injection-biliary-tract-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/irinotecan-liposome-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/irinotecan-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iron-isomaltoside-injection-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/isatuximab-bortezomib-lenalidomide-dexamethason-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/isoniazid-aminosalicylate-tablets-reinfection-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/isoniazid-kidney-transplant-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/isoniazid-tuberculosis-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/isosorbide-dinitrate-5-mg-post-ercp-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/itraconazole-sporotrichosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/iv-ibuprofen-extremely-premature-infants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ivonescimab-combined-with-tp-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ivosidenib-venetoclax-azacitidine-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ivosidenib-venetoclax-gilteritinib-selinexor-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jak-inhibitor-antisynthetase-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jdb0131-drug-resistant-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jejunostomy-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jiangtang-tiaozhi-recipe-type2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jianpi-qinghua-granules-nonerosive-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jianpixiaozhong-particles-and-wuse-dietotherapy-idiopathic-membranous-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jiedu-tongluo-granules-post-stroke-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jiu-wei-zhen-xiao-granule-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/js004-limited-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jwk002-x-linked-retinoschisis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jwk007-single-intravenous-infusion-administratio-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jy231-injection-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jy231-injection-systemic-lupus-erythematosus-sle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/jyest-cell-injection-infusion-prevention-of-ebv-infection-after-allogeneic-hem 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/kang-guan-recipe-treat-coronavirus-disease-2019 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/kanglaite-injection-chemotherapy-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/khk7580-secondary-hyperparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/kl003-cell-injection-drug-product-transfusion-dependent-beta-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/kl003-cell-injection-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/kukoamine-b-mesilate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/l-ornithine-l-aspartate-decompensated-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/laba-lama-or-placebo-inhalation-bronchiectasis-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lactulose-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lamivudine-compensated-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lansoprazole-amoxicillin-clarithromycin-metronid-gastric-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lb1410-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lcar-aio-cells-acute-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lcar-f33s-cells-intravenous-infusion-relapsed-refractory-multiple-myeloma-mm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lci-white-light-early-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ld-and-gc012f-car-t-cell-injection-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/learning-with-3d-mr-visualization-models-teaching-innovation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ledipasvir-90mg-sofosbuvir-400-mg-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/leflunomide-anca-associated-vasculitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/len-sin-deb-tace-haic-hepatocellular-carcinoma-non-resectable 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lenalidomide-and-gemcitabine-dose-level-11-peripheral-t-cell-lymphomas-ptcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lenvima-4-mg-oral-capsule-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/letrozole-berberine-polycystic-ovary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/letrozole-uterine-cervical-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/leucovorin-5-fu-colonic-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/leucovorin-oxaliplatin-docetaxel-s-1-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/levamlodipine-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/levonorgestrel-100-mcg-and-ethinyl-estradiol-20-oral-contraceptive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/licsbr-locally-advanced-pancreatic-ductal-adenocarcinom 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lidocaine-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lidocaine-hydrochloride-2-injection-solution-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lidocaine-hydrochloride-injectable-postoperative-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lidocaine-hydrochloride-injectable-primary-liver-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/linperlisib-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/linperlisib-relapsed-refractory-large-granular-t-lymphocytic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lipid-lowing-tea-hyperlipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/liposomal-mitoxantrone-hydrochloride-dose-level-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lithium-carbonate-250-mg-sleep-deprivation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lithium-carbonate-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/live-combined-bacillus-subtilis-and-enterococcus-immunoglobulin-light-chain-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/live-combined-bifidobacterium-and-lactobacillus-radiation-proctitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lm-108-antibody-and-sintilimab-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/loperamide-diarrhea-predominant-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/loratadine-rhinitis-allergic-perennial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/losartan-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-density-lipoprotein-receptor-mrna-exosomes-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-dose-complex-b-vitamins-hyperhomocysteinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-dose-msh2-tumor-cell-vaccine-pmmr-mss-advanced-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-dose-recombinant-covid-19-vaccine-sf9-cells-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-dose-recombinant-sars-cov-2-vaccine-cho-cell-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-dose-rivaroxaban-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-dose-tenecteplase-intravenous-thrombolysis-acute-ischemic-stroke-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-level-laser-therapy-orthodontic-appliance-complication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-molecular-weight-heparins-calcium-injection-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/low-potassium-content-vegetables-end-stage-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lp-98-20-mg-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/luo-fu-shan-plaster-arthritis-rheumatoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/luspatercept-hsct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lusutrombopag-oral-tablet-idiopathic-thrombocytopenic-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/luvometinib-langerhans-cell-histiocytosis-lch 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lvivo-tavec400-product-multiple-myeloma-mm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/lysogenic-hsv-virus-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/macitentan-10-mg-tablet-once-daily-coronary-microvascular-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/marine-active-hyperuricemia-anserine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mcapox-plus-cetuximab-colorectal-cancer-crc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/measles-rubella-combined-vaccine-mr-measles 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/medical-collagen-membrane-with-msc-wounds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/medical-treatment-carotid-artery-stenting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/medical-treatment-decompensated-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/meiji-yogurt-group-h-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/memantine-oral-tablet-radiation-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mep-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-progenitor-cells-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stem-cell-infusion-immune-effector-cell-associated-hematotoxicity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stem-cell-kidney-transplant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stem-cell-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stem-cells-chronic-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stem-cells-hematopoietic-stem-cell-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stem-cells-peripheral-vascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stromal-cells-chronic-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mesenchymal-stromal-cells-msc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/metformin-pretreatment-before-ovarian-stimulatio-metformin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/methosulide-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/methotrexate-primary-central-nervous-system-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/methylene-blue-50-mg-10ml-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/methylhydroxypropylcellulose-dry-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/methylprednisolone-and-mycophenolate-mofetil-autoimmune-hepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/metoclopramide-10mg-oral-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/metronidazole-vaginal-suppositories-bacterial-vaginosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/micafungin-aspergillosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/midazolam-delirium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/midazolam-mechanical-ventilation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/middle-dose-norovirus-bivalent-gi-1-gii-4-vaccin-norovirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mie-esophageal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mifepristone-tablets-uterine-fibroid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mirabegron-sjogren-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/misoprostol-hypotonic-labor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/misoprostol-labor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/misoprostol-labor-induction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mitomycin-c-based-hyperthermic-intraperitoneal-c-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mitomycin-c-obstructive-airway-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mitoxantrone-hydrochloride-liposome-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mitoxantrone-hydrochloride-liposome-injection30m-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/miyairi-588-depression-mild 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mk-1045-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mobile-surgical-vehicle-echocardiography-guided-asd-atrial-septal-defect 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/modafinil-oral-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/modified-gegen-qinlian-decoction-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/modified-wenxin-decoction-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/moluodan-gastric-precancerous-condition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mosapride-citrate-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mosunetuzumab-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mps-hematological-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mrg003-combined-with-dalpicicilip-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mrg003-combined-with-pucotenlimab-head-and-neck-squamous-cell-carcinoma-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mscs-derived-exosomes-coronavirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mtx-gestational-trophoblastic-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/muc1-cll1-cd33-cd38-cd56-cd123-specific-gene-eng-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/mudan-granule-diabetic-peripheral-neuropathy-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/multi-component-intervention-package-multimorbidity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/multi-component-interventions-multimorbidity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/multi-intervention-program-and-protein-foods-sup-sarcopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/n-3-polyunsaturated-fatty-acid-cardiovascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/n-butyl-2-cyanoacrylate-gastric-varices 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/n-methyl-glycine-obsessive-compulsive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nab-paclitaxel-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nab-paclitaxel-combined-with-cadonilimab-ak104-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nab-paclitaxel-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nadroparin-calcium-and-warfarin-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nadroparin-long-term-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nafamostat-mesilate-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nal-iri-experimental-metastatic-gastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/naldebain-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nalirifox-adebrelimab-pancreatic-ductal-adenocarcinoma-pdac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nano-crystalline-megestrol-acetate-oral-suspensi-extensive-stage-small-cell-lung-cancer-es-sclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nanoliposomal-irinotecan-head-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nasogastric-tube-decompression-pancreaticoduodenectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nedaplatin-central-nervous-system-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/neoadjuvant-chemotherapy-epithelial-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/neoadjuvant-sugemalimab-chemotherapy-followed-by-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nerve-growth-factor-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/neu2000kwl-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/neuroepo-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/neuroregen-scaffold-with-bmmcs-or-mscs-transplan-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/next-generation-sequencing-gastrointestinal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nextdose-nextdose-org-thrombosis-embolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nicorandil-5mg-tid-coronary-artery-bypass-graft 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nicorandil-non-obstructive-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nicorandil-stable-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nicorandil-stemi-st-segment-elevation-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nicorette-extra-mint-2-mg-gum-tobacco-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nicotinamide-adenine-dinucleotid-nicotinamide-mo-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nicotinamide-cutaneous-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nilotinib-chronic-myeloid-leukemia-chronic-phase 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/niraparib-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nitric-oxide-pressure-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nitrofurazone-group-1-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nivolumab-advanced-biliary-tract-cancer-btc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nivolumab-effect-of-drug 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nivolumab-ipilimumab-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nk-cell-perfusion-group-abortion-missed 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nk-cells-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nk510-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/evofem-biosciences/projects/acidform-5-g-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nmdae-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nmdae-plus-aifa-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nmdae-prodromal-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nmdae-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/norepinephrine-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/norepinephrine-septic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/normal-saline-stemi-st-elevation-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/novel-stent-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nutrilite-protein-metx-pro-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nutrition-treat-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/nutritional-therapy-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/obinutuzumab-injection-gazyva-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/obinutuzumab-marginal-zone-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/octreotide-enterocutaneous-fistulas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oka-strain-varicella-attenuated-live-vaccine-chickenpox-vaccines 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/olfactory-ensheathing-cells-infarction-middle-cerebral-artery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oliceridine-hypoxemia-during-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/olverembatinib-apg-2575-dexamethasone-lymphoblastic-leukemia-acute-childhood 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/olverembatinib-ino-hsct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/olverembatinib-philadelphia-chromosome-positive-acute-lymphobla 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/omega-3-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/omega-3-fatty-acid-male-infertility-due-to-hypospermatogenesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/omega-3-polyunsaturated-fatty-acids-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/omicron-covid-19-vaccine-vero-cell-inactivated-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oncolytic-virus-ovv-01-injection-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oncolytic-virus-sdj001-malignant-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/only-antiemetic-ramosetron-tropisetron-and-dexam-chemotherapy-induced-nausea-and-vomiting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/only-conventional-drug-therapy-pulmonary-artery-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/open-discectomy-lumbar-disc-herniation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/open-mini-laparotomy-hydrocephalus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oral-entecavir-0-5mg-daily-and-adefovir-10mg-dai-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oral-levetiracetam-neonatal-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oral-oxytocin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oral-sulfate-solution-oss-bowel-preparation-for-colonoscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oral-supplementation-of-vitamin-d-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/orelabrutinib-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oss-bowel-preparation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxaliplatin-rectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxaliplatin-stomach-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxycodone-hydrochloride-analgesia-patient-controlled 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxycodone-oxynorm-injection-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxycodone-tamper-resistant-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-interoception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-lower-does-24iu-healthy-adult-male 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-lower-dose-24iu-healhty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-mental-health-wellness-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-nasal-spray-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-oxytocin-effect-on-memory-performance-during-pha 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-postpartum-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-social-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxytocin-treatment-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/paclitaxel-eluting-ptca-balloon-coronary-in-stent-restenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/paclitaxel-oral-solution-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/paeoniflorin-phosphatidylcholine-or-silymarin-hepatitis-autoimmune 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pancreatoduodenectomy-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/papillary-epinephrine-spraying-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/partially-hydrolyzed-whey-protein-formula-mild-allergic-symptoms-in-infants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/patients-were-assigned-to-receive-tnt-or-itnt-ma-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pbsc-stem-cell-transplantation-hematopoietic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pbsc-transplantation-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pcsk9-inhibitor-pcsk9i-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pcsk9-inhibitors-combined-with-atorvastatin-rosu-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pd-1-inhbitor-shr0302-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pd-1-rectal-cancer-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pectin-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pectin-slow-transit-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/peficitinib-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/peficitinib-rheumatoid-arthritis-ra 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/peg-rhg-csf-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/peg-somatropin-growth-hormone-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pegylated-recombinant-human-interferon-alpha-2b-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pembrolizumab-200-mg-iv-infusion-stage-iiib-n2-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pemetrexe-central-nervous-system-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pemetrexed-500mg-m2-iv-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pemetrexed-brain-metastases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pex168-or-placebo-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pg2-acute-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pgs-2-0-recurrent-pregnancy-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/phacoemulsification-astigmatism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/photo-responsive-nanozyme-radiation-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/phytosterols-placebo-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pi3k-inhibitor-lymphoma-t-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pik3ca-inhibitor-breast-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pitavastatin-and-placebo-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/placebo-1-to-probiotic-a-gastrointestinal-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/placebo-compared-to-vasoconstrictor-healthy-adult-male 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/placebo-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/placebo-intramuscular-injection-chronic-spontaneous-uriticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/placebo-plus-high-intensity-statin-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/platinum-based-two-drug-chemotherapy-cisplatin-c-non-small-cell-lung-cancer-stage-iiia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pm8002-locally-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/poliovirus-vaccine-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/polyethylene-glycol-colonoscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/postbiotics-adhd-attention-deficit-disorder-with-hyperactivi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/posterior-approach-compression-distraction-reduc-basilar-invagination-associated-with-atlantoaxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/postoperative-adjuvant-chemotherapy-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/postoperative-radiotherapy-oral-tongue-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pralatrexate-refractory-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/prebiotics-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/prednisone-langerhans-cell-histiocytosis-of-bone 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/prednisone-undifferentiated-connective-tissue-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pregabalin-capsule-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pregabalin-herpetic-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/preoperative-0-5-ropivacaine-hydrochloride-preop-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/preoperative-short-course-radiotherapy-rectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/prepackaged-low-residue-diet-colon-polyp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/probiotics-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/probiotics-daily-sars-cov-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/probiotics-necrotizing-enterocolitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/propofol-gastroscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/propofol-nausea-and-vomiting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/propofol-postoperative-sleep-quality 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/propofol-urinary-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/propranolol-liver-cirrhoses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/propranolol-portal-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/propranolol-retinopathy-of-prematurity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/proton-pump-inhibitors-upper-gastrointestinal-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pulsed-dye-laser-pdl-port-wine-stain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pure-give-pectin-20g-d-for-five-days-inflammatory-bowel-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/pyrotinib-low-dose-group-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qams-containing-pmma-oral-health 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qfr-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qianjin-capsule-of-gynaecology-pelvic-inflammatory-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qinbudan-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qingying-oral-liquid-and-modified-da-huang-huang-radiation-induced-oral-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qishen-granules-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qizhi-weitong-granules-high-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qizhitongluo-capsule-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ql1706-platinum-resistant-recurrent-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qls32015-relapsed-refractory-multiple-myeloma-rrmm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/qt-019c-sle-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/quick-acting-heart-reliever-coronary-artery-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/r-epoch-in-combination-with-ibrutinib-richter-transformation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rabbit-atg-cyclosporine-levamisole-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rabbit-atg-genzyme-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/raman-spectrum-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/randomized-double-blinded-placebo-controlled-prevention-of-covid-19-caused-by-sars-cov-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rapamycin-graves-ophthalmopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rbc-transfusion-based-on-different-protocols-transfusion-related-complication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rc48-adc-neoadjuvant-treatment-of-her2-positive-muscle-in 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rd13-02-severe-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rd14-01-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-14-valent-human-papillomavirus-vacci-hpv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-covid-19-vaccine-cho-cell-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-covid-19-vaccine-cho-cell-nvsi-06-08-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-covid-19-vaccine-cho-cell-nvsi-06-09-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-covid-19-vaccine-sf9-cell-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-erythropoietin-hypoxic-ischemic-encephalopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-erythropoietin-premature-birth 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-erythropoietin-rhepo-infant-premature 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-growth-hormone-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-growth-hormone-r-hgh-dwarfism-pituitary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-thrombopoietin-rhtpo-dexametha-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-thrombopoietin-rhtpo-rituximab-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-human-thrombopoietin-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-interferon-alpha-essential-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-novel-coronavirus-vaccine-adenovirus-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-respiratory-syncytial-virus-vaccine-respiratory-syncytial-virus-rsv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/recombinant-tissue-plasminogen-activator-rt-pa-pulmonary-thromboembolisms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/reduction-ctvp1-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/regend001-cell-therapy-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/regimen-bic-ftc-taf-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/regimen-tdf-3tc-efv-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/regorafenib-regorafenib 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rematazolam-besylate-emergence-agitation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/remifentanil-analgesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/remimazolam-besylate-analgesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/remimazolam-besylate-sedative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/remimazolam-general-anesthetic-drug-adverse-reaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/remote-ischemic-preconditioning-ripc-cerebrovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/evofem-biosciences/projects/amphora-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/reyanning-mixture-acute-tonsillitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rezvilutamide-metastatic-hormone-sensitive-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rhgm-csf-pulmonary-alveolar-proteinosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rhtpo-in-combination-with-rituximab-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rifaximin-small-intestine-bacterial-overgrowth 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ringer-s-solution-acetate-cholecystolithiasis-and-thyroid-nodule 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/riociguat-chronic-thromboembolic-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-combined-with-daratumumab-anti-cd38-mo-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-head-and-neck-squamous-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-immune-thrombocytopenic-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-paclitaxel-ruxolitinib-refractory-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-peripheral-t-cell-lymphoma-not-otherwise-specifi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-recombinant-human-thrombopoietin-rhtpo-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rituximab-severe-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rivaroxaban-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rivaroxaban-ventricular-mural-thrombosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rjmty19-cd19-car-dnt-cells-b-cell-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/romiplostim-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/romiplostim-immune-thrombocytopenia-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ropivacaine-hydrochloride-10-mg-ml-naropin-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rosuvastatin-5mg-10mg-20mg-carotid-atherosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/rosuvastatin-infarction-anterior-cerebral-artery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/roux-en-y-anastomosis-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ruxolitinib-5-mg-bid-oral-tablet-the-prophylactic-value-of-ruxolitinib-for-agvhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ruxolitinib-agvhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/s-ketamine-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/s1-metastatic-gastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/s1ra-plus-nmdae-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sabin-ipv-and-dtap-vaccination 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sabin-ipv-bopv-bopv-vaccination 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/coronavac-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sacituzumab-tirumotecan-and-limertinib-egfr-mutant-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sacituzumab-tirumotecan-extensive-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sacituzumab-tirumotecan-tnbc-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sacubitril-valsartan-stemi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/saline-0-9-sterile-for-infusion-pneumocystis-jiroveci-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/salmeterol-fluticasone-propionate-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/salvianolate-injection-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/salvianolate-injection-angina-stable 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sanchi-tongshu-capsule-enteric-coated-pellets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sapropterin-dihydrochloride-tablets-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sarcosine-capsule-parkinson-s-disease-with-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sarcosine-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sarcosine-schizophrenias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sars-cov-2-vaccine-vero-cell-inactivated-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/saussurea-involucrata-liquid-tonic-postpartum-rheumatism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/scout-assisted-review-workflow-coronary-heart-disease-chd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/seasonal-influenza-vaccine-influenza-human 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/selective-serotonin-reuptake-inhibitor-ssri-anxiety-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/self-expandable-125i-radioactive-seeds-loaded-st-cholangiocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sertraline-plus-placebo-of-jwxyjn-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sevelamer-degenerative-heart-valve-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sevoflurane-intra-abdominal-and-intrapelvic-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sevoflurane-middle-aged-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sg-i-tnbc-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sglt2-inhibitor-kidney-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/shenfu-injection-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/shenfu-injection-septic-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/shenfu-injection-septic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sheng-yu-tang-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/shenhuang-granule-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/shenlingcao-oral-liquid-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/shexiang-baoxin-pill-coronary-artery-disease-cad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/apl2-fsgs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/shr-a1921-injection-and-adebrelimab-injection-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sibp-a13-formulation-for-injection-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/silk-suture-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/simiaowan-gout-flare 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/simvastatin-hyperlipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sindillimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/single-agent-of-cyclophosphamide-doxorubicin-epi-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/single-dose-intravenous-injection-of-bbm-002-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/single-dose-of-2l-peg-health-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-anti-pd-1-antibody 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-approved-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-ibi310-chemotherapy-nsclc-stage-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-in-combination-with-multimodality-rad-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-injection-plus-inlyta-treatment-carcinoma-renal-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-lung-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-non-small-cell-lung-cancer-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintilimab-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sintiliman-plus-ldrt-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sipv-dtap-hepa-vaccination 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sirolimus-antiphospholipid-apl-positive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sirolimus-hemangioendothelioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sirolimus-kaposiform-hemangioendothelioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sirolimus-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sirolimus-plastic-bronchitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/siwu-tang-brain-hypoperfusion-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/six-courses-of-zanubrutinib-rituximab-and-lenali-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sodium-bicarbonate-ringer-s-injection-septic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sodium-valproate-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/solifenacin-succinate-overactive-bladder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/solifenacin-urinary-incontinence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/somatostatin-gallbladder-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/songling-xuemaikang-capsules-hypertension-essential 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sorafenib-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sox-chemotherapy-gastroesophageal-junction-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/spermidine-radiation-induced-xerostomia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/spleen-invigorating-and-weight-reducing-decoctio-traditional-chinese-medicine-treatment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/split-dose-of-4l-peg-health-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/split-virion-pandemic-influenza-vaccine-h5n1-str-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/spray-of-spirulina-derivatives-radiation-induced-oral-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ss-1-sj-gren-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ssris-snris-selective-serotonin-reuptake-inhibit-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/standard-first-line-therapy-unresectable-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/standard-of-care-imaging-psma-fdg-pet-ct-acp3-pe-prostate-cancer-diagnosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/standard-triple-region-helicobacter-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/start-antiplatelet-monotherapy-intracerebral-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/stereotactic-body-radiotherapy-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/stereotactic-body-radiotherapy-sbrt-hsct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/steroid-nasal-spray-radiation-induced-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/steroid-therapy-sudden-hearing-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/streptococcus-salivarius-k12-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/study-product-a-high-dose-2x-hyperuricemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/subconjunctival-dexamethasone-and-general-anesth-cataract 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/subxiphoid-uniportal-vats-lung-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/subxiphoid-uniportal-vats-mediastinal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/succinylcholine-the-effect-of-succinylcholine-on-barrier-pressur 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sunitinib-or-pazopanib-metastatic-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sunvozertinib-potentially-resectable-egfr-exon-20-insertion-no 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sup19-car-t-b-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/supportive-care-prednisone-minimal-change-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/surgery-combined-with-target-reduction-intensity-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/surgery-radiotherapy-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/surufatinib-biliary-tract-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/suzhou-sceneray-dbs-system-opiate-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/sys6055-relapsed-refractory-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/systematic-oral-health-education-malignant-tumor-of-head-and-or-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/t3011-malignant-ascites 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ta-nps-2-tumor-volume-locally-recurrent-retroperitoneal-soft-tissue-sa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-capsule-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-capsule-myasthenia-gravis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-capsules-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-liver-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-moderate-severe-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-mycophenolate-mofetil-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-ointment-tacrolimus-kaposiform-hemangioendothelioma-tufte 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tacrolimus-sustained-release-capsule-renal-transplant-recipients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tadalafil-pulmonary-arterial-hypertension-pah 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tafolecimab-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tamoxifen-breast-cancer-female 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tamsulosin-formulation-a-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tamsulosin-hydrochloride-benign-prostatic-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tang-min-lin-pill-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tangweian-recipe-diabetic-gastroenteropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/target-cd7-car-t-cells-t-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tavr-aortic-valve-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tcm-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tegafur-gimeracil-oteracil-potassium-capsule-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tegafur-gimeracil-oteracil-potassium-stomach-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/telbivudine-roadmap-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/telbivudine-treatment-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/telitacicept-connective-tissue-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/telmisartan-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tenecteplase-0-0938mg-kg-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tenecteplase-tnk-0-25-mg-kg-to-maximum-of-25mg-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/teniposide-administration-extensive-stage-small-cell-lung-cancer-es-sclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tenofovir-alafenamide-fumarate-25mg-oral-tablet-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tenofovir-disoproxil-fumarate-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tenofovir-lamivudine-lopinavir-ritonavir-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/teriflunomide-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/terlipressin-treatment-septic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/test-preparation-methylcholine-chloroacetate-for-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/test-preparation-methylcholine-chloroacetate-for-healthy-people 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tetrahydrobiopterin-radiation-enteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tetrahydrobiopterin-radiation-induced-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tgrx-326-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/th-sc01-umbilical-cord-mesenchymal-stem-cells-rectal-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/thalidomide-and-methotrexate-t-lgl-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/the-10mg-dose-group-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/the-absorbable-hemostat-and-suture-ovarian-cyst-benign 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/the-standard-3-7-regimen-newly-diagnosed-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/the-traditional-chinese-medicine-prescription-sh-diabetic-kidney-disease-dkd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/the-usage-of-olverembatinib-combined-with-inotuz-ph-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/thiotepa-hematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/thiscart19a-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/thiscart7-cells-t-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/thoracoscopic-bullectomy-surgery-stability-during-surgical-operation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/thymosin-alpha-1-pancreatitis-acute-necrotizing 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ticagrelor-and-aspirin-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ticagrelor-brain-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ticagrelor-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ticagrelor-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tirofiban-hydrochloride-sodium-chloride-injectio-branch-atheromatous-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tirofiban-in-pv-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-colonic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-combined-with-lenvatinib-initially-unresectable-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-esophageal-squamous-cell-carcinoma-escc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-gastric 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-locally-advanced-rectal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-neoadjuvant-head-and-neck-squamous-cell-carcinomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-rectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tislelizumab-thyroid-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tissue-plasminogen-activator-alteplase-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tnf-monoclonal-antibody-spinal-cord-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tnk-plus-standard-medical-treatment-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tntl-capsule-accidental-exposure-while-preparing-drug-for-adm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tofacitinib-and-acitretin-capsules-primary-cutaneous-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tofacitinib-tablets-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tolecizumab-pcsk9-inhibitor-colon-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tong-jiang-granules-non-erosive-reflux-disease-diarrheal-irritable-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/topical-application-of-periplaneta-americana-der-radiation-induced-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/topical-compound-tripterygium-active-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/topical-diclofenac-sodium-gel-hand-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/toripalimab-chemotherapy-thymic-epithelial-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/toripalimab-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/toripalimab-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/toripalimab-neoadjuvant-therapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/toripalimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/toripalimab-tracheal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/toripalimab-triple-negative-breast-cancer-tnbc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tpo-ra-primary-immune-thrombocytopenic-purpura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tpo-ras-primary-immune-thrombocytopenia-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tqb3616-capsules-combined-with-abiraterone-aceta-prostatic-neoplasms-castration-resistant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/traditional-chinese-medicine-prescription-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/traditional-chinese-medicine-treatment-frail-elderly-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tramadol-hip-fractures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tranexamic-acid-iatrogenic-endobronchial-bleeding 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tranexamic-acid-liver-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tranexamic-acid-txa-blood-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/transarterial-chemoembolization-unresectable-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/transcutaneous-auricular-vagus-nerve-stimulation-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/transesophageal-echocardiography-critically-ill 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/traumastem-liver-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/treatment-group-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/treatment-of-tongbi-capsule-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/treatment-with-caz-avi-patients-with-critically-ill-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/treatment-with-or-without-colistin-carbapenem-resistant-enterobacteriaceae-infectio 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/trichosanthes-root-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/trimetazidine-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/triple-combination-therapy-group-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/triplitode-aids-hiv-problem 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/triptergium-wilfordii-psoriasis-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/triptorelin-infertility-and-at-high-risk-of-ohss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/trolamine-biafine-radiation-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/tumor-specific-antigen-loaded-dendritic-cells-tumor-gastric 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ub-221-chronic-spontaneous-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ub-421-25-mg-kg-q2w-hiv-1-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ub-421-hiv-1-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ub-621-recurrent-genital-herpes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/uc-msc-transplantation-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/uc-mscs-2019-novel-coronavirus-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/uc-mscs-cirrhosis-due-to-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ucbmc-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ucd7-cart-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ucmsc-bronchopleural-fistula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ucmscs-bronchopulmonary-dysplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ulinastatin-and-thymosin-1-aortic-dissection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ulinastatin-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/umbilical-cord-mesenchymal-stem-cells-cartilage-damage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/umbilical-cord-mesenchymal-stem-cells-peripheral-arterial-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/umbilical-cord-mesenchymal-stem-cells-spinal-cord-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/umbilical-cord-mesenchymal-stem-cells-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/unfractionated-heparin-primary-pci 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/urapidil-stroke-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ursodeoxycholic-acid-combined-with-total-glucosi-hepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ursodeoxycholic-acid-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/utidelone-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ux-gip001-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vaccinated-with-sabin-ipv-polio 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/valerian-menopausal-women 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vancomycin-and-bowel-lavage-slow-transit-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vardenafil-erectile-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vasoconstrictor-and-oxytocin-treatment-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vats-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vebreltinib-potentially-resectable-met-altered-non-small-cel 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vemurafenib-oral-tablet-zelboraf-braf-v600e-mutated-mss-metastatic-colorectal-can 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/venetoclax-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/venetoclax-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/venetoclax-azacitidine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/venetoclax-flt3-gene-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ventoclax-aml-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/venues-p-valve-pulmonary-regurgitation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/verum-acupuncture-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vgb-r04-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vibecotecotamab-combined-with-putilimab-for-egfr-cancer-of-biliary-duct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/village-doctor-led-tailored-health-management-cardiovascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vincristine-precursor-cell-lymphoblastic-leukemia-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vincristine-sulfate-liposome-adult-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vitamin-a-retinopathy-of-prematurity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vitamin-a-vitamin-a-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vitamin-b6-restricted-diet-immunotherapy-solid-tumor-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/vitamin-c-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/voglibose-tablets-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/walnuts-30-grams-cardiovascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/wangbi-granules-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/warfarin-anticoagulation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/wei-li-bai-capsules-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/wen-xin-granule-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/wgc-0201-injection-hepatocellular-carcinoma-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/wpqw-granule-non-erosive-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/wsk-im05-4-10-10-vp-hpv-positive-oropharyngeal-squamous-cell-carcino 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/wumeiwan-jiawei-fang-dry-eye-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xiang-sha-liu-jun-zi-decoction-dry-powder-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xiang-sha-liu-jun-zi-tang-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xiangsha-liujunzi-granules-functional-dyspepsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xingnaojing-injection-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xuebi-formula-diabetic-peripheral-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xuebijing-injection-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xuesaitong-soft-capsule-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/xueshuanxinmaining-tablet-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yang-yin-fu-zheng-jie-du-therapy-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yi-qi-yang-yin-decoction-primary-sj-gren-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yigansan-tourette-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yin-and-yang-tonic-granules-osteopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yinhu-qingwen-granula-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yinhu-qingwen-granules-viral-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yinxingmihuan-oral-solution-chronic-stable-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yiqifang-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yishen-qutong-granules-esophageal-squamous-cell-carcinoma-escc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yishenshujin-decoction-fibromyalgia-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ym178-healthy-chinese-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ymn-a02-100-g-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/ymn101-malignant-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yts104-cells-injection-relapsed-or-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yts109-cell-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yts109-cell-injection-lupus-nephritis-ln 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yts109-cell-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/yts109-cell-systemic-lupus-erythematosus-sle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zanubrutinib-antiphospholipid-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zanubrutinib-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zanubrutinib-fludarabine-cyclophosphamide-and-ri-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zanubrutinib-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zanubrutinib-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zanubrutinib-refractory-relapsed-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zaunbrutinib-bendamustine-and-rituximab-for-indu-waldenstr-m-macroglobulinemia-wm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zhenqi-buxue-koufuye-menstrual-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zhenyuan-capsule-stable-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zoledronic-acid-congenital-dyserythropoietic-anemia-cda 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zs801-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zuberitamab-hsct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zushima-plaster-with-high-dose-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenetic-biosciences/projects/sodium-cridanimod-endometrial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xtl-biopharmaceuticals-ltd/projects/bicifadine-chronic-peripheral-neuropathy-pain-in-diabetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xtl-biopharmaceuticals-ltd/projects/bicifadine-diabetic-peripheral-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xtl-biopharmaceuticals-ltd/projects/xtl-2125-chronic-hepatitis-c-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xtl-biopharmaceuticals-ltd/projects/xtl-6865-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/0-9-nacl-2000ml-brain-infarct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/a-single-step-culture-medium-icsi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/accelerated-partial-breast-irradiation-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/amorphous-calcium-carbonate-calcium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/amorphous-calcium-carbonate-placebo-calcium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/amoxicillin-human-gut-microbiota 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/aromatase-inhibitor-litrezole-plus-ufsh-arm-polycystic-ovary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/autologous-cd5-car-t-cells-t-cell-acute-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/autologous-cd7-car-t-cell-t-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/autologous-fl-33-car-t-therapy-refractory-relapsed-acute-myeloid-leukaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/baidi-quzhi-granule-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/bilateral-permanent-occlusion-of-uterine-arterie-other-abnormal-uterine-and-vaginal-bleeding 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/blood-glucose-meter-systems-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/cd19-car-t-cell-b-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/chinese-herbal-concoction-twice-a-day-for-6-mont-myelodysplastic-syndrome-mds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/cyproterone-acetate-ethinylestradiol-cpa-ee-polycystic-ovarian-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/dengzhan-shengmai-capsule-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/donepezil-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/donepezil-total-knee-arthroplasty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/ear-pills-intradialytic-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/eicosapentaenoic-acid-monoglycerid-mag-epa-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/escitalopram-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/estradiol-plus-progesterone-100-mg-im-injection-ivf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/etn-alone-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/experimental-group-bushen-culuan-decoction-and-c-anovulatory-infertility 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/ext608-safety-issues 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/external-chinese-medicine-diabetic-foot 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/formoterol-fumarate-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/furoic-acid-loperamide-hydrochloride-cream-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/g-pen-insulin-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/galantamine-acute-ischemic-stroke-ais 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/ginkgo-diterpene-lactone-meglumine-injection-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/ginkgo-diterpene-lactone-meglumine-injection-ischemic-stroke-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/glucagon-hypoglycemia-unawareness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/goserelin-3-6-mg-implant-postpartum-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/guben-kechuan-granules-group-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/high-fiber-diet-intervention-dietary-fiber 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/home-based-food-malnutrition-child 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/hou-gu-mi-xi-gastrointestinal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/huafu-shengji-ointment-diabetic-foot 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/huoluo-pills-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/huzhang-granule-gouty-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/improved-warm-meridians-and-relieve-pain-plaster-pelvic-inflammatory-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/infliximab-increased-frequency-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/infliximab-methotrexate-ifx-mtx-arthritis-psoriatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/infliximab-remicade-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/intensive-medical-therapy-myocardial-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/ixekizumab-jueyin-granules-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/juanbi-pill-juanbi-pill 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/jueyin-granules-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/methotrexate-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/methylprednisolone-injectable-form-unruptured-intracranial-aneurysms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/modified-ma-xing-shi-gan-decoction-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/mometasone-furoate-nasal-spray-mfns-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/mometasone-rhinitis-allergic-seasonal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/niubangzi-pill-or-niubangzi-pill-placebo-niu-bang-zi-pill 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/oxaliplatin-previously-treated-metastatic-non-small-cell-lun 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/peg-interferon-a-2b-ribavirin-chronic-hepatitis-c-infection-in-hiv-infected-pe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/peg-interferon-alpha-2b-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/peginterferon-alfa-2b-sch-54031-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/pegintron-peginterferon-alfa-2b-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/peiyuan-guben-tongluo-ointment-ejiao-concentrate-sarcopenia-in-elderly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/personalized-functional-profiling-oncology 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/physiotherapeutic-treatment-morquio-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/picosulfate-sodium-magnesium-oxide-citric-acid-bowel-preparation-before-colonoscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/placebo-gelatin-pill-vaginosis-bacterial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/placebo-postprandial-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/placebo-purpura-schoenlein-henoch 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/point-of-care-testing-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/preoperative-three-dimensional-reconstruction-kidney-neoplasms-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/prepackaged-low-residue-diet-bowel-preparation-solution 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/progesterone-100-im-day-progesterone-luteal-support-in-icsi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/propranolol-bleomycin-infantile-hemangioma-ih 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/qing-e-pills-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/rabeprazole-peptic-ulcer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/sevoflurane-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/shenling-baizhu-granules-tcm-patent-medicine-low-risk-colorectal-adenoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/step-up-hp-u-fsh-polycystic-ovary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/surgery-and-hipec-with-lobaplatin-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/taodan-granules-psoriasis-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/temozolomide-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/tiotropium-respimat-5-mcg-chronic-obstructive-airway-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/tirofiban-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/tongjiang-granule-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/triamcinolone-acetonide-acetate-and-urea-cream-psoriasis-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/western-medicine-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/xingnaojing-injection-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/integrated-biopharma-inc/projects/yiqi-wenyang-sanhan-formula-combined-with-acupoi-allergic-rhinitis-with-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/20-mg-kg-tru-016-rituximab-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/alg-apv-527-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/apvo210-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/apvo436-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/apvo436-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/es414-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/tru-016-and-bendamustine-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/tru-016-anti-cd37-protein-therapeutic-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptevo-therapeutics/projects/tru-016-b-cell-small-lymphocytic-lymphoma-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-101-darinaparsin-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/ad-rts-hil-12-and-veledimex-breast-cancer-nos-metastatic-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/ad-rts-hil-12-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/ad-rts-hil-12-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/ad-rts-hil-12-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/ad-rts-hil-12-pediatric-brain-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/carboplatin-extensive-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/darinaparsin-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/darinaparsin-hematologic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/darinaparsin-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/darinaparsin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/darinaparson-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/doxorubicin-in-combination-with-palifosfamide-tr-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/il-2-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/indibulin-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/indibulin-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/indibulin-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/indibulin-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/neoantigen-specific-tcr-t-cell-drug-product-gynecologic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/oral-palifosfamide-tris-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/palifosfamide-adult-central-nervous-system-germ-cell-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/palifosfamide-tris-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/palifosfamide-tris-and-doxorubicin-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/palifosfamide-tris-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-101-c-darinaparsin-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-101-c-darinaparsin-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-101-darinaparsin-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-101-darinaparsin-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-101-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-201-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-201-advanced-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alaunos-therapeutics/projects/zio-201-t-and-doxorubicin-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/transcode-therapeutics/projects/ttx-mc138-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/transcode-therapeutics/projects/ttx-mc138-nodaga-cu64-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inmed-pharmaceuticals/projects/inm-755-cannabinol-cream-epidermolysis-bullosa-simplex 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/reviva-pharmaceuticals-holdings-inc/projects/brilaroxazine-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/reviva-pharmaceuticals-holdings-inc/projects/lipoaspiration-hereditary-corneal-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dermata-therapeutics/projects/dmt210-topical-gel-5-acne-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dermata-therapeutics/projects/dmt210-topical-gel-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dermata-therapeutics/projects/dmt310-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dermata-therapeutics/projects/topical-powder-acne-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adial-pharmaceuticals-inc/projects/erythromycin-lactobionate-diabetes-mellitus-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adial-pharmaceuticals-inc/projects/nizatidine-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adial-pharmaceuticals-inc/projects/trametinib-gsk1120212-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/abc294640-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/bekinda-irritable-bowel-syndrome-with-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/opaganib-coronavirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/opaganib-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/part-a-upamostat-200-mg-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rhb-102-gastroenteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rhb-104-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/purple-biotech-ltd/projects/nt219-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rhb-104-fixed-dose-combination-95-mg-clarithromy-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rhb-104-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rhb-105-dyspepsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rhb-105-helicobacter-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rhb-204-pulmonary-mycobacterium-avium-complex-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/rifamycin-sv-mmx-traveler-s-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/redhill-biopharma/projects/upamostat-sars-cov-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/purple-biotech-ltd/projects/cm-24-and-nivolumab-dose-escalation-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/purple-biotech-ltd/projects/nt219-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/apto-253-acute-myelogenous-leukemia-in-relapse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/cg-806-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/cg-806-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/gti-2040-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/gti-2040-carcinoma-renal-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/lor-253-hcl-advanced-or-metastatic-solid-tumours 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/tuspetinib-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aptose-biosciences/projects/virulizin-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/coversin-paroxysmal-nocturnal-haemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/coversin-paroxysmal-nocturnal-hemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/mrx-6-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/nomacopan-rva576-bullous-pemphigoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/nomacopan-rva576-thrombotic-microangiopathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/rva576-bullous-pemphigoid-bp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/rva576-keratoconjunctivitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/rva576-paroxysmal-nocturnal-hemoglobinuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/akari-therapeutics-plc/projects/rva576-paroxysmal-nocturnal-hemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revelation-biosciences-inc/projects/intravenous-gemini-renal-insufficiency-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eloxx-pharmaceuticals/projects/elx-02-alport-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eloxx-pharmaceuticals/projects/elx-02-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eloxx-pharmaceuticals/projects/elx-02-genetic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eloxx-pharmaceuticals/projects/elx-02-genetic-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eloxx-pharmaceuticals/projects/elx-02-impaired-renal-function 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eloxx-pharmaceuticals/projects/exaluren-alport-syndrome-x-linked 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eloxx-pharmaceuticals/projects/placebo-genetic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/480-mg-piperaquine-phosphate-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/administration-of-the-malaria-inoculum-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/alpn-101-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/berubicin-glioblastoma-multiforme-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/ctx-4430-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/dab-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/dsm265-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/estradiol-estriol-progesterone-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/intravenous-vitamin-c-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/mmv390048-40-mg-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/mmv390048-40mg-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/oz439-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/paclitaxel-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/pra-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/rtms-repetitive-transcranial-magnetic-stimulatio-obsessive-compulsive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/sertraline-antibiotic-penicillin-azithromycin-pandas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/609a-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/sj000557733-plasmodium-falciparum-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/spr206-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/transcranial-magnetic-stimulation-gambling-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cns-pharmaceuticals/projects/vitamin-c-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/amphotericin-b-candidiasis-chronic-mucocutaneous 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/drug-omega-3-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/encochleated-amphotericin-b-cryptococcal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/mat2203-cryptococcal-meningitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/omega-3-pentaenoic-acid-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/oral-encochleated-amphotericin-b-camb-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/oral-encochleated-amphotericin-b-camb-vulvovaginal-candidiases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/oral-encochleated-amphotericin-b-camb-vulvovaginitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/matinas-biopharma-holdings/projects/placebo-severe-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/amilo-5mer-inflammatory-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-free-acid-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-free-acid-tablet-600mg-single-dose-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-gallstones 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-meglumine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-meglumine-primary-sclerosing-cholangitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/aramchol-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/610-100mg-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/galmed-pharmaceuticals/projects/mfolfox6-bibf-1120-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/60-degrees-pharmaceuticals-inc/projects/celgosivir-dengue-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/60-degrees-pharmaceuticals-inc/projects/tafenoquine-100mg-chronic-babesiosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/60-degrees-pharmaceuticals-inc/projects/tafenoquine-babesiosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/60-degrees-pharmaceuticals-inc/projects/tafenoquine-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/60-degrees-pharmaceuticals-inc/projects/tafenoquine-oral-tablet-covid-19-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/shuttle-pharmaceuticals-holdings/projects/ropidoxuridine-glioblastoma-idh-wildtype 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ensysce-biosciences/projects/pf614-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ensysce-biosciences/projects/pf614-capsule-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ensysce-biosciences/projects/pf614-capsule-postoperative-pain-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ensysce-biosciences/projects/pf614-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ensysce-biosciences/projects/pf614-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ensysce-biosciences/projects/pf614-recreational-drug-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/clearmind-medicine/projects/cmnd-100-alcohol-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hepion-pharmaceuticals/projects/14c-rencofilstat-225mg-nash-with-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hepion-pharmaceuticals/projects/crv431-75mg-nash-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hepion-pharmaceuticals/projects/crv431-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hepion-pharmaceuticals/projects/rencofilstat-75-mg-nash-with-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hepion-pharmaceuticals/projects/rencofilstat-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/2-methoxyestradiol-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/cid-103-chronic-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/cid-103-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/enmd-2076-advanced-adult-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/enmd-2076-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/enmd-2076-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/enmd-2076-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/enmd-2076-relapsed-or-refractory-hematological-malignancie 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/enmd-2076-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/melphalan-hydrochloride-for-injection-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/mkc-1-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/mkc-1-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/mkc-1-hematological-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/mkc-1-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/mkc-1-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/panzem-2-methoxyestradiol-ncd-avastin-bevacizuma-carcinoid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/panzem-nanocrystal-colloidal-dispersion-ncd-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/panzem-nanocrystal-colloidal-dispersion-recurrent-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/panzem-ncd-metastatic-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/panzem-ncd-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/panzem-ncd-recurrent-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/casi-pharmaceuticals/projects/recombinant-human-angiostatin-protein-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biodexa-pharmaceuticals-plc/projects/encapsulated-rapamycin-erapa-familial-adenomatous-polyposis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biodexa-pharmaceuticals-plc/projects/erapa-encapsulated-rapamycin-familial-adenomatous-polyposis-fap 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biodexa-pharmaceuticals-plc/projects/mtx110-recurrent-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/1-clascoterone-cream-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14028-injection-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14c-antaitavir-hasophate-healthy-male-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14c-clifutinib-healthy-adult-male 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14c-hec585-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14c-larotinib-healthy-adult-male-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14c-rongliflozin-healthy-adult-male-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14c-sss17-healthy-subjects-hs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/14c-yiqibuvir-healthy-male-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/304-injection-cd20-positive-b-cell-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/5-minoxidil-foam-androgenetic-alopecia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/601-1-25mg-branch-retinal-vein-occlusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/601-1-25mg-central-retinal-vein-occlusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/601-pathological-myopic-choroidal-neovascularization 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/608-axial-spondyloarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/608-axial-spondyloarthritis-non-radiographic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/608-dose-a-ankylosing-spondylitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/608-dose-ankylosing-spondylitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/608-moderate-to-severe-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/608-q2w-plaque-psoriasis-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/608-q2w-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/609a-sarcoma-soft-tissue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/610-30mg-group-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/610-add-on-maintenance-treatment-of-patients-with-se 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/610-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/611-150mg-dermatitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/611-300-mg-q2w-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/611-dermatitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/611-pulmonary-disease-chronic-obstructive-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/611-q2w-dermatitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/611-sinusitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/626-healthy-subjects-hs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/626-systemic-lupus-erythematosus-sle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/627-healthy-subjects-hs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/627-ulcerative-colitis-uc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ceftolozane-tazobactam-bronchiectasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/clascoterone-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/clascoterone-cream-1-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/clifutinib-besylate-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/clifutinib-besylate-acute-myeloid-leukemia-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/clifutinib-healthy-adult-subject 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/clifutinib-leukemia-acute-myeloid-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/clifutinib-with-fed-state-acute-myeloid-leukemia-in-children 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/cpgj602-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ct053ptsa-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ct053ptsa-advanced-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ct053ptsa-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ct053ptsa-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ct053ptsa-renal-cell-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/drug-601-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/drug-601-wet-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/epiao-renal-anaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/eprex-renal-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/etanercept-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/experimental-cognitive-health 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec30654acoh-capsule-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/freethiadine-tablets-part-i-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/gls4-chronic-hbv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/gls4-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hbt-708-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec-007-injection-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec-151-injection-healthy-adult-male 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec-68498-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec110114-tablet-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec113995-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec113995-pa-h2o-tablets-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec113995pa-h2o-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec116094-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec121120-tablets-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec122505msoh-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec169096-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec169584-capsule-non-alcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec53856-chronic-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec53856-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec53856-hemodialysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec585-dose-a-progressive-fibrosing-interstitial-lung-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec585-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec585-idiopathic-pulmonary-fibrosis-ipf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec68498-advanced-refractory-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec73077-tablets-diabetic-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec74647pa-capsule-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec74647pa-hec110114-chronic-hcv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec83518-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec83518-tablets-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec89736-relapsed-or-refractory-b-cell-hematologic-malign 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec93077-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec96719-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec96719-non-alcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec96719-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/hec96719-tablets-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/human-erythropoiesis-injection-cho-cell-kidney-failure-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/humanized-tnf-monoclonal-antibody-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/injection-of-humanized-nerve-growth-factor-ngf-a-cancer-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/insulin-degludec-and-insulin-aspart-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/insulin-degludec-injection-rd15003-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/kangdaprevir-sodium-tablet-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/kn046-pd-l1-ctla4-bsab-advanced-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/larotinib-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/larotinib-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/lerotinib-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/liraglutide-injection-rd12014-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/litapiprant-tablet-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/midazolam-syrup-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-707-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/mingo-x-linked-dystonia-parkinsonism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/mitizodone-phosphate-tablets-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/nalfurafine-hydrochloride-uremic-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/new-formulations-of-611-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/pegylated-recombinant-candida-urate-oxidase-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/pegylated-recombinant-candida-utilis-uricase-for-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/power-line-program-metabolic-health 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/prefilled-liquid-etanercept-yisaipu-ankylosing-spondylitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/program-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/pyroglutamate-rongliflozin-capsules-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/pyroglutamate-rongliflozin-capsules-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-anti-il-1-humanized-monoclonal-antib-acute-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-anti-il-1-humanized-monoclonal-antib-gout-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-anti-il-17a-humanized-monoclonal-ant-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-anti-interleukin-4-receptor-alpha-mo-dermatitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-anti-pd-1-humanized-monoclonal-antib-sarcoma-soft-tissue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-erythropoietin-stimulating-protein-chronic-renal-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-human-erythropoiesis-injection-cho-c-chronic-renal-failure-with-hemodialysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-human-thrombopoietin-injection-liver-disease-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/recombinant-human-thrombopoietin-liver-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/redefine-obesity-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/rhtpo-previously-treated-primary-immune-thrombocytopen 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/rhtpo-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/rongliflozin-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sof-chronic-hcv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/spgl008-advanced-malignant-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/spgl008-nmibc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-612-advanced-malignant-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-613-arthritis-gouty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-613-systemic-juvenile-idiopathic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-705-locally-advanced-recurrent-or-metastatic-maligna 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-705-receptor-erbb-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-706-advanced-solid-tumors-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-706-first-line-advanced-nsclc-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-706-xelox-gastric-gastroesophageal-junction-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-707-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-707-advanced-recurrent-endometrial-cancer-and-platin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-707-first-line-advanced-nsclc-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-707-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/ssgj-709-advanced-malignant-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss06-chemotherapy-induced-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss17-anemia-in-chronic-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss17-anemia-in-pre-dialysis-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss17-capsule-6-dose-levels-postoperative-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss17-healthy-subjects-hs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss39-safety-and-tolerability-in-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss59-malignant-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sulforaphane-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/tpo-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/yimitasvir-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/yimitasvir-phosphate-capsule-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/yimitasvir-phosphate-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/z650-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/z650-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/universe-pharmaceuticals-inc/projects/olive-oil-severe-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zyversa-therapeutics/projects/2hp-cd-diabetic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/evofem-biosciences/projects/conceptrol-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/evofem-biosciences/projects/evo100-chlamydia-trachomatis-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/evofem-biosciences/projects/evo100-sexually-transmitted-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/evofem-biosciences/projects/lipo-202-central-abdominal-bulging 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avenue-therapeutics-inc/projects/artemether-lumefantrine-plasmodium-falciparum-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avenue-therapeutics-inc/projects/pyridoxal-5-phosphate-supplement-neural-inhibition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avenue-therapeutics-inc/projects/tramadol-pain-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lipella-pharmaceuticals-inc/projects/ferumoxytol-ic-interstitial-cystitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lipella-pharmaceuticals-inc/projects/lp-08-80mg-interstitial-cystitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lipella-pharmaceuticals-inc/projects/lp-10-hemorrhagic-cystitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lipella-pharmaceuticals-inc/projects/lp-10-liposomal-tacrolimus-oral-lichen-planus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/a-1-lucinactant-acute-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/aerosolized-lucinactant-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/istaroxime-cardiogenic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-175-mg-kg-respiratory-distress-syndrome-newborn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-acute-hypoxemic-respiratory-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-delivered-via-investigational-delive-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-first-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-for-inhalation-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-for-inhalation-respiratory-distress-syndrome-newborn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/lucinactant-meconium-aspiration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/placebo-acute-decompensated-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/windtree-therapeutics-inc-de/projects/th1902-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/petros-pharmaceuticals/projects/colostrum-supplementation-for-bone-loss-osteopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/petros-pharmaceuticals/projects/neutral-environment-with-radiation-heat-stress 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/petros-pharmaceuticals/projects/thermal-stress-and-performance-without-a-pre-coo-risk-of-heat-stress 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/io102-io103-in-combination-with-pembrolizumab-lung-cancer-non-small-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/io102-io103-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/irx4204-lung-cancer-nonsmall-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/irx4204-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/irx4204-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/irx5183-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/nrx-194204-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/pd-l1-ido-peptide-vaccine-high-risk-non-muscle-invasive-bladder-urothelial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/pd-l1-pd-l2-peptides-with-montanide-isa51-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/pd-l1-peptide-smoldering-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/pembrolizumab-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/autologous-bone-marrow-derived-mononuclear-cells-congenital-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/autologous-cell-based-delivery-hypoplastic-left-heart-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/autologous-mononuclear-cells-congenital-heart-disease-srv-dependent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/autologous-self-mononuclear-cells-derived-from-u-hypoplastic-left-heart-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/cellular-matrix-a-cp-ha-kit-genitourinary-syndrome-of-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/extracellular-vesicles-from-mesenchymal-stem-cel-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/hyaluronic-acid-platelet-rich-plasma-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/msc-derived-exosomes-long-covid-19-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/placebo-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regen-biopharma-inc/projects/regen-matrix-prp-xlha-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edesa-biotech/projects/cohort-a-vilobelimab-acute-respiratory-distress-syndrome-ards 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edesa-biotech/projects/cohort-b-paridiprubart-acute-respiratory-distress-syndrome-ards 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edesa-biotech/projects/cohort-c-bevacizumab-acute-respiratory-distress-syndrome-ards 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edesa-biotech/projects/eb01-cream-placebo-allergic-contact-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edesa-biotech/projects/soc-plus-15mg-kg-eb05-iv-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/100u-ev71-vaccine-with-adjuvant-infection-viral-enterovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/100u-inactivated-enterovirus-type-71-vaccine-hand-foot-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/2-doses-of-hav-hepatitis-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/2012-2013-trivalent-seasonal-influenza-vaccine-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/2wipv-1sipv-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/36-71-months-old-children-experimental-ev71-vacc-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/400-u-ev71-vaccine-with-adjuvant-infection-viral-enterovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/400u-0-5ml-ev71-vaccine-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/5000-volunteers-6-35-months-ev71-vaccine-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/adsorbed-covid-19-inactivated-vaccine-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/adult-group-in-immunogenicity-and-safety-study-o-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/an-inactivated-whole-virion-h5n1-vaccine-adjuvan-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/bivalent-enterovirus-vaccine-vero-cell-inactivat-hand-foot-and-mouth-disease-hfmd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/combined-vaccination-with-quadrivalent-influenza-influenza-and-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/concomitant-administration-of-ev71-vaccine-with-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/concomitant-administration-of-ev71vaccine-with-e-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/covid-19-vaccine-inactivated-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/covid-19-vaccine-vero-cell-inactivated-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/covid-19-vaccine-vero-cell-inactivated-medium-do-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/covid-19-vaccine-vero-cell-inactivated-omicron-s-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/covid-19-vaccine-vero-cell-inactivated-omicron-v-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/ev71-inactived-vaccine-vero-cells-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/ev71-vaccine-ev71-vaccine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/ev71-vaccine-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/experimental-23-valent-pneumococcal-pneumococcal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/experimental-23-valent-ppv-pneumococcal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/experimental-group-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/experimental-vaccine-1-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/experimental-vaccine-epidemic-meningitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/experimental-vaccine-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/experimental-vaccine-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/h1n1-influenza-a-vaccine-panflu-1-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/h1n1-influenza-a-vaccine-split-virion-inactivate-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/healive-healive-hepatitis-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/healive-hepatitis-a-vacine-human-diploid-cell-in-hepatitis-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/healive-lot-1-hepatitis-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/high-dosage-of-covid-19-vaccine-vero-cell-inacti-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/high-dosage-sars-cov-2-vaccine-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/high-dose-group-acyw135x-meningococcal-conjugate-meningococcal-meningitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/inactivated-enterovirus-type-71-vaccine-infection-viral-enterovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/inactivated-hav-vaccine-hepatitis-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/inactivated-hepatitis-a-vaccine-hav-hepatitis-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/inactivated-sars-cov-2-vaccine-vero-cell-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/inactivated-sars-cov-2-vaccine-vero-cell-lot-1-o-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/influenza-vaccine-split-virion-inactivated-quadr-seasonal-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/investigational-13-valent-pneumococcal-polysacch-pneumococcal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/investigational-23-valent-ppv-pneumococcal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/investigational-live-attenuated-mumps-vaccine-mumps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/investigational-live-attenuated-varicella-vaccin-varicella 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/investigational-sipv-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/investigational-tetanus-vaccine-adsorbed-tetanus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/live-attenuated-varicella-vaccine-varicella 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/live-attenuated-varicella-vaccines-manufactured-varicella 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/low-dose-bivalent-enterovirus-vaccine-vero-cell-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/low-dose-experimental-vaccine-herpes-zoster 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/low-dose-of-tetravalent-inactivated-enterovirus-hand-foot-and-mouth-disease-hfmd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/low-dose-rsv-mrna-vaccine-rsv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/medium-dosage-covid-19-vaccine-inactivated-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/medium-dose-covid-19-vaccine-vero-cell-inactivat-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/mumps-vaccine-live-mv-mumps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/mumps-vaccine-mumps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/one-dose-of-investigational-vaccine-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/oral-hexavalent-reassortant-rotavirus-attenuated-rotavirus-gastroenteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/pandemic-influenza-a-h1n1-vaccine-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/pandemic-influenza-vaccine-h5n1-strain-nibrg-14-pandemic-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/pandemic-influenza-vaccine-h5n1-strain-nibrg-14-pandemic-influenza-vaccine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/participants-will-receive-one-dose-of-vaccine-0-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/provarix-varicella-chickenpox 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/quadrivalent-influenza-vaccine-0-25ml-seasonal-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/quadrivalent-influenza-vaccine-seasonal-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/quadrivalent-influenza-vaccine-split-virion-inac-seasonal-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/rabies-vaccine-rabies-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/rabies-vaccine-serum-free-vero-cell-freeze-dried-rabies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sa55-injection-infection-of-upper-respiratory-tract-caused-by-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sa55-nasal-spray-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sa58-nasal-spray-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sabin-strain-inactivated-poliovirus-vaccine-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sars-cov-2-inactivated-vaccine-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sars-cov-2-inactivated-vaccine-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sars-cov-2-vaccine-inactivated-sars-cov2-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/seasonal-split-influenza-vaccine-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/single-dose-regimen-of-high-dosage-investigation-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sinovac-low-dosage-pcv24-pneumococcal-infectious-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sinovac-pcv13-pneumococcal-infectious-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sinovac-pcv24-formulation-1-pneumococcal-infectious-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sinovac-pcv24-pneumococcal-infectious-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sinovac-rabies-vaccine-rabies-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sipv-bopv-bopv-vaccination-schedule-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sipv-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sipv-sipv-bopv-vaccination-schedule-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sipv-vaccine-dtap-vaccine-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/sna02-48-tetanus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/split-virion-adjuvanted-h1n1-vaccine-of-7-5-g-pe-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/tetravalent-influenza-vaccine-developed-by-sinov-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/the-live-attenuated-varicella-vaccine-and-the-in-varicella 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/three-consecutive-lots-of-ev71-vaccine-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/three-doses-of-experimental-sipv-of-lot-1-at-the-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/three-doses-of-low-dosage-investigational-sipv-v-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/trivalent-covid-19-vaccine-vero-cell-inactivated-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/trivalent-seasonal-influenza-vaccine-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/two-doses-of-commercial-scale-inactivated-sars-c-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/two-doses-of-inactivated-sars-cov-2-vaccine-at-t-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/two-doses-of-low-dosage-inactivated-sars-cov-2-v-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/two-doses-of-medium-dosage-inactivated-sars-cov-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/two-doses-of-quadrivalent-influenza-vaccine-seasonal-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/vaccine-manufactured-at-commercialized-scale-varicella 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/vaicella-vaccine-dtap-on-day-0-mmr-on-day-30-varicella-chickenpox 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/varicella-vaccine-tiv-varicella 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/varicella-vaccine-varicella 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/varicella-vaccine-varicella-chickenpox 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sinovac-biotech-ltd/projects/varicella-vaccine-vzv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/apl-2-geographic-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/apl-2-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/apl-2-pegcetacoplan-geographic-atrophy-secondary-to-age-related-macu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/apl-2-warm-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/apl-3007-pegcetacoplan-apl-2-geographic-atrophy-secondary-to-age-related-macu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/apl-9-covid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-apl-2-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-apl-2-geographic-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-apl-2-geographic-atrophy-secondary-to-age-related-macu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-delayed-graft-function 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-geographic-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-paroxysmal-nocturnal-hemoglobinuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-paroxysmal-nocturnal-hemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/pegcetacoplan-transplant-associated-thrombotic-microangiopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apellis-pharmaceuticals/projects/virtual-reality-vr-contrast-function-test-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/soleno-therapeutics-inc/projects/dccr-diazoxide-choline-extended-release-tablets-sh2b1-deficiency-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/soleno-therapeutics-inc/projects/dccr-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/medicenna-therapeutics/projects/mdna11-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/medicenna-therapeutics/projects/mdna55-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/anebulo-pharmaceuticals/projects/aneb-001-acute-cannabinoid-intoxication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/anebulo-pharmaceuticals/projects/selonabant-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/anti-sema4d-monoclonal-antibody-vx15-2503-colon-carcinoma-metastatic-in-the-liver 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/anti-sema4d-monoclonal-antibody-vx15-2503-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/avelumab-and-pepinemab-metastatic-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/dendritic-cell-dc1-vaccine-her2-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/ipilimumab-pathologic-stage-iiib-cutaneous-melanoma-ajcc-v8 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/pepinemab-pembrolizumab-recurrent-metastatic-squamous-cell-carcinoma-of 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/vx15-2503-avelumab-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/vx15-2503-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/vx15-2503-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/vx15-2503-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vaccinex-inc/projects/vx15-2503-squamous-cell-carcinoma-of-the-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axim-biotechnologies-inc/projects/chewing-gum-thc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/carisma-therapeutics/projects/ct-0508-her2-positive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/carisma-therapeutics/projects/ct-0525-her2-positive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/sulopenem-urinary-tract-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/azithromycin-plus-hydroxychloroquine-respiratory-tract-infection-viral 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/finch-therapeutics-group/projects/cp101-clostridium-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/ciprofloxacin-uti-lower-urinary-tract-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/ertapenem-intra-abdominal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/sulopenem-complicated-urinary-tract-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/sulopenem-etzadroxil-and-probenecid-pharmacokinetics-after-oral-intake 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/sulopenem-etzadroxil-probenecid-uncomplicated-urinary-tract-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iterum-therapeutics-plc/projects/sulopenem-etzadroxil-probenecid-urinary-tract-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/finch-therapeutics-group/projects/cp101-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/finch-therapeutics-group/projects/cp101-recurrent-c-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/finch-therapeutics-group/projects/fecal-microbiota-transplantation-enterobacteriaceae-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/finch-therapeutics-group/projects/full-spectrum-microbiota-clostridium-difficile-infection-recurrence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/blinatumomab-adult-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/abeona-therapeutics-inc/projects/abo-102-mps-iiia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/4d-molecular-therapeutics/projects/4d-110-choroideremia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/4d-molecular-therapeutics/projects/4d-125-ivt-injection-x-linked-retinitis-pigmentosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tg-1801-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/actuate-therapeutics-inc/projects/9-ing-41-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/abvc-biopharma-inc/projects/pdc-1421-capsule-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/vats-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aeon-biopharma/projects/use-of-mitomycin-c-mmc-in-trabeculectomy-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adial-pharmaceuticals-inc/projects/ad04-ondansetron-alcohol-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adial-pharmaceuticals-inc/projects/axitinib-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/14c-vx-993-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/alpn-101-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/als-002158-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/soy-protein-photoaging 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/tpm-xr-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-262-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx4211-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/study-agent-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/precision-biosciences-inc/projects/anti-cd19-car-nk-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inovio-pharmaceuticals-inc/projects/v930-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lisata-therapeutics-inc/projects/clbs119-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5093-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/hpv-t-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5381-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn846-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/oxygen-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn846-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/advate-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/zs802-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/adynovate-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sunshine-biopharma/projects/sss11-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/io-biotech/projects/io102-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/als-002200-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/avn-944-capsules-for-oral-administration-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/avn944-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/avn944-refractory-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/biological-vaccine-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/biricodar-dicitrate-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/cethrin-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ctx001-beta-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ixp-focal-segmental-glomerulosclerosis-fsgs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/exa-cel-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/inaxaplin-proteinuric-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/iva-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ivacaftor-150-mg-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ivacaftor-25-mg-75-mg-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ivacaftor-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ivacaftor-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ixp-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/lum-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/lum-iva-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/lumacaftor-200-mg-q12h-ivacaftor-250-mg-q12h-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/lumacaftor-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/lumacaftor-plus-ivacaftor-combination-cystic-fibrosis-homozygous-for-the-f508del-cftr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/lumacaftor-plus-ivacaftor-combination-cystic-fibrosis-homozygous-or-heterozygous-for-t 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/merimepodib-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/mp-424-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/mp-424-h-peg-ifn-a-2b-rbv-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/mp-424-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/mp-424-telaprevir-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/mp-424-telaprevir-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/p-1037-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/peginterferon-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/pegylated-interferon-alfa-2a-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/pegylated-interferon-alfa-2a-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/placebo-cystic-fibrosis-homozygous-for-the-f508del-cftr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/placebo-matched-to-vx-121-suspension-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/placebo-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-150-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/placebo-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/povetacicept-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/povetacicept-myasthenia-gravis-generalized 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/povetacicept-primary-membranous-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/prednisone-drug-interactions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ribavirin-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/ribavirin-genotype-1-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/standard-ogtt-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suz-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suz-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suzetrigine-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suzetrigine-diabetic-peripheral-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vch-916-hcv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suzetrigine-diabetic-peripheral-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suzetrigine-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suzetrigine-pain-acute-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/suzetrigine-suz-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-and-sofosbuvir-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-chronic-hepatitis-c-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-formulation-a-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-moxifloxacin-placebo-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-or-matching-placebo-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/telaprevir-vx-950-hepatic-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/tez-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/tez-iva-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/tezacaftor-ivacaftor-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/tezacaftor-ivacaftor-ivacaftor-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/treatment-sequence-ab-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vanzacaftor-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vc-02-combination-product-type-1-diabetes-mellitus-with-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vch-222-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vch-222-or-matching-placebo-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vch-759-bch-27759-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vnz-tez-d-iva-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-118-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tachosil-group-lymphocele 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-121-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-147-focal-segmental-glomerulosclerosis-fsgs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-147-glomerulosclerosis-focal-segmental 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-147-proteinuric-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-150-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-150-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-150-small-fiber-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-152-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-210-cervical-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-222-chronic-hepatitis-c-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-264-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-272-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-371-hs-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-371-primary-ciliary-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-548-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-407-autosomal-dominant-polycystic-kidney-disease-adp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-433-narcolepsy-type-1-nt1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-440-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-445-tez-iva-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-509-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-509-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/china-sxt-pharmaceuticals/projects/chidamide-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-522-mrna-therapy-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-548-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-548-painful-lumbosacral-radiculopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-561-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-581-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-634-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-659-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-708-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-659-tez-iva-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-661-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-661-ivacaftor-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-661-plus-ivacaftor-combination-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-668-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-670-myotonic-dystrophy-type-1-dm1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-702-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-708-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-765-part-a-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-765-partial-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-765-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-770-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-770-in-development-for-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-787-influenza-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-809-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-814-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-828-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-840-apol1-mediated-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-864-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-864-alpha1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-880-diabetes-mellitus-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-950-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-973-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-985-or-matching-placebo-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-993-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-993-diabetic-peripheral-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vertex-pharmaceuticals-inc-ma/projects/vx-993-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/2-0-mg-intravitreal-aflibercept-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tachosil-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/2-mg-intravitreous-aflibercept-injection-proliferative-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/8-mg-aflibercept-bay-86-5321-high-dose-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/89zr-dfo-regn3504-advanced-pd-l1-positive-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/89zr-dfo-regn5054-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-2-0-mg-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-2-0-mg-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-2-0-mg-macular-edema-with-central-retinal-vein-occlusio 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-8-mg-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-8-mg-pfs-diabetic-macular-edema-dme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-8-mg-vegf-trap-eye-bay86-5321-diabetic-macular-edema-dme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-advanced-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ave0005-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ave0005-colorectal-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ave0005-neoplasm-malignant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ave0005-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-bay86-5321-eylea-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-colorectal-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-every-2-months-radiation-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-exudative-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-eylea-bay-86-5321-glaucoma-neovascular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-eylea-bay86-5321-glaucoma-neovascular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-eylea-vegf-trap-eye-bay86-5321-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-eylea-vegf-trap-eye-bay86-5321-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-eylea-vegf-trap-eye-bay86-5321-neovascular-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-eylea-vegf-trap-eye-bay86-5321-wet-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-fibrovascular-pigment-epithelial-detachment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-folfiri-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-high-dose-vegf-trap-eye-bay86-5321-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-injection-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-injection-eylea-vegf-trap-eye-bay86-retinal-vein-occlusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-injection-vegf-trap-eye-bay86-5321-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-irvine-gass-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-lymphoma-non-hodgkin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-neovascular-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-neovascular-wet-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ophthalmic-wet-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-proliferative-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-prostatic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-radiation-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-retinal-vein-occlusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-submacular-vascularized-pigment-epithelial-detac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-vegf-trap-eye-eylea-bay86-5321-highe-macular-edema-secondary-to-retinal-vein-occlusio 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ziv-aflibercept-ave0005-vegf-trap-za-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ziv-aflibercept-ave0005-vegf-trap-za-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ziv-aflibercept-ave0005-vegf-trap-za-ovarian-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ziv-aflibercept-ave0005-vegf-trap-za-pancreatic-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aflibercept-ziv-aflibercept-ave0005-vegf-trap-za-pulmonary-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-150-mg-ml-praluent-hemodialysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-150-mg-ml-subcutaneous-injection-saphenous-vein-graft-atherosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-and-cemiplimab-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-atherosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-atherosclerotic-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-coronary-vessel 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-hypercholesterolaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-nephrotic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-sar236553-hypercholesterolaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-sar236553-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-sar236553-regn727-hypercholesterolaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-sar236553-regn727-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-solution-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/alirocumab-type2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-ang3-diabetic-kidney-disease-dkd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-apoc3-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-cfb-paroxysmal-nocturnal-hemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-cideb-metabolic-dysfunction-associated-steatotic-liver 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-f1202-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-hsd-metabolic-dysfunction-associated-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-pnp-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-pnp-metabolic-dysfunction-associated-steatotic-liver 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-pnp-nonalcoholic-fatty-liver-disease-nafld 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-snca-parkinsons-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aln-sod-amyotrophic-lateral-sclerosis-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/arm-1-cemiplimab-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/asp8374-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aspirin-challenge-aspirin-exacerbated-respiratory-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aspirin-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/aspirin-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/atorvastatin-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ave0005-aflibercept-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/bbt369-diffuse-large-b-cell-lymphoma-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/bnt111-melanoma-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/bnt116-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/bpx-601-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/bpx-601-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/capecitabine-colorectal-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/casirivimab-and-imdevimab-antibody-cocktail-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/casirivimab-imdevimab-combination-therapy-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/casirivimab-imdevimab-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/casirivimab-imdevimab-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/casirivimab-imdevimab-immunocompromised 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemdisiran-paroxysmal-nocturnal-hemoglobinuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-350-mg-i-v-on-day-1-of-every-21-days-merkel-cell-carcinoma-stage-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-350-mg-intravenous-solution-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-advanced-cutaneous-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-advanced-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-anaplastic-thyroid-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-basal-cell-carcinoma-bcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-bladder-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-carcinoma-basal-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-colo-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-colon-and-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-colon-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-cutaneous-basal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-cutaneous-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-cutaneous-squamous-cell-carcinoma-cscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-epithelial-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-fianlimab-fixed-dose-combination-fdc-colon-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-hepatitis-b-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-high-grade-glioma-hgg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-hormone-receptor-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-hpv-related-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-locally-advanced-basal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-locally-advanced-head-and-neck-squamous-cell-car 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-locally-recurrent-oral-cavity-squamous-cell-carc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-metastatic-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-monotherapy-relapsed-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-pleural-mesotheliomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-plus-gemcitabine-pancreatic-ductal-adenocarcinoma-mpdac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-recurrent-lung-non-small-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-relapsed-refractory-aggressive-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-rwlc-cutaneous-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-rwlc-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-rwlc-merkel-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cemiplimab-rwlc-non-small-cell-lung-cancer-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cisplatin-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cmp-001-malignant-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cmp-001-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cmp-001-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/cmp-001-squamous-cell-carcinoma-of-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/colchicine-colcrys-intercritical-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/db-oto-congenital-hearing-loss-secondary-to-biallelic-m 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/degarelix-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-300-mg-2-ml-subcutaneous-solution-dupi-eosinophilic-esophagitis-eoe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-300mg-solution-for-injection-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-allergic-contact-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-allergies-food-milk 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-alopecia-areata 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-asthma-allergic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-atopic-dermatitis-ad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-atopic-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-atopic-keratoconjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-blinded-eosinophilic-gastritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-bullous-pemphigoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-chronic-rhinosinusitis-with-nasal-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-chronic-sinusitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-dermal-hypersensitivity-reaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-dermatitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-eosinophilic-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-eosinophilic-esophagitis-eoe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-eosinophilic-gastritis-eog 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-eosinophilic-oesophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-injectable-product-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-keloid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-lichen-simplex-chronicus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-moderate-to-severe-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-moderate-to-severe-atopic-hand-and-foot-dermatit 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-only-product-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-peanut-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-prefilled-syringe-asthma-control 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-prefilled-syringe-nasal-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-prurigo-nodularis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-pruritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-allergic-fungal-rhinosinusitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fianlimab-advanced-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-neurodermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-chronic-rhinosinusitis-with-nasal-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-chronic-rhinosinusitis-without-nasal-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-chronic-spontaneous-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-cold-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-dermatitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-regn668-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-sar231893-regn668-chronic-rhinosinusitis-phenotype-with-nasal-poly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-severe-atopic-dermatitis-ad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupilumab-wheezing 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupixent-allergic-rhinoconjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/dupixent-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/encorafenib-binimetinib-melanoma-braf-v600e-k-mutated 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ervebo-ebola-virus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/evinacumab-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/evinacumab-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/evinacumab-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/evinacumab-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/evinacumab-severe-hypertriglyceridemia-shtg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/eylea-aflibercept-bay86-5321-retinopathy-of-prematurity-rop 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/eylea-intravitreal-aflibercept-vegf-trap-eye-bay-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fasinumab-ai-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fasinumab-chronic-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fasinumab-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fasinumab-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fasinumab-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fasinumab-osteoarthritis-of-the-knee-or-hip 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fdc-fianlimab-cemiplimab-head-and-neck-squamous-cell-carcinoma-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fianlimab-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fianlimab-advanced-renal-cell-carcinoma-arcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fianlimab-cemiplimab-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fianlimab-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fianlimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/fianlimab-resectable-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/garetosmab-fibrodyplasia-ossificans-progressiva-fop 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/garetosmab-fibrodysplasia-ossificans-progressiva 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/garetosmab-fibrodysplasia-ossificans-progressiva-fop 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/garetosmab-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/gemcitabine-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/gluten-powder-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/hyperpolarized-xe129-pulmonary-artery-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-2-0mg-polypoidal-choroidal-vasculopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-2mg-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-central-retinal-vein-occlusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-central-serous-chorioretinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-cystoid-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-iai-age-related-macular-degeneration-amd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-iai-chorioretinal-vascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-iai-eylea-bay-branch-retinal-vein-occlusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-iai-eylea-bay-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-iai-proliferative-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/intravitreal-aflibercept-injection-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ipilimumab-stage-iii-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/isa101b-squamous-cell-carcinoma-of-the-oropharynx 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/itepekimab-ai-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/itepekimab-sar440340-bronchiectasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/itepekimab-sar440340-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/itepekimab-sar440340-chronic-rhinosinusitis-with-nasal-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/itepekimab-sar440340-chronic-rhinosinusitis-without-nasal-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-food-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-high-risk-smoldering-multiple-myeloma-hr-smm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-monoclonal-gammopathy-of-undetermined-significan 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-multiple-myeloma-mm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-recurrent-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-relapsed-and-or-refractory-multiple-myeloma-rrmm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-relapsed-refractory-multiple-myeloma-rrmm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-relapsed-refractory-systemic-light-chain-amyloid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/linvoseltamab-smoldering-multiple-myeloma-smm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/lmt-atorvastatin-simvastatin-or-rosuvastatin-heterozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/maat033-capsule-nsclc-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/mibavademab-functional-hypothalamic-amenorrhea-fha 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/mibavademab-generalized-lipodystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/mibavademab-monogenic-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/motixafortide-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/nesvacumab-regn910-sar307746-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/nexiguran-ziclumeran-neuromuscular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ntla-2001-transthyretin-amyloidosis-attr-with-cardiomyopat 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/odronextamab-b-cell-non-hodgkins-lymphoma-b-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/odronextamab-diffuse-large-b-cell-lymphoma-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/odronextamab-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/odronextamab-multiple-dose-levels-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/odronextamab-recurrent-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/odronextamab-relapsed-refractory-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/olatorepatide-overweight-or-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/oxaliplatin-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pexastimogene-devacirepvec-pexa-vec-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/placebo-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/placebo-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/placebo-for-alirocumab-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/placebo-for-dupilumab-nasal-polyps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/placebo-generalized-lipodystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/placebo-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/placebo-heterozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-age-related-macular-degeneration-amd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-cd55-deficient-protein-losing-enteropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-cemdisiran-generalized-myasthenia-gravis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-cemdisiran-sporadic-inclusion-body-myositis-sibm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-chaple-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-geographic-atrophy-ga 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/pozelimab-paroxysmal-nocturnal-hemoglobinuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/praluent-heterozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/prompt-aflibercept-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/prompt-aflibercept-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/r475-thermal-injury-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ranibizumab-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1033-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1033-sar391786-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1033-sar391786-sarcopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn10597-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1400-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn10933-regn10987-combination-therapy-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn10933-regn10987-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn10933-regn10987-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1154-or-placebo-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1193-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1193-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn13335-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn13335-pulmonary-arterial-hypertension-pah 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn14256-sars-cov-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn14284-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1908-1909-cat-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1500-250-mg-sc-15-mg-kg-iv-450-mg-sc-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1500-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1500-metabolic-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn15160-iv-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn15505-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn17092-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1908-1909-allergic-rhinitis-due-to-cat-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1908-1909-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn1908-allergic-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2009-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn20423-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn20934-overweight-or-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2176-3-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2176-3-neovascular-wet-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn22044-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2222-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2222-sar438584-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2477-fibrodysplasia-ossificans-progressiva 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2477-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2477-regn1033-sporadic-inclusion-body-myositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2810-advanced-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2810-ipi-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2810-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2810-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2810-prostate-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn2810-recurrent-squamous-cell-carcinoma-of-head 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn3470-3471-3479-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn3500-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn3500-asthma-allergic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn3500-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn3500-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn3767-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn3918-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn421-sar153192-advanced-solid-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn4336-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn4461-familial-partial-lipodystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn4461-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn4659-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn475-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn475-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn475-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn475-sar164877-abdominal-pain-upper 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn475-sar164877-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn475-sar164877-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn475-sciatica 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5069-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5069-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5093-m114-advanced-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5381-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5381-uncontrolled-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5459-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5668-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5678-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5678-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5713-5714-5715-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5713-allergic-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn5713-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn6490-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn6569-squamous-cell-carcinoma-of-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn668-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn668-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn668-injection-rate-1-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7041-active-noninfectious-uveitis-affecting-the-poste 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7075-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamin-a-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7257-severe-aplastic-anemia-saa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn727-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn727-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn727-sar236553-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn728-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7508-atrial-fibrillation-af 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7508-cancer-associated-thrombosis-cat 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7508-iv-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7508-peripheral-artery-disease-pad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7508-symptomatic-venous-thromboembolism-vte 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7508-venous-thromboembolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7508-venous-thromboembolism-vte 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7544-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7544-postural-orthostatic-tachycardia-syndrome-pots 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7544-sepsis-induced-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7999-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn7999-non-transfusion-dependent-beta-thalassemia-ntdt 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn88-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn9035-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn910-3-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn910-3-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn9533-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn9933-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regn9933-venous-thromboembolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/caphosol-oral-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/regv131-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rescue-intravitreal-aflibercept-injection-neovascular-polypoidal-choroidal-vasculopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-160-mg-familial-cold-autoinflammatory-syndrome-fcas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-80-mg-intercritical-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-acute-gout-flare 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-autoimmune-neurosensory-hearing-loss-anshl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-cold-contact-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-il-1-trap-systemic-juvenile-idiopathic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/rilonacept-scleroderma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/s095018-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sar153191-regn88-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sar231893-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sar231893-regn668-dp1-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sar231893-regn668-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sar440340-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sar440340-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sar444881-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-ankylosing-spondylitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-juvenile-idiopathic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-morphea-plaque-form 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-polymyalgia-rheumatica 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-ra 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-sar153191-corona-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-sar153191-giant-cell-arteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-sar153191-regn88-juvenile-idiopathic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-sar153191-regn88-polymyalgia-rheumatica 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sarilumab-sar153191-regn88-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sc-daric33-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sdregn2810-advanced-non-small-cell-lung-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sns-101-anti-vista-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/sub-tenon-injection-of-saline-followed-by-a-sub-thyroid-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/subconjunctival-aflibercept-corneal-neovascularization 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/suptavumab-30-mg-kg-respiratory-syncytial-virus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/tirzepatide-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/trevogrumab-part-a-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ubamatamab-advanced-metastatic-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ubamatamab-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ubamatamab-recurrent-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ubamatamab-smarcb1-deficient-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-eye-2-0mg-macular-edema-secondary-to-central-retinal-vein 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-eye-bay86-5321-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-eye-bay86-5321-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-eye-bay86-5321-myopia-pathological 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-eye-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-eye-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vegf-trap-neovascular-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vidutolimod-merkel-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vonsetamig-chronic-kidney-disease-ckd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vonsetamig-lupus-nephritis-ln 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/vv1-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ziv-aflibercept-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ziv-aflibercept-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ziv-aflibercept-metastatic-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-ivonescimab 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/regeneron-pharmaceuticals-inc/projects/ziv-aflibercept-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/1-84-parathyroid-hormone-shoulder-fractures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/1-tachosil-hemostatic-sponge-9-5-cm-x-4-8-cm-pla-prostate-or-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/14c-alisertib-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/14c-subasumstat-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/14c-tak-385-oral-solution-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/14c-tak-954-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/19-t2-28z1xx-car-t-cells-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/19-t2-28z1xx-trac-t-cell-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/25-mg-ontamalimab-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/25mcg-rhpth-1-84-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax-826-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/30-mg-dexlansoprazole-capsules-manufactured-at-t-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/68ga-mln6907-imaging-of-solid-gastrointestinal-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/75mg-shp647-pf-00547659-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/851b-papillomavirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/actos-pioglitazone-multiple-sclerosis-relapsing-remitting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/actovegin-peripheral-arterial-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/actovegin-post-stroke-cognitive-impairment-psci 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ad-4833-15-mg-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/adalimumab-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/adcetris-levact-clinical-efficacy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/adclec-syn1-car-t-cells-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/adjuvant-excipients-norovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/aerosolized-recombinant-alpha-1-antitrypsin-alpha1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/aes-103-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/agalsidase-alfa-fabry-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-acinar-cell-adenocarcinoma-of-the-pancreas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-adenocarcinoma-of-the-prostate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-advanced-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-b-cell-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-malignant-rhabdoid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-mln8237-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-ovarian-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-relapsed-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alisertib-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-and-glimepiride-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-and-glyburide-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-and-insulin-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-and-metformin-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-and-metformin-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-and-pioglitazone-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-and-voglibose-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-benzoate-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-pharmacokinetics-and-pharmacodynamics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alogliptin-pioglitazone-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alpha1-proteinase-inhibitor-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alpha1-proteinase-inhibitor-alpha1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alpha1-proteinase-inhibitor-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alx-0600-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alx1-11-50-mcg-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alx1-11-drug-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/alx1-11-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/amg-479-adenocarcinoma-of-the-pancreas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/amg-706-advanced-gastrointestinal-stromal-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/amg-706-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/amlodipine-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/amoxicillin-mmx-placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ampicillin-surgical-site-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/anagrelide-0-5-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/anagrelide-hydrochloride-essential-thrombocythaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/anagrelide-hydrochloride-essential-thrombocythemia-et 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/anagrelide-thrombocythemia-hemorrhagic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/anti-macrophage-migration-inhibitory-factor-anti-metastatic-adenocarcinoma-of-the-colon-or-rectum 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/anti-macrophage-migration-inhibitory-factor-anti-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/antidepressant-spd489-lisdexamfetamine-dimesylat-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/antihemophilic-factor-manufactured-and-formulate-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/antihemophilic-factor-recombinant-manufactured-p-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/antihemophilic-factor-recombinant-plasma-albumin-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/antihemophilic-factor-recombinant-porcine-sequen-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ao-128-impaired-glucose-tolerance-igt 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/aralast-alpha1-proteinase-inhibitor-alpha1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/aralast-np-60-mg-kg-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/aralast-np-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ascs-cx401-company-code-anal-fistula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/askbio009-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/aspirin-and-or-clopidogrel-early-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azacitidine-myelodysplastic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azacitidine-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-essential-hypertension-complicated-by-type-2-dia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-essential-hypertension-with-stable-angina-and-dy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoximil-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-and-amlodipine-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-and-chlorthalidone-essential-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-and-chlorthalidone-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-and-chlorthalidone-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-and-olmesartan-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-placebo-essential-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-tak-491-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-medoxomil-with-or-without-add-on-chlo-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/azilsartan-pediatric-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/b-mad-chemotherapy-extranodal-nk-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax-326-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax-326-recombinant-factor-ix-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax-888-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax326-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax69-infusional-5-fu-lv-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax69-single-route-arm-refractory-ovarian-cancer-with-recurrent-symptom 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bax855-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/binimetinib-alk-gene-rearrangement 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/blinatumomab-accelerated-phase-chronic-myelogenous-leukemia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/blood-sampling-alpha-galactosidase-lysogb3-fabry-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bortezomib-non-germinal-b-cell-like-gcb-diffuse-large-b-cel 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bortezomib-plasma-cell-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/bortezomib-recurrent-plasma-cell-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-enteropathy-associated-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-hodgkin-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-in-combination-with-tisleliz-nk-t-cell-lymphoma-nos 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-malignant-neoplasms-stated-as-primary-lymphoid-h 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-primary-cutaneous-anaplastic-large-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-relapsed-or-refractory-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximab-vedotin-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brentuximabvedotin-bv-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-alk-advanced-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-alk-positive-advanced-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-anaplastic-large-cell-lymphoma-alk-positive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-anaplastic-lymphoma-kinase-positive-alk-anaplast 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-lymphoma-large-cell-anaplastic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-neurofibromatosis-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/brigatinib-nsclc-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/budesonide-eosinophilic-esophagitis-eoe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/budesonide-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/budesonide-oral-suspension-eosinophilic-esophagitis-eoe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/c1-esterase-inhibitor-human-c1inh-nf-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/c1-esterase-inhibitor-human-liquid-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/c1-esterase-inhibitor-injection-cinryze-subarachnoid-hemorrhage-aneurysmal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/c1-inhibitor-human-c1-inh-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/c1-inhibitor-human-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cabozantinib-advanced-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cabozantinib-advanced-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cabozantinib-metastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/caffeine-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/calcichew-d3-calcium-and-vitamin-d-deficiencies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/calcichew-d3-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/calcitriol-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/calcium-500-mg-and-vitamin-d3-800-iu-calcium-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-and-hydrochlorothiazide-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-and-standard-chronic-heart-disease-t-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-cerebrovascular-accident 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-cilexetil-and-hydrochlorothiazide-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-cilexetil-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-cilexetil-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/candesartan-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cardiovascular-drugs-strategies-high-risk-hypertensive-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cdpath-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/celaderm-frozen-cultured-epidermal-allograft-leg-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ciclesonide-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ciclesonide-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/gdx012-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ciclesonide-xrp1526-respiratory-tract-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cinryze-500-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cinryze-500-u-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cinryze-acute-antibody-mediated-rejection-amr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cinryze-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cinryze-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ga-gcb-gaucher-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cinryze-with-rhuph20-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ciprofloxacin-xr-mmx-placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/clarithromycin-helicobacter-pylori 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/clarithromycin-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/clopidogrel-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cohort-1-lubiprostone-capsule-fasted-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/colchicine-0-6-mg-po-bid-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/colchicine-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/colchicine-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/colonoscopy-cd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/gi-1-gii-4-15-15-norovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/coumarin-troxerutin-chronic-venous-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cuvitru-ig-subcutaneous-human-20-copd-exacerbation-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cx501-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cx601-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cx611-bacterial-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cyclobenzaprine-hcl-neck-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cyclophosphamide-b-acute-lymphoblastic-leukemia-with-t-9-22-q34-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cyclophosphamide-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cyclosporine-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/cyproterone-acetate-adenocarcinoma-prostate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/danavorexton-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/danavorexton-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/daratumumab-ixazomib-dexamethasone-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/daratumumab-newly-diagnosed-primary-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/darvadstrocel-complex-perianal-fistulas-in-adult-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/darvadstrocel-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dasatinib-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dazostinag-solid-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/deferitazole-disodium-salt-granule-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/delayed-and-extended-release-mesalazine-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-60-mg-gerd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-barrett-s-esophagus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-delayed-release-orally-disintegr-bioavailability 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-erosive-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-gastroesophageal-reflux-disease-gerd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-heartburn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-homeostasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-laryngo-pharyngeal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-laryngopharyngeal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-mr-esophagitis-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-mr-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-mr-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-mr-qd-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dexlansoprazole-pediatric-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dhap-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/digital-engagement-application-gd-app-gaucher-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/digoxin-cytomegalovirus-cmv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/docetaxel-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dose-of-60-mg-kg-fraction-iv-1-alpha1-proteinase-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/double-dose-of-ppi-dyspepsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/doxorubicin-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dx-2930-300mg-2wk-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dx-2930-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dx-88-ecallantide-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dynepo-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/dynepo-epoetin-delta-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/easc-localized-adverse-reaction-to-administration-of 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ecallantide-60-mg-ace-inhibitor-induced-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ecallantide-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/elaprase-for-intravenous-iv-infusion-hunter-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/elaprase-hunter-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/elaprase-mucopolysaccharidosis-mps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/elritercept-myelodysplastic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/elritercept-myelofibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/emicizumab-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/epoetin-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/escitalopram-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/esomeprazole-capsule-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/everolimus-clear-cell-metastatic-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/expanded-autologous-adipose-derived-adult-stem-c-complex-perianal-fistula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/extended-release-guanfacine-hcl-intuniv-spd503-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/extended-release-guanfacine-hydrochloride-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/extended-release-guanfacine-hydrochloride-spd503-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/factor-ix-concentrate-purified-virus-inactivated-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/factor-viii-inhibitor-bypassing-activity-nanofil-hemophilia-a-or-b-with-inhibitors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fasiglifam-tak-875-glycemic-control 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fazirsiran-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fazirsiran-injection-alpha1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-hyperuricosuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-ir-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-joint-damage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-xr-80-mg-capsule-f1-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-xr-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/febuxostat-xr-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/feiba-hemophilia-a-or-b-with-inhibitors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/feiba-hemophilia-a-with-inhibitor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ferric-carboxymaltose-cardiac-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fibrinogen-human-thrombin-human-tachosil-surgical-resection-of-superficial-renal-tumour 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/flomoxef-urinary-tract-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fosrenol-lanthanum-carbonate-chronic-kidney-disease-stage-5 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fruquintinib-colon-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fruquintinib-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fruquintinib-combined-with-chemotherapy-metastatic-colorectal-cancer-crc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fst-100-acute-adenoviral-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fst-100-acute-viral-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fst-100-ophthalmic-suspension-acute-adenoviral-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fst-201-dexamethasone-0-1-otic-suspension-acute-fungal-otitis-externa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fst-201-dexamethasone-0-1-otic-suspension-acute-otitis-externa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fst201-dexamethasone-0-1-with-povidone-iodine-1-acute-otitis-externa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/fucoidan-extract-of-laminaria-japonica-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ga-gcb-velaglucerase-alfa-gaucher-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/glassia-alpha1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/glassia-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/glimepiride-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/gluten-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/guanfacine-hydrochloride-tak-503-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hepatitis-a-vaccine-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hgt-1110-metachromatic-leukodystrophy-mld 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hgt-1111-late-infantile-metachromatic-leukodystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hgt-1410-sanfilippo-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/high-dose-colchicine-4-8-mg-total-dose-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/human-butyrylcholinesterase-hubche-derived-from-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/human-plasma-derived-coagulation-factor-viii-con-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hydrocortisone-modified-release-oral-tablet-20-a-adrenal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hyqvia-chronic-inflammatory-demyelinating-polyradiculon 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hyqvia-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/hyqvia-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ibi363-io-resistant-sqnsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/icatibant-30-mg-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/icatibant-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/icatibant-angiotensin-converting-enzyme-inhibitor-induced 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/icatibant-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/icatibant-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/iduronate-2-sulfatase-enzyme-replacement-therapy-mucopolysaccharidosis-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/idursulfase-hunter-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/idursulfase-it-1-mg-hunter-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/idursulfase-it-hunter-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/igi-10-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/igsc-20-infusion-primary-immunodeficiency-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ilaprazole-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immediate-release-guanfacine-hydrochloride-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-infusion-human-10-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-infusion-human-10-solution-hematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-igiv-10-400-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-igiv-10-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-multifocal-motor-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-solution-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-solution-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-triple-vira-immune-thrombocytopenic-purpura-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-human-10-tvr-triple-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-intravenous-igiv-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/immune-globulin-subcutaneous-human-20-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/infs-intranasal-fentanyl-spray-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/intranasal-fentanyl-spray-infs-break-through-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/inv21-low-dose-hand-foot-and-mouth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/iti-214-dose-a-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-1-mg-human-immunodeficiency-virus-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-2-5-mg-nonhematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-advanced-non-hematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-all-childhood 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-citrate-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ldx-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-light-chain-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-myeloid-hematologic-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-newly-diagnosed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-ninlaro-capsules-matching-placebo-capsu-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-pomalidomide-dexamethasone-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-precursor-cell-lymphoblastic-leukemia-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-relapsed-and-or-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-relapsed-and-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-relapsed-or-refractory-systemic-light-chain-amyl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-smoldering-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-thalidomide-dexamethasone-itd-re-induct-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ixazomib-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ketamine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ketamine-ketamine-induced-brain-activity-changes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanadelumab-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanadelumab-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanadelumab-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanadelumab-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanadelumab-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanadelumab-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-and-naproxen-and-aspirin-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-functional-dyspepsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-microgranules-suspension-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-prevacid-zollinger-ellison-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lansoprazole-stomach-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanthanum-carbonate-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanthanum-carbonate-granule-formulation-end-stage-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanthanum-carbonate-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lanthanum-carbonate-kidney-failure-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-and-atorvastatin-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-and-current-lipid-lowering-t-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-and-fenofibrate-hyperlipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-and-lipid-lowering-therapy-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-and-rosuvastatin-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-and-simvastatin-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-and-stable-statin-therapy-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lapaquistat-acetate-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ldx-30-mg-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ldx-venlafaxine-xr-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lenalidomide-myeloma-multiple 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/leuprorelin-acetate-depot-3m-central-precocious-puberty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/leuprorelin-central-precocious-puberty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/leuprorelin-gf-uterine-fibroids 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/leuprorelin-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/leuprorelin-prostatic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/leuprorelin-sr-prostatic-neoplasms-locally-advanced 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/levothyroxine-sodium-new-formulation-hypothyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lifestyle-modification-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lifitegrast-allergic-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lifitegrast-dry-eye 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lifitegrast-dry-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lifitegrast-keratoconjunctivitis-sicca 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-ldx-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-ldx-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lisdexamfetamine-dimesylate-spd489-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/low-dose-rtpa-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lu-aa21004-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-amitiza-colonoscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-bowel-preparation-for-colonoscopy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-chronic-constipation-methanogenesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-chronic-idiopathic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-constipation-functional 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-constipation-predominant-irritable-bowel-syndrom 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-diabetes-mellitus-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-inflammatory-bowel-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-irritable-bowel-syndrome-with-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lubiprostone-other-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/lumbar-puncture-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/magnesium-pantoprazole-20-mg-gastric-ph-control 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/magnesium-pantoprazole-gerd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/manidipine-20mg-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/maribavir-400-mg-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/maribavir-commercial-tablet-formulation-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/maribavir-cytomegalovirus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/maribavir-cytomegalovirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/maribavir-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/maribavir-transplant-complication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mcc-135-congestive-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/medi1341-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/melphalan-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mesalamine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/metformin-on-top-of-intensive-insulin-therapy-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/metformin-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/metformin-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/methylphenidate-spd503-guanfacine-hydrochloride-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/metronidazole-mmx-mesalazine-mesalamine-placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mezagitamab-immune-thrombocytopenic-purpura-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mezagitamab-relapsed-refractory 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midazolam-carcinoma-advanced-alk-or-ros1-non-small-cell-lu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midazolam-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midazolam-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midazolam-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midodrine-hcl-orthostatic-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midodrine-hcl-symptomatic-orthostatic-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midodrine-hydrochloride-hypotension-orthostatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/midodrine-hydrochloride-proamatine-hypotension-orthostatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mifamurtide-osteosarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mixed-amphetamine-salts-adderall-xr-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mixed-salts-of-a-single-entity-amphetamine-adder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mixed-salts-of-a-single-entity-amphetamine-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln0128-advanced-solid-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln0264-adenocarcinoma-of-the-stomach 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln0264-advanced-gastrointestinal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln0264-advanced-gastrointestinal-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln0264-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln1117-advanced-and-metastatic-gastric-or-gastroesophag 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln1202-atherosclerotic-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln1202-healthy-japanese-and-caucasian-male-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln1202-placebo-diabetic-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln2480-advanced-nonhematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln2480-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln3126-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln3126-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln4924-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln4924-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln4924-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mln7243-advanced-malignant-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mmx-mesalamine-mesalazine-low-dose-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mmx-mesalamine-mesalazine-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mmx-mesalamine-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mobocertinib-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mobocertinib-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mobocertinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mobocertinib-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/motesanib-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/moviprep-bowel-preparation-prior-to-endoscopic-radiologic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mt203-80-mg-or-matching-placebo-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/multivalent-recombinant-ospa-lyme-borreliosis-va-prophylaxis-of-lyme-borreliosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/mvc-101-solid-tumour 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/naltrexone-hcl-bupropion-hcl-placebo-weight-regain-post-bariatric-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/namilumab-mt203-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/namilumab-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/namilumab-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ndi-034858-psoriatic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ndi-034858-study-drug-moderate-to-severe-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ne-58095-ir-involutional-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nesina-act-tab-25-15mg-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/neutral-salts-of-dextroamphetamine-sulfate-usp-a-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ninlaro-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/niraparib-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/niraparib-bevacizumab-platinum-sensitive-recurrent-ovarian-cancer-pati 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/niraparib-efficacy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/niraparib-epithelial-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/niraparib-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nivolumab-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/no-intervention-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/norovirus-bivalent-vaccine-prevention-from-norovirus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/norovirus-bivalent-vlp-vaccine-norovirus-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/norovirus-gi-1-gii-4-bivalent-vlp-vaccine-norovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/norwalk-vlp-vaccine-acute-gastroenteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nov-gi-1-gii-4-bivalent-vlp-vaccine-gastroenteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nov-gi-1-gii-4-bivalent-vlp-vaccine-norovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nov-placebo-matching-saline-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nov-vaccine-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nps-1776-800-mg-migraine-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/npsp558-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/npsp795-autosomal-dominant-hypocalcemia-adh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/nycoplus-magnesium-120-mg-x-3-daily-for-2-weeks-cramps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/obi-1-acquired-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/obi-1-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/octocog-alfa-recombinant-human-coagulation-facto-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/omega-3-acid-ethyl-esters-90-tak-085-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ondansetron-nausea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ontamalimab-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ontamalimab-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ontamalimab-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/oral-budesonide-suspension-mb-9-eosinophilic-esophagitis-eoe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/oral-budesonide-suspension-obs-eosinophilic-esophagitis-eoe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/orteronel-300mg-bid-metastatic-or-advanced-non-resectable-granulosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/orteronel-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/oxaliplatin-oxa-levofolinate-calcium-l-lv-5-fu-p-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/oxaliplatin-oxa-levofolinate-calcium-l-lv-5-fu-p-colorectal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/paclitaxel-and-tak-228-metastatic-urothelial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/paclitaxel-endometrial-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/paclitaxel-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pacritinib-primary-myelofibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/panitumumab-squamous-cell-carcinoma-of-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pantoprazole-20-mg-drug-chronic-use-of-acid-suppressive-medication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pantoprazole-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pantoprazole-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/parathyroid-hormone-disruption-or-dehiscence-of-closure-of-sternum-o 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/parathyroid-hormone-pth-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/peginesatide-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/peginesatide-chronic-renal-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pegylated-recombinant-factor-viii-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pegylated-recombinant-factor-viii-rfviii-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pembrolizumab-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-25-mg-m-2-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-advanced-solid-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-advanced-solid-tumors-neoplasms-advanced-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-myelodysplastic-syndromes-mds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-myelofibroses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pevonedistat-refractory-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pf-00547659-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pf-00547659-sc-injection-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/phentermine-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-15mg-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-and-atorvastatin-cardiovascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-graft-rejection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-and-azilsartan-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-and-azilsartan-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-and-glimepiride-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-and-insulin-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-and-metformin-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-azilsartan-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-bone-metabolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-chronic-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-diabetes-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-hiv-associated-lipodystrophy-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-impaired-glucose-tolerance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-metabolic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-mild-cognitive-impairment-due-to-alzheimer-s-dis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-oxidative-stress 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-then-placebo-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-type-ii-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pioglitazone-uric-acid-kidney-stone-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-and-escitalopram-panic-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-chronic-idiopathic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-chronic-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-control-hemophilia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-endometriosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-essential-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-generalized-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-lennox-gastaut-syndrome-lgs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-male-subjects-with-chronic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-narcolepsy-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-non-cancer-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-non-erosive-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-primary-immune-thrombocytopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-short-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/placebo-virus-zika 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pramlintide-metreleptin-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/prednisone-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ponatinib-30-mg-qd-chronic-phase-chronic-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ponatinib-chronic-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ponatinib-chronic-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ponatinib-gist 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ponatinib-phase-1-chronic-myeloid-leukemia-cml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ponatinib-philadelphia-chromosome-positive-acute-lymphobla 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/protein-c-concentrate-human-vapor-heated-protein-c-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/prothrombin-complex-concentrate-coagulation-fact-prothrombin-complex-factor-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/prucalopride-chronic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/prucalopride-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/prucalopride-functional-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pth-calcium-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/purified-inactivated-zika-virus-vaccine-pizv-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pvp001-100-mg-digestive-system-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/pvs-10200-peripheral-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/r1-ixazomib-lenalidomide-dexamethasone-ird-induc-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/radiolabeled-prucalopride-succinate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/radiolabeled-spd557-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/radiolabeled-spd602-fbs0701-ssp-004184-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-8-mg-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-adhd-with-sleep-onset-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-and-doxepin-sleep-initiation-and-maintenance-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-and-gabapentin-sleep-initiation-and-maintenance-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-and-placebo-25-possible-combinations-t-chronic-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-and-placebo-9-possible-combinations-to-chronic-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-and-placebo-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-and-zolpidem-chronic-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-balance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-chronic-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-circadian-dysregulation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-migraine-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-or-placebo-sleep-apnea-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-rozeremr-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-seasonal-affective-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-sl-acute-depressive-episode 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-sl-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-sl-dose-1-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-sleep-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-sleep-disorders-circadian-rhythm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-sleep-initiation-and-maintenance-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-transient-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-triazolam-and-placebo-56-possible-comb-drug-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ramelteon-zolpidem-and-placebo-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-adamts13-hereditary-thrombotic-thrombocytopenic-purpura-t 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-antihemophilic-factor-manufactured-a-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-antihemophilic-factor-plasma-albumin-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-factor-ix-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-factor-viia-bi-rfviia-bi-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-human-arylsulfatase-a-metachromatic-leukodystrophy-mld 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-human-arylsulfatase-a-rhasa-late-infantile-metachromatic-leukodystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-human-c1-esterase-inhibitor-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-human-heparan-n-sulfatase-rhhns-mucopolysaccharidosis-mps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-human-heparan-n-sulfatase-rhhns-sanfilippo-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-human-hyaluronidase-immune-globulin-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-human-hyaluronidase-rhuph20-immune-g-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-protein-free-factor-viii-rahf-pfm-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-von-willebrand-factor-recombinant-fv-von-willebrand-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/recombinant-von-willebrand-factor-rvwf-von-willebrand-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/relugolix-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/relugolix-uterine-fibroids 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/replagal-agalsidase-alfa-fabry-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/replagal-fabry-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rhasa-dose-level-1-metachromatic-leukodystrophy-mld 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rhhns-10-mg-sanfilippo-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rhigf-1-rhigfbp-3-retinopathy-of-prematurity-rop 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rhigf-i-rhigfbp-3-retinopathy-of-prematurity-rop 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rhpth-1-84-chronic-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rhpth-1-84-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rhpth-1-84-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rituximab-375-mg-m-2-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rixubis-on-demand-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rnaseq-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/roflumilast-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/roflumilast-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/romidepsin-lymphoma-t-cell-peripheral 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rozerem-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rozerem-rem-behavior-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rt-pa-lacunar-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rvwf-von-willebrand-disease-vwd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/rymphysia-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/sabin-based-inactivated-poliomyelitis-vaccine-si-poliomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/sapanisertib-non-hematologic-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/sc-treatment-with-igsc-10-with-rhuph20-followed-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/scopolamine-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp465-12-5mg-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp465-12-5mg-capsules-one-capsule-daily-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp465-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp611-metachromatic-leukodystrophy-mld 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp615-nervous-system-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp639-n-60-primary-open-angle-glaucoma-poag 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp640-adenoviral-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp640-bacterial-conjunctivitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp643-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp648-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp655-acquired-thrombotic-thrombocytopenic-purpura-att 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/shp681-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/simvastatin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/sm101-immunoglobulin-a-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/soticlestat-15q-duplication-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/soticlestat-300-mg-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/soticlestat-complex-regional-pain-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/soticlestat-dravet-syndrome-ds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/soticlestat-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ssp-002358-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/soticlestat-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/soticlestat-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd422-anagrelide-hydrochloride-essential-thrombocythemia-et 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd422-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd465-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd476-1-2g-diverticulitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd476-is-a-polymeric-matrix-formulation-that-di-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd476-is-a-polymeric-matrix-formulation-that-di-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd476-mesalazine-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd476-mmx-mesalazine-1-2g-extended-release-tabl-diverticulitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd476-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-20-mg-sleep-deprivation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-40mg-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-adhd-specifically-with-executive-function-impair 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-lisdexamfetamine-dimesylate-antidepressan-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-lisdexamfetamine-dimesylate-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-lisdexamfetamine-dimesylate-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-lisdexamfetamine-dimesylate-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-lisdexamfetamine-dimesylate-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-lisdexamfetamine-dimesylate-schizophrenia-and-predominant-negative-symptoms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-low-dose-negative-symptoms-of-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd489-low-dose-range-40mg-80mg-and-100mg-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd503-1-mg-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd503-am-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd503-extended-release-guanfacine-hydrochloride-generalized-anxiety-disorder-gad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd503-guanfacine-hcl-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd503-guanfacine-hydrochloride-2-mg-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd503-guanfacine-hydrochloride-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd503-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd544-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd557-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd602-fbs0701-ssp-004184-transfusional-iron-overload 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd602-iron-overload-due-to-repeated-red-blood-cell-tra 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spd602-transfusional-iron-overload 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/spironolactone-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/srm003-arteriovenous-fistula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/srm003-arteriovenous-graft 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ssp-002358-0-1-mg-ppi-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ssp-004184-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ssp-004184-impaired-renal-function 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ssp-004184aq-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ssp-004184aq-iron-overload-due-to-repeated-red-blood-cell-tra 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ssp-004184ss-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/stem-cells-rheumatoid-arthritis-aggravated 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/steroid-and-proton-pump-inhibitor-therapy-suspected-eosinophilic-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/subcutaneous-injection-of-tak-850-influenza-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/sulfamethoxazole-mmx-placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/syr-472-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/syr-472-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/syr-619-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tachosil-bleeding 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tachosil-cerebrospinal-fluid-leaks 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tacrolimus-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-003-dengue-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-004-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-007-refractory-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-007-relapsed-or-refractory-r-r-b-cell-non-hodgkin-ly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-018-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-019-prevention-of-infection-disease-caused-by-severe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-020-captisol-oral-solution-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-020-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-058-env8058-dose-finding-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-058-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-058-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-062-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-063-20-mg-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-063-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-063-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-071-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-071-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-079-autoimmune-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-079-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-079-myasthenia-gravis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-079-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-102-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-103-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-105-a-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-114-10-mg-capsule-clinical-pharmacology 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-117-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-117-neoplasm-advanced-or-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-123-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-128-diabetic-neuropathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-137-5-mg-tablet-tak-137-placebo-tablet-healthy-japanese-adult-male 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-137-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-137-dose-finding-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-164-gastrointestinal-neoplasms-esophageal-stomach-pa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-165-breast-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-186-squamous-cell-cancer-of-head-and-neck-scchn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-188-advanced-or-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-226-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-227-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-228-advanced-nonhematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-228-tak-117-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-233-clinical-pharmacology 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-272-japanese-healthy-adult-males 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-272-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-272-type-2-diabetes-mellitus-and-microalbuminuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-279-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-279-generalized-pustular-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-279-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-279-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-279-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-279-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-279-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-329-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-330-coagulation-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-341-multiple-system-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/spyre-therapeutics/projects/spy002-072-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-360-narcolepsy-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-379-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-385-40-mg-japanese-premenopausal-healthy-adult-women 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-385-hormone-treatment-na-ve-participants-with-prosta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-385-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-385-t2-formulation-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-385-uterine-fibroids 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-411-chronic-inflammatory-demyelinating-polyradiculon 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-418-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-418-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-ascending-single-dose-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-dose-finding-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-duodenal-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-erosive-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-erosive-esophagitis-ee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-gastric-ulcers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-h-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-non-erosive-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438-od-japanese-healthy-adult-male 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-438asa-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-442-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-442-venous-thromboembolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-448-hypogonadotropic-hypogonadism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-448-low-testosterone 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-491-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-500-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-505-malignant-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-510-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-536-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-536-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-536-japanese-healthy-adult-male-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-536-tablet-japanese-healthy-adult-males 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-536ccb-grade-i-or-ii-essential-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-536tch-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-536tch-tablet-essential-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-559-and-glyburide-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-559-and-insulin-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-559-and-metformin-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-559-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-580-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-583-diabetic-neuropathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-583-neuralgia-postherpetic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-625-alagille-syndrome-algs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/xm17-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-625-progressive-familial-intrahepatic-cholestasis-pf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apogee-therapeutics/projects/apg777-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-648-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-648-tablet-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-648-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-653-treatment-resistant-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-659-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-659-lymphoma-non-hodgkin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-662-congenital-protein-c-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-11417-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-667-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-671-coronavirus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-676-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-700-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-715-and-methotrexate-arthritis-rheumatoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-755-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-755-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-850-influenza-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-755-thrombotic-thrombocytopenic-purpura-ttp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-771-chronic-inflammatory-demyelinating-polyradiculon 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-781-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-783-and-methotrexate-arthritis-rheumatoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-788-advanced-metastatic-non-small-cell-lung-cancer-n 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-788-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-788-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-788-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-792-30-mg-healthy-male-adults-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-816-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-828-dose-finding-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-828-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-850-0-5-ml-injection-influenza-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-850-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-850-influenza-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-853-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-861-narcolepsy-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-861-narcolepsy-type-1-nt1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-875-and-glimepiride-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-875-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-875-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-875-diabetic-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-875-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/celastrol-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-875-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-881-chronic-inflammatory-demyelinating-polyradiculon 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-881-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-881-primary-immunodeficiency-diseases-pid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-906-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-906-japanese-healthy-adult-male-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-906-maleate-diabetes-mellitus-and-gastroparesis-idiopathic-g 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-906-maleate-diabetic-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-906-maleate-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-906-oral-capsule-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-915-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-915-suspension-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-919-coronavirus-disease-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-925-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-925-healthy-participants-and-patients-with-narcoleps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-925-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-925-idiopathic-hypersomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-925-obstructive-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-931-metastatic-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-931-nonhematologic-neoplasms-advanced 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-931-pic-neoplasms-advanced-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-935-developmental-and-or-epileptic-encephalopathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-935-epilepsy-molecular-mechanisms-of-pharmalogical-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-935-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-935-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-935-oral-tablet-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-935-tablets-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-951-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-951-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-951-nausea-and-vomitting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-951-placebo-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-951-postoperative-nausea-and-vomiting-ponv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-954-critical-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-954-diabetic-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-954-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-954-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-954-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-954-placebo-postoperative-gastrointestinal-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-954-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-981-advanced-or-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/celastrol-safety-issues 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-981-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-981-lymphoma-non-hodgkin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-981-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-981-relapsed-and-or-refractory-multiple-myeloma-rrmm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-988-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-994-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/sonrotoclax-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-994-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-994-narcolepsy-type-1-nt-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-994-narcolepsy-type-1-nt1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak-994-oral-tablet-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tak228-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/takc-02-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/takeda-s-dengue-tetravalent-vaccine-live-attenua-dengue-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-4630-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/takeda-s-tetravalent-dengue-vaccine-candidate-td-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/bt-001-type2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tap-144-sr-6m-premenopausal-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tap-144-sr-6m-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tbio-6517-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/td-8954-enteral-feeding-intolerance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tdv-dengue-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tdv-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tdv-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tdv-liquid-formulation-1-dengue-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tdv-low-dose-dengue-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/technochrom-c1-inh-kit-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/ted-short-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-0-05-mg-kg-d-short-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-0-05mg-kg-short-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-alx-0600-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-pharmacokinetics-and-safety-of-elevated-doses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-postoperative-fistula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/teduglutide-short-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tetravalent-dengue-vaccine-tdv-dengue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tetravalent-dengue-vaccine-tdv-dengue-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/theophylline-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/timp-glia-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tislelizumab-minimal-residual-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/treatment-algorithm-a-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/trebananib-3-mg-kg-neoplasms-advanced-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/trelagliptin-25-mg-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/trelagliptin-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/trifluridine-tipiracil-metastatic-oesogastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/troxacitabine-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tvp-1012-1mg-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/tvp-1012-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/udenafil-erectile-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/umuline-nph-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-300-mg-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-300-mg-injection-entyvio-immune-checkpoint-inhibitor-related-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-allogeneic-hematopoietic-stem-cell-transplantati 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-collagenous-gastritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-intravenous-injection-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-iv-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-iv-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-iv-crohn-s-disease-cd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-iv-moderately-to-severely-active-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-moderately-to-severely-active-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-placebo-hematopoietic-stem-cells 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-placebo-pouchitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-pouchitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-primary-sclerosing-cholangitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-sc-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-sc-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vedolizumab-sc-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/velaglucerase-alfa-gaucher-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/velaglucerase-alfa-gaucher-disease-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/velaglucerase-alfa-gaucher-disease-type-3 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/veltuzumab-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/venticute-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vitamin-d-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/von-willebrand-factor-recombinant-von-willebrand-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonicog-alfa-von-willebrand-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonicog-alfa-von-willebrand-disease-vwd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonoprazan-erosive-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonoprazan-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonoprazan-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonoprazan-helicobacter-pylori 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonoprazan-reflux-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vonvendi-von-willebrand-disease-vwd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-10-mg-age-related-cognitive-decline 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-10-mg-day-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-generalized-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-healthy-adult-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-iv-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-lu-aa21004-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-severe-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-tablets-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-tbi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-treatment-outcome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-type2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vortioxetine-unipolar-major-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vp-20629-friedreich-s-ataxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/agee-cream-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vp20621-clostridium-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vpriv-gaucher-disease-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vyvanse-lisdexamfetamine-dimesylate-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/vyvanse-lisdexamfetamine-dimesylate-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/yf-17d-dengue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/zasocitinib-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/zasocitinib-dose-a-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/zasocitinib-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/zasocitinib-nonsegmental-vitiligo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/zasocitinib-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/takeda-pharmaceutical-co-ltd/projects/zed1227-sige-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/16-mg-buprenorphine-with-4-mg-naloxone-sublingua-evaluation-of-qtc-interval 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/40-mg-glatiramer-acetate-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/45-mg-hydrocodone-bitartrate-extended-release-ta-drug-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/5-mg-500-mg-glipizide-metformin-hydrochloride-ta-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/5-mg-500-mg-metaglip-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/600-mg-amoxicillin-42-9-mg-clavulanate-postassiu-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/80-mg-dr-6mp-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/90-mg-dose-of-the-hydrocodone-bitartrate-extende-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/91-day-levonorgestrel-oral-contraceptive-bone-mineral-density 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/91-day-levonorgestrel-oral-contraceptive-hemostasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/91-day-levonorgestrel-oral-contraceptive-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/a-60-mg-dose-of-the-hydrocodone-bitartrate-exten-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/abemaciclib-triple-negative-breast-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/acr16-huntington-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/acr16-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/actiq-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/actiq-oral-transmucosal-fentanyl-citrate-breakthrough-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/actiq-oral-transmucosal-fentanyl-citrate-otfc-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/adapalene-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/adasuve-bipolar 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/advair-diskus100-50-g-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/airduo-digihaler-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-aerosol-by-hfa-mdi-exercise-induced-bronchospasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-dry-powder-inhaler-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-emdpi-ds-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/anastrozole-teva-pharmaceuticals-usa-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-emdpi-ds-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-hfa-boi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-hfa-mdi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-mdpi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-spiromax-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-spiromax-exercise-induced-bronchoconstriction-eib 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-sulfate-abs-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/albuterol-sulfate-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/alcohol-wipes-vs-no-alcohol-wipes-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/alendronate-sodium-tablets-70mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/alfacalcidol-accidental-falls 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/alprazolam-extended-release-3-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/amlodipine-benazepril-10-mg-20-mg-capsules-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/amlodipine-besylate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/amoxicillin-clavulanic-acid-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/anastrozole-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/anle138b-tev-56286-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/arava-20-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/meat-biscuit-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-100-to-250-mg-day-excessive-daytime-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-150-mg-day-excessive-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-150-mg-day-fatigue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-150-mg-day-obstructive-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-250-mg-day-obstructive-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-bipolar-i-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-excessive-daytime-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-excessive-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-sleep-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/armodafinil-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/arsenic-trioxide-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/arsenic-trioxide-acute-promyelocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/arsenic-trioxide-chronic-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/arsenic-trioxide-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/autologous-mesenchymal-stem-cells-implantation-tibial-fracture 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/azelastine-hydrochloride-and-fluticasone-propion-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/azilect-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/azithromycin-600-mg-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/azithromycin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/balugrastim-chemotherapy-induced-neutropenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/balugrastim-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bdp-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bdp-hfa-nasal-aerosol-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bdp-hfa-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bdp-nasal-aerosol-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-qvar-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-640-persistent-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rehabilitation-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-bai-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-bai-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-breath-actuated-inha-persistent-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-hfa-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-hfa-nasal-aerosol-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-hydrofluoroalkane-hf-rhinitis-allergic-perennial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-rhinitis-allergic-perennial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-dipropionate-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beclomethasone-qvar-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/beeam-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/benazepril-hcl-40-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-and-rituximab-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-hcl-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-hydrochloride-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-hydrochloride-non-hodgkin-s-lymphoma-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bendamustine-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bicalutamide-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bronchodilator-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/budesonide-and-formoterol-fumarate-dehydrate-bf-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/budesonide-formoterol-fumarate-dihydrate-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/budesonide-formoterol-spiromax-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/buprenorphine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/bupropion-hcl-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/buspar-30-mg-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/carboplatin-prostatic-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/placebo-spiromax-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/midodrine-syncope 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/carboplatin-tubular-breast-cancer-stage-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/carvedilol-25-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cd56-enriched-donor-lymphocyte-infusion-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cefadroxil-500-mg-capsules-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cefdinir-capsules-300-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cefdinir-for-oral-suspension-250-mg-5ml-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cefprozil-for-oral-suspension-250-mg-5-ml-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cefprozil-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cefzil-500-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cenestin-0-3-mg-tablets-hot-flashes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-10953-armodafinil-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-11981-kinase-inhibitor-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-1347-10mg-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-18770-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-26401-cognitive-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-33457-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-37247-sciatica 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-37250-khk2804-solid-tumour 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-37251-bone-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-37440-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-701-20mg-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-701-60mg-leukemia-myeloid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-701-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-701-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-9722-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-9722-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cep-9722-solid-tumors-or-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/chlorambucil-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cilostazol-100-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cilostazol-50-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/clarithromycin-er-500-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/clarithromycin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/clindamycin-300-mg-capsule-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/copaxone-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ct-011-chronic-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ct-011-primary-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/custirsen-cardiac-conduction-and-repolarization 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/custirsen-paclitaxel-and-carboplatin-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/custirsen-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/custirsen-sodium-castrate-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cyclobenzaprine-hydrochloride-chronic-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cyproterone-acetate-5-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cytarabine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/cytarabine-acute-myeloid-leukemia-with-multilineage-dysplas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/decitabine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/delayed-release-6-mercaptopurine-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/delayed-release-6-mercaptopurine-crohns-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/delayed-release-6mp-or-calcitriol-vs-purinethol-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/desmopressin-acetate-0-2-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/desogestrel-ethinyl-estradiol-and-ethinyl-estrad-follicle-development 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/desogestrel-ethinyl-estradiol-and-ethinyl-estrad-hemostasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/deutetrabenazine-6-mg-dystonia-primary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/deutetrabenazine-huntington-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/deutetrabenazine-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/deutetrabenazine-oral-capsule-tardive-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dexmethylphenidate-hydrochloride-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/diclofenac-sodium-actinic-keratosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/diclofenac-sodium-topical-gel-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/digoxin-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/divalproex-sodium-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/donepezil-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/donepezil-hydrochloride-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/doxycycline-monohydrate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-1011-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-102-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-1021-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-1021-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-103-pregnancy-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-1031-breakthrough-bleeding 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-104-emergency-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-2001a-endometriosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-2011-infertility 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-2021a-amenorrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-2041a-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-3001-overactive-bladder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-3001a-urinary-incontinence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/dr-5001-respiratory-tract-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/drospirenone-ethinyl-estradiol-gianvi-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/duvakitug-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/duvakitug-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/edratide-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/estradiol-dyspareunia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/estradiol-norethindrone-acetate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/etiprednol-dicloacetate-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/11c-cppc-pet-ligand-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/extrafine-hfa-beclomethasone-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/famciclovir-500-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fentanyl-buccal-tablet-advanced-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fentanyl-buccal-tablet-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fentanyl-buccal-tablet-fbt-cancer-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fentanyl-buccal-tablets-compared-with-immediate-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fentanyl-buccal-tablets-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fentanyl-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fexofenadine-180-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/finasteride-5-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fluoxetine-hydrochloride-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fluticasone-propionate-and-salmeterol-inhalation-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fluticasone-propionate-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fluticasone-propionate-mdpi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fluticasone-propionate-pressurized-metered-dose-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fluticasone-propionate-salmeterol-fs-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fluticasone-propionate-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/formoterol-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fp-abs-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fp-mdpi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fp-mdpi-persistent-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-chronic-cluster-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-cluster-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-episodic-cluster-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-interstitial-cystitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-migraine-prophylaxis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-post-traumatic-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fremanezumab-prefilled-syringe-ajovy-migraine-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/fs-mdpi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ga-20-mg-ml-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/gabitril-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/gabitril-anxiety-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/gabitril-generalized-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/gabitril-tiagabine-hydrochloride-cep-6671-general-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/generic-budesonide-formoterol-fumarate-dihydrate-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/generic-estradiol-vaginal-cream-usp-0-01-atrophic-vaginitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/generic-ivermectin-lotion-0-5-head-lice 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-20-mg-0-5-ml-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-20-mg-relapse-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-20-mg-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-crohns-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-db-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-ga-40-mg-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-ga-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-injection-with-oral-cetirizin-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-n-acetylcysteine-relapse-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-optic-neuritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glatiramer-acetate-with-minocycline-relapse-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glimepiride-4-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glucophage-xr-750-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/glyburide-metformin-5-mg-500-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/gmx1777-solid-tumors-and-lymphomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/granisetron-hydrochloride-1-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/gx15-070ms-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/hgh-viaderm-system-hgh-or-somatropin-growth-hormone-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/homoharringtonine-myeloid-leukemia-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/hydrocodone-bitartrate-extended-release-tablet-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/hydrocodone-bitartrate-extended-release-tablet-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/hydrocodone-er-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/hydrocodone-er-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/hydroxychloroquine-hcq-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/imiquimod-cream-3-75-actinic-keratosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/infusion-of-myocet-cerebral-lymphoma-b-cell-refractory 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/inhaled-delta-8-thc-300mcg-or-600mcg-per-dose-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ketamine-treatment-resistant-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lamotrigine-25-mg-chewable-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lamotrigine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lansoprazole-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-0-3-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-0-6-relapsing-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-lupus-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-relapsing-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/topiramate-25-mg-capsules-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/laquinimod-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/larazotide-acetate-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lbr-101-high-dose-chronic-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lbr-101-high-dose-episodic-migraine-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lbr-101-iv-bioavailability-and-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/leflunomide-20-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lestaurtinib-polycythemia-vera 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/levetiracetam-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/levonorgestrel-ee-0-15-0-03-and-ee-0-01-mg-table-dysmenorrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/levonorgestrel-ee-0-15-0-03-mg-and-ee-0-01-mg-ta-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/li-squamous-cell-carcinoma-of-the-oral-cavity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lipegfilgrastim-aggressive-b-cell-non-hodgkin-lymphomas-at-high 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lipegfilgrastim-ewing-family-of-tumors-rhabdomyosarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/lipegfilgrastim-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/liposomal-doxorubicin-hydrochloride-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/losartan-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/losartan-potassium-hydrochlorothiazide-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/medroxyprogesterone-acetate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/meloxicam-15-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/methylprednisolone-multiple-sclerosis-ms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/metronidazole-bacterial-vaginosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/metronidazole-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/mirtazapine-15-mg-orally-disintegrating-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/modafinil-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/modafinil-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/modafinil-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/modafinil-sleep-apnea-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/modakafusp-alfa-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/modakafusp-alfa-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/moexipril-hcl-hydrochlorothiazide-15-25-mg-table-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/mometasone-furoate-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/mycophenolate-mofetil-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/mycophenolate-mofetil-myfenax-stable-renal-transplant-recipients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/myocet-early-primary-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/naproxen-menorrhagia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/nebulized-ivx-0142-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/neugranin-chemotherapy-induced-neutropenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/nevirapine-hiv-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/non-pegylated-liposomal-doxorubicin-tubular-breast-cancer-stage-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/norethindrone-ethinyl-estradiol-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/norethindrone-ethinyl-estradiol-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/np101-compare-bioequivalence-patches-previously-used-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/np101-migraine-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/np101-sumatriptan-iontophoretic-transdermal-patc-migraine-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-extensive-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-250-ml-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-carboplatine-and-etoposide-extensive-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-gx15-070ms-hematological-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-gx15-070ms-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-gx15-070ms-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-gx15-070ms-myelofibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-lymphoma-follicular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/obatoclax-mesylate-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/olanzapine-extended-release-schizophrenia-schizoaffective-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/omacetaxine-acute-myelogenous-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/omacetaxine-hematologic-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/omacetaxine-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/omacetaxine-mepesuccinate-chronic-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/omacetaxine-mepesuccinate-hematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/omacetaxine-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ondansetron-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oral-cep-701-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oravescent-fentanyl-citrate-chronic-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oravescent-fentanyl-citrate-chronic-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oravescent-fentanyl-citrate-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oravescent-fentanyl-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oravescent-fentanyl-ovf-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oravescent-fentanyl-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oxcarbazepine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oxybutinyn-vaginal-ring-4mg-overactive-bladder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/oxymetazoline-hydrochloride-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/paclitaxel-bevacizumab-liposomal-doxorubicin-cap-human-epidermal-growth-factor-2-negative-carcino 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/pagoclone-stuttering 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/pantoprazole-sodium-40-mg-delayed-release-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/paroxetine-hcl-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/placebo-mdpi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/placebo-nasal-aerosol-perennial-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/placebo-primary-progressive-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/pramipexole-dihydrochloride-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/pravastatin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/pravastatin-sodium-80-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/pravastatin-sodium-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/progesterone-vaginal-ring-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/prot-cl-np101-015-01-acute-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/provigil-200-mg-chronic-shift-work-sleep-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/qvar-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/qvar-beclometasone-dipropionate-hfa-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ramipril-10-mg-capsule-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-depressive-symptoms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-mesylate-multiple-system-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-mesylate-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-placebo-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-progressive-supranuclear-palsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-restless-legs-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rasagiline-sleep-disturbances 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-asthma-eosinophilic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-eosinophilic-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-eosinophilic-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-eosinophils-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-iv-absolute-bioavailability 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-severe-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/reslizumab-severe-persistent-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ribavirin-200-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/risperidone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ropinirole-hcl-0-25-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/rowasa-4-gm-60-ml-rectal-enema-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sce-b-nocturnal-vasomotor-symptoms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sd-809-chorea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sd-809-chorea-associated-with-huntington-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sd-809-tardive-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sd-809-tourette-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sdx-101-r-etodolac-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sdx-105-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/seasonale-levonorgestrel-and-ethinyl-estradiol-osteopenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/seasonale-levonorgestrel-lng-ethinyl-estradiol-e-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/shared-solutions-plus-ms-center-v-shared-solutio-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/stemex-hematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sublingual-tizanidine-12-mg-spasticity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sublingual-tizanidine-hcl-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sumatriptan-succinate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/sumatriptan-succinate-migraine-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/synthetic-conjugated-estrogens-b-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/t-jet-containing-tevtropin-growth-hormone-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tacrolimus-bid-medication-adherence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tak-573-relapsed-and-or-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/talampanel-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/talampanel-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/talampanel-dyskinesias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/talampanel-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/talampanel-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/talampanel-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/talampanel-non-radiolabeled-14c-talampanel-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tamsulosin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tapinarof-cream-1-plaque-type-psorisis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tbo-filgrastim-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tbo-filgrastim-neutropenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/terbinafine-hcl-250mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-45478-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-45779-chronic-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-48125-1-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-48574-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-48574-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-48574-dose-regimen-a-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-50717-cerebral-palsy-dyskinetic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-50717-tourette-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-53275-dose-a-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-53408-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-53408-vitiligo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-56248-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-56278-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-56286-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-56286-multiple-system-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tev-56286-test-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tiotropium-hfa-bai-4-5-mcg-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tiotropium-hfa-bai-5-mcg-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tizanidine-sublingual-or-oral-muscle-spasticity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tl011-anti-cd20-for-the-treatment-of-rheumatoid-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tl011-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/topiramate-2-x-25-mg-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/topiramate-capsules-25-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/topiramate-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tp-38-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tp-38-recurrent-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/trandolapril-4-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/treatment-a-fp-mdpi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/trifarotene-0-005-topical-cream-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-1106-growth-hormone-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-1380-150-mg-cocaine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-44749-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-45070-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-45070-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-45070-postherpetic-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-46000-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-46046-400-mg-ml-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-46046-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv-46763-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv46017-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tv48108-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/tvb-009-osteoporosis-postmenopausal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/ursodiol-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/valacyclovir-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/venlafaxine-25-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/venlafaxine-hydrochloride-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/volcolon-sugar-free-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/zaleplon-10-mg-capsules-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/zithromax-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/zoloft-100-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/teva-pharmaceutical-industries-ltd/projects/zolpidem-10-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/99mtc-pyrophosphate-scintigraphy-transthyretin-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-2232-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-4285-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-4324-obese-or-overweight-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-4324-type-2-diabetes-mellitus-t2dm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-4915-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-5288-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-6400-hereditary-hemorrhagic-telangiectasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-6400-von-willebrand-disease-vwd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-aat-antitrypsin-deficiency-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-aat02-zz-type-alpha-1-antitrypsin-deficiency-liver-dis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-agt01-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-agt01-rvr-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-agt01-rvr-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-app-early-onset-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-bcat-advanced-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-cc5-paroxysmal-nocturnal-hemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-hbv-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-hsd-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-htt02-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-khk-type-2-diabetes-mellitus-t2dm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-pcs02-elevated-ldl-cholesterol-ldl-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-pcssc-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-rsv01-respiratory-syncytial-virus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-ttr01-transthyretin-mediated-amyloidosis-attr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-ttr02-patisiran-administered-by-intravenous-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-ttr02-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-ttrsc-revusiran-for-subcutaneous-administrat-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-ttrsc-revusiran-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-ttrsc02-transthyretin-mediated-amyloidosis-attr-amyloido 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-ttrsc04-transthyretin-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-vsp02-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/aln-xdh-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/cemdisiran-atypical-hemolytic-uremic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/computer-algorithm-for-attr-transthyretin-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/givosiran-acute-hepatic-porphyria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/givosiran-acute-intermittent-porphyria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/givosiran-acute-intermittent-porphyria-aip 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/givosiran-aln-as1-acute-intermittent-porphyria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/indapamide-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/lumasiran-haemodialysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/lumasiran-ph1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/lumasiran-primary-hyperoxaluria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/lumasiran-primary-hyperoxaluria-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/lumasiran-primary-hyperoxaluria-type-1-ph1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/lumasiran-recurrent-calcium-oxalate-kidney-stone-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/patisiran-aln-ttr02-transthyretin-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/patisiran-aln-ttr02-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/patisiran-amyloidosis-familial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/patisiran-amyloidosis-hereditary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/patisiran-polyneuropathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/patisiran-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/placebo-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/placebo-primary-hyperoxaluria-type-1-ph1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/placebo-transthyretin-amyloidosis-attr-with-cardiomyopat 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/pozelimab-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/revusiran-aln-ttrsc-transthyretin-ttr-mediated-familial-amyloidotic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/revusiran-aln-ttrsc-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/revusiran-transthyretin-ttr-mediated-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/vir-2218-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/vir-2218-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/vutrisiran-transthyretin-amyloidosis-attr-with-cardiomyopat 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/zilebesiran-high-cardiovascular-risk 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/alnylam-pharmaceuticals-inc/projects/zilebesiran-mild-to-moderate-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/amg-509-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/atezolizumab-advanced-liver-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-60366-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-68501-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-71332-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-75098-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-75202-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-11417-mature-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-89894-advanced-or-metastatic-mtap-deleted-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-a3004-skin-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-c0902-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-c0979-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-c137-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-c477-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bg-c9074-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-10188-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-11417-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-15025-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-16673-b-cell-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-16673-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-16673-chronic-spontaneous-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-16673-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-16673-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-21447-hormone-receptor-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-21447-relapsed-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-24714-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-26808-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-43395-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-43395-hr-her2-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-45035-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-45035-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-53038-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-58067-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-58067-glioblastoma-gbm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-58067-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-a3055-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-a445-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-b3227-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-b455-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-c354-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/bgb-r046-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/io-202-aml-with-monocytic-differentiation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/blinatumomab-b-cell-precursor-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/blinatumomab-relapsed-refractory-b-cell-precursor-acute-lymph 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/ccrt-with-maintenance-tislelizumab-and-metronomi-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/cyclophosphamide-recurrent-transformed-chronic-lymphocytic-leukem 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/drug-bg-t187-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/gimistotug-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/io-108-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/io-108-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/io-202-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/lbl-007-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/lifirafenib-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/long-course-radiotherapy-capecitabine-pd-1-monoc-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/pamiparib-capsule-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/pd-1-pd-l1-inhibitors-borderline-resectable-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/rituximab-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/sonrotoclax-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/sonrotoclax-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/sonrotoclax-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/sonrotoclax-waldenstrom-macroglobulinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/subcutaneous-tislelizumab-metastatic-gastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/surzebiclimab-locally-advanced-or-metastatic-solid-tumors-for 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tarlatamab-extensive-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-advanced-unresectable-gastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-bgb-a317-msi-h-dmmr-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-classical-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-esophageal-squamous-cell-carcinoma-escc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-gastroesophageal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-resectable-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tislelizumab-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/tunlametinib-pd-1-mab-gastric-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanidatamab-gastric-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-chronic-lymphocytic-leukemia-small-lymphocytic-l 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-diffuse-large-b-cell-lymphoma-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-mantle-cell-lymphoma-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-mature-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-primary-membranous-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-relapsed-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-relapsed-refractory-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-relapsed-refractory-follicular-non-hodgkin-lymph 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zanubrutinib-waldenstr-m-s-macroglobulinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beone-medicines/projects/zw25-zanidatamab-her2-amplified-biliary-tract-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/daraxonrasib-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/daraxonrasib-nsclc-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/daraxonrasib-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/elironrasib-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-4630-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-4630-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-5127-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-5552-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-5552-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-6236-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-6236-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-6236-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/rmc-9805-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/tng462-pdac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/revolution-medicines/projects/vociprotafib-metastatic-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/0-1-bupivacaine-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/0-2-mg-kg-ketamine-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/1-0-c31g-savvy-vaginal-gel-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/1-1-1-blood-transfusion-ratio-trauma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/1-intranasal-oxytocin-spray-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/10-ge-xenokidney-esrd-end-stage-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/123i-5-ia-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/123i-b-cit-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/123i-cit-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/123i-ibvm-and-spect-imaging-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/177lu-j591-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/177lu-psma-617-metastatic-hormone-naive-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/18f-peg6-ipqa-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/18f-v-6-bp-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/2-deoxyglucose-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/2-mg-melatonin-anxiety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/20-grams-protein-muscle-disuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/225ac-j591-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/2mg-buprenex-and-380mg-vivitrol-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/3-4-methylenedioxymethamphetamine-mdma-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/3-dimensional-conformal-radiation-therapy-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/3-dimensional-conformal-radiation-therapy-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/3t-mr-imaging-of-the-cervical-spinal-cord-cervical-spondylosis-with-myelopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/4-aminopyridine-spinal-muscular-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/50-000-units-ergocalciferol-pruritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/60-mg-prednisone-airway-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/600-mg-ibuprofen-tibial-fractures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/70-ml-red-beetroot-juice-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/89zr-dfo-ys5-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/89zr-trastuzumab-breast-cancer-metastases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/95-condensed-proanthocyanidins-from-grape-seed-e-iron-deficiency-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/abamectin-and-fenpyroximate-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/abemaciclib-breast-cancer-female 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/abiraterone-acetate-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/abiraterone-acetate-prostate-cancer-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/abituzumab-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/academic-detailing-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/acalabrutinib-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/accelerated-intermittent-theta-burst-stimulation-long-covid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/acceptance-and-commitment-therapy-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/acetazolamide-hypobaric-hypoxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/acetylsalicylic-acid-precancerous-condition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/active-ctbs-post-concussion-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/active-ctc-assessment-adenocarcinoma-of-the-prostate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/active-procedure-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/active-tdcs-and-cognitive-training-intervention-brain-concussion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/active-tdcs-task-oriented-practice-cervical-spinal-cord-injruy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/acupuncture-migraine-headaches 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/acupuncture-persian-gulf-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/adaptive-planning-organ-localisation-a-polo-plan-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/adenovirus-psa-vaccine-hormone-refractory-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/administration-of-ui018-hyperlipemia-mixed 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/administration-of-ui058-gerd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/administration-of-ui068-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/administration-of-ui087-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/adoptive-cell-therapy-with-tumor-infiltrating-ly-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/advair-hfa-altitude-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aerobic-exercise-training-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/afatinib-and-paclitaxel-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/al-coartem-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/albendazole-400-mg-and-or-vitamin-a-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/albendazole-ascariasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/albendazole-helminthiasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/green-tea-extract-dysbiosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/albumin-human-burn-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aldesleukin-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/alemtuzumab-kidney-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/alfuzosin-kidney-stones 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aliskiren-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/allergy-immunotherapy-allergy-shots-eosinophilic-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/allogeneic-human-mesenchymal-stem-cells-hmscs-non-ischemic-dilated-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/allogeneic-msc-mesenchymal-stromal-cells 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/allogeneic-msc-s-application-to-the-burn-wounds-skin-burn-degree-second 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/allopregnanolone-injection-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/allopurinol-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/alpelisib-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/alteplase-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/alteplase-or-tenecteplase-cva-cerebrovascular-accident 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/alvac-hiv-vcp1521-aidsvax-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ambulatory-oxygen-lung-disease-fibroid-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/amiloride-secondary-progressive-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/amino-acid-based-formula-cow-milk-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/amlodipine-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/amobarbital-gel-one-one-dose-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/amodiaquine-plus-artesunate-co-administration-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/amoxycillin-non-severe-pneumonia-with-wheeze 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/anakinra-100mg-and-placebo-depo-medrone-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/anastrozole-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/angiotensin-1-7-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/anodal-tdcs-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/anplag-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/anti-cd40-agonist-monoclonal-antibody-cdx-1140-ovarian-clear-cell-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/anti-cs6-bsigg-product-lot-pd1601105cs-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/anti-thymocyte-globulin-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/antibody-ub-421-hiv-1-infection-in-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/antibody-ub-421-hiv-1-infection-in-adults-asymptomatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/antiepileptic-drug-therapy-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/antioxidant-berry-supplementation-heat-intolerance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/antiplatelet-aspirin-dipyridamole-clopidogrel-cervical-artery-dissection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/antipyrine-benzocaine-otic-solution-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/apd811-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/apixaban-cerebral-vein-thrombosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/apple-cider-vinegar-kidney-stones-urolithiasis-hypocitraturia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/arcofolin-5-methyltetrahydrofolate-pre-eclampsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aripiprazole-hyperprolactinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/arm-a-abc-3tc-nnrti-human-immunodeficiency-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/arm-b-a-combination-of-pentoxifylline-and-tocoph-head-and-neck-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/arn-75039-oral-capsules-healthy-adult-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aromatase-inhibitors-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/artemether-lumefantrine-aln-uncomplicated-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/artemether-lumefantrine-combination-plasmodium-vivax-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/artemether-lumefantrine-uncomplicated-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/artesunate-amodiaquine-combination-malaria-falciparum 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/asparaginase-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aspirin-75mg-acute-lung-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aspirin-and-atorvastatin-cardiovascular-risk-factor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aspirin-node-positive-her2-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/aspirin-vestibular-schwannoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/astx660-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/atezolizumab-locally-advanced-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/atezolizumab-metastatic-colorectal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/atorvastatin-20mg-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/atorvastatin-calcium-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/atorvastatin-major-coronary-event 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/atovaquone-oral-suspension-locally-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/atra-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-engineered-urethral-construct-urologic-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-fat-transfer-wound 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-human-schwann-cell-peripheral-nerve-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-room-temperature-stored-platelet-tran-reversal-of-platelet-aggregation-inhibitors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-skin-fibroblasts-amputation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-skin-fibroblasts-wounds-and-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-tissue-engineered-corpora-urologic-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/autologous-volar-fibroblast-injection-into-the-t-amputation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/avastin-bevacizumab-corneal-neovascularization 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/avutometinib-glioblastoma-multiforme-gbm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/axitinib-clear-cell-metastatic-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azd2014-3-on-4-off-weekly-paclitaxel-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azd2014-neurofibromatosis-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azd5069-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azd5363-adenocarcinoma-of-the-prostate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azd6738-breast-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azd8931-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azithromycin-malnutrition-in-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azithromycin-pill-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/azithromycin-typhoid-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/b-cit-and-spect-imaging-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bal-glu-energy-supply-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bcg-tokyo-172-vaccine-tuberculosis-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bcg-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/beclometasone-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/behavior-therapy-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/binimetinib-metastatic-colorectal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bemarituzumab-flot-regimen-gastric-and-gastro-oesophageal-junction-gej-aden 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/benzyl-penicillin-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bep-500-stage-i-testicular-non-seminomatous-germ-cell-tu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bevacizumab-colorectal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bevacizumab-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bevacizumab-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bevacizumab-recurrent-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/binimetinib-locally-advanced-pancreatic-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bio-300-oral-powder-acute-radiation-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/biofoam-surgical-matrix-intraoperative-bleeding 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/biomarker-transplantation-liver 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/biospecimen-collection-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bipap-procedure-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bipap-synchrony-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/blf-bovine-lactoferrin-neonatal-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/blueberries-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/itx-5061-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/blueberry-cranberry-green-tea-extract-cocoa-stress-psychological 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bomedemstat-myelofibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bont-a-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/boost-to-the-tumour-bed-early-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/botulinum-toxin-a-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bpmri-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/brachytherapy-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/breathlessness-support-service-breathless-patients-with-any-established-underly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ls11-neurofibroma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/brentuximab-vedotin-ann-arbor-stage-ib-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bubble-enhanced-fast-befast-abdominal-trauma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bupivacaine-amputation-stumps 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bupivacaine-liposome-injection-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/bupivacaine-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ca-vit-d-bone-health 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cabg-mitral-valve-annuloplasty-mitral-regurgitation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cabozantinib-oral-tablet-neurofibromatosis-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/caffeine-post-dural-puncture-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/calcium-gluconate-trauma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/calcium-vitamin-d-nutrition-status 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/calcium-vitamin-d-stress-fracture 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cam2020-m2sr-h3n2-influenza-vaccine-influenza-vaccine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cambridge-weight-plan-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/camel-milk-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/camostat-mesilate-severe-acute-respiratory-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/celecoxib-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/campylobacter-jejuni-strain-cg8421-campylobacter-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/capsule-1-or-capsule-2-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carbetocin-post-partum-haemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carbetocin-short-infusion-complications-cesarean-section 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carbidopa-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carboplatin-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carboplatin-hormone-refractory-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carboplatin-plus-paclitaxel-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carboplatin-recurrent-fallopian-tube-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cardiac-mri-with-gadolinium-contrast-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/carraguard-pc-515-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cct3833-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cd105-yb-1-sox2-cdh3-mdm2-polyepitope-plasmid-dn-her2-negative-breast-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ce-marked-philips-motiva-system-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cediranib-alveolar-soft-part-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cefecin-tab-acute-sinusitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/celecoxib-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cellulose-sulfate-gel-6-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ceralasertib-gynaecological-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cetrorelix-acetate-infertility 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cetuximab-braf-v600e-negative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ch14-18-nci-neuroblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/chemotherapy-malignant-mesothelioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/chemotherapy-transitional-cell-carcinoma-of-ureter 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/d-chad63-ca-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/chlorhexidine-infant-newborn-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/chlorhexidine-peri-implantitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/chlorhexidine-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/chloroquine-malaria-falciparum 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cho-pro-high-altitude 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cholecalciferol-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cholecalciferol-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cholecalciferol-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cholecalciferol-vitamin-d-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cholecalciferol-vitamin-d-vigantol-oil-respiratory-tract-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/chr-2797-tosedostat-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ciclosporin-myocardial-reperfusion-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ciprofloxacin-acute-lymphoblastic-leukaemia-category 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ciprofloxacin-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cisplatin-advanced-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cisplatin-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/citalopram-low-mood 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/citrus-limonoid-beverage-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cladribine-mavenclad-advanced-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/clinical-center-reference-endotoxin-ccre-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/clobetasol-propionate-colon-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/clp-nutrition-child-nutritional-status 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cmf-regimen-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cnp8-burns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/co-trimoxazole-960mg-dispersible-tablet-spontaneous-bacterial-peritonitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/coartem-artemether-lumefantrine-combination-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cocoavia-supplement-cold-exposure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/coenzyme-q10-and-lisinopril-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/coenzyme-q10-charcot-marie-tooth-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/coenzyme-q10-gulf-war-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cold-stored-platelets-acute-blood-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cold-stored-platelets-csp-trauma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cold-stored-platelets-in-100-plasma-stored-for-1-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/combination-of-palbociclib-and-aromatase-inhibit-hormonal-receptors-positive-her2-negative-advanc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/combined-fixed-dose-combination-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/concord-grape-juice-gulf-war-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cone-beam-computed-tomography-scanning-cbct-endodontic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/control-body-weight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/convalescent-plasma-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/conventional-radiotherapy-74-gy-delivered-in-37-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/copper-iud-mucosal-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/corticosteroid-chronic-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cosyntropin-postdural-puncture-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/covid-hig-sars-cov-2-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/covid-higiv-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cp12-thermal-burns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/croc-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/crossboss-catheter-arteriosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/csb-drum-dried-amylase-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/csb14-child-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/csii-insulin-pump-plus-dafne-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ct-011-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ct-scan-hospital-acquired-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ctca-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cxd101-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cyclophosphamide-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cyclophosphamide-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cyd-dengue-vaccine-dengue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/cytovir-adv-adv-infection-post-allo-hsct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/d-cycloserine-autistic-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/d-cycloserine-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/d-galactose-focal-segmental-glomerulosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/d1me100-dengue-1-premembrane-envelope-dna-vaccin-dengue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dairy-based-toddler-nutrition-weight-gain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dasatinib-malignant-pleural-mesothelioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dc1-vaccine-breast-cancer-female 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dcs-d-cycloserine-prolonged-imaginal-exposure-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/decision-aid-chronic-kidney-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dendritic-cell-tumor-fusion-vaccine-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dendritic-cell-vaccine-leptomeningeal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/depo-medroxyprogesterone-acetate-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/desmopressin-injection-stroke-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/destress-pc-posttraumatic-stress-disorder-ptsd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dexamethasone-shoulder-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dexamethasone-voice-change 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mapmysmoke-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dexmedetomidine-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dexmedetomidine-dexmedetomidine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dexmedetomidine-injection-delirium-in-old-age 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dfups-diabetic-foot 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dha-piperaquine-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dihydroartemisinin-piperaquine-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dinutuximab-ganglioneuroblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dinutuximab-neuroblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dinutuximab-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dipyridamole-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/direct-acting-oral-anticoagulants-used-as-per-lo-traumatic-intracranial-haemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/distress-thermometer-and-problems-list-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dmpa-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dna-vaccine-prime-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/docetaxel-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dose-chronic-migraine-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dovitinib-lactate-gastrinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/doxazosin-mesylate-extended-release-stress-disorders-post-traumatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/doxorubicin-hydrochloride-stage-iii-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/doxorubicin-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/doxycycline-200mg-day-or-placebo-persian-gulf-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/doxycycline-advanced-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/doxycycline-lymphedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/drawtex-dressing-pilonidal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/drug-covid19-0001-usr-sars-cov-2-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/drug-isotretinoin-13-cis-retinoic-acid-capsules-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dsm265-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/dt2216-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/durvalumab-stage-ib-hepatocellular-carcinoma-ajcc-v8 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/e-coli-etvax-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/eaa-military-operational-stress-reaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/eaa-w-carbohydrate-energy-deficit 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ebola-vaccine-low-dose-ebola-virus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/echogo-coronary-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/educational-dementia-training-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/educational-internet-site-on-prostate-cancer-scr-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/educational-intervention-hematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/eicosapentaenoic-acid-and-docosahexaenoic-acid-e-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/elliptical-exercise-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/embryoglue-laboratory-culture-medium-infertility 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/empagliflozin-10-mg-acute-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/emtricitabine-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/emtricitabine-tenofovir-alafenamide-acceptability-of-health-care 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/encapsulated-calcium-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/endo-tool-burns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/endoscopic-submucosal-dissection-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/energy-balance-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/enfortumab-vedotin-metastatic-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/engineered-autologous-t-cells-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/enhanced-standard-management-pacemaker-complication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/enoxaparin-40-mg-q12h-traumatic-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/enzalutamide-40mg-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/epcoritamab-diffuse-large-b-cell-lymphoma-not-otherwise-spec 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/epoetin-alfa-exercise-induced-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/erenumab-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ergocalciferol-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/eribulin-mesylate-breast-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/erlotinib-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/erlotinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/esketamine-nasal-spray-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/esocheck-esoguard-barrett-esophagus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/essential-amino-acid-enriched-whey-protein-whole-body-protein-balance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/estrogen-bazedoxifene-hand-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/etanercept-gulf-war-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/etanercept-lupus-erythematosus-discoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/etec-strain-b7a-o148-h28-cs6-lt-st-lot-0481-in-b-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ethinyl-estradiol-and-levogestrel-hiv-aids 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/everolimus-malignant-peripheral-nerve-sheath-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/everolimus-pediatric-heart-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/evolve104-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/exercise-programme-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/exercise-training-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/exoskeletal-assisted-walking-spinal-cord-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/experimental-continuous-peripheral-nerve-blocks-lower-extremity-surgical-amputation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/expressive-writing-posttraumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/extended-release-niacin-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/extensively-hydrolyzed-formula-cow-milk-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/extensively-hydrolyzed-rice-protein-formula-milk-hypersensitivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/external-non-invasive-stimulation-tbi-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/facility-hivst-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/famotidine-2019-novel-coronavirus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/farletuzumab-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fenfluramine-cognitive-function 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fenofibrate-145-mg-diabetic-retinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fentanyl-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ferric-carboxymaltose-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ferric-carboxymaltose-iron-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fgf-2-tympanic-membrane-perforation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fgi-101-1a6-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fisetin-femoroacetabular-impingement 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fludeoxyglucose-f-18-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fludeoxyglucose-f-18-testicular-germ-cell-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fluorouracil-clinical-stage-ii-esophageal-adenocarcinoma-ajcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fluorouracil-metastatic-biliary-tract-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fluoxetine-depression-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fmp012-with-as01b-adjuvant-system-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fmp1-as02a-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fmp2-1-as01b-plasmodium-falciparum-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fortified-food-rations-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fresh-frozen-plasma-ffp-anticoagulant-reversal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fresh-organic-vegetables-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fruit-bar-bioavailability 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ftc-tdf-prep-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fulvestrant-advanced-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/fulvestrant-with-enzalutamide-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/functional-precision-oncology-breast-cancer-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/g03-52-01-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gene-expression-analysis-kidney-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gabapentin-peripheral-nerve-disorder-associated-with-repair 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gabapentin-sciatica 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/galinpepimut-s-montanide-gm-csf-malignant-pleural-mesothelioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gallium-68-citrate-prostatic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gallium-ga-68-gozetotide-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ganetespib-malignant-peripheral-nerve-sheath-tumors-mpnst 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gardasill-9-vaccine-neoplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ge-logiq-e10-clinical-ultrasound-scanner-breast-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/general-anesthesia-facial-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/genetic-testing-for-4-mody-genes-gck-hnf1a-hnf4a-maturity-onset-diabetes-of-the-young 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ggta1-ko-thymokidney-esrd-end-stage-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gip-glp-1a-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/glucagon-type-1-diabetes-mellitus-with-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/glucose-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/glutamine-hemorrhagic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gluten-and-casein-free-diet-autism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/glyburide-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/glycerin-suppository-encopresis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/glyoxalase-1-glo1-inducer-glucose-intolerance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/goji-berry-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/goserelin-acetate-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/grain-fed-beef-hamburger-inflammatory-response 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/granexin-gel-200-m-second-degree-burn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/granulocyte-colony-stimulating-factor-biliary-atresia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/green-tea-lung-cancer-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/group-1-10-ug-fmp012-with-2-ug-gla-se-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/group-a-deactivated-tens-with-beeping-sound-15-s-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/group-a-fmp2-1-as01b-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/gsk-influenza-virus-h5n1-vaccine-1557484a-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/guadecitabine-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/haloperidol-migraine-headaches 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hb-admsc-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/heliox-inspirate-work-of-breathing 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hfms-mrc-activlim-pedsql-4-0-flaccid-hemiplegia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/high-amylose-maize-starch-acetate-butyrate-aerobic-endurance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/high-energy-high-protein-peptide-feed-study-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/high-fat-cold-exposure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hiv-1-peptide-vaccine-microparticulate-monovalen-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hiv-self-test-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hiv-self-testing-among-female-sex-workers-human-immunodeficiency-virus-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hormonal-contraception-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hormone-replacement-therapy-estrogen-progestin-anorexia-nervosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/household-based-water-treatment-with-nadcc-table-diarrhoea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/htnv-puuv-dna-vaccine-hemorrhagic-fever-with-renal-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/human-interferon-alfa-1b-inhalation-solution-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/human-mesenchymal-stromal-cells-respiratory-distress-syndrome-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hydrogen-peroxide-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hydroxyurea-thrombocythemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hylan-g-f-20-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hyperbaric-oxygen-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hyperpolarized-129xenon-gas-pulmonary-vascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hyperpolarized-xenon-lung-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hypo-fractionated-srs-metastatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/hypo-osmolar-ors-diarrhoea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ibrutinib-560-mg-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ibrutinib-asymptomatic-covid-19-infection-laboratory-confi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ibuprofen-800-mg-bone-resorption 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ibuprofen-immune-system-and-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ibuprofen-tonsillectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ibuprofen-tonsillectomy-with-or-without-adenoidectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ic9-gd2-car-il-15-t-cells-neuroblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ic9-gd2-car-il-15-t-infusion-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/icasp9m28z-t-cell-infusions-malignant-pleural-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/il-1ra-kineret-intracerebral-haemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/il-1ra-subarachnoid-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/image-guided-dynamic-dosimetry-locally-confined-adenocarcinoma-of-the-prostate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/imatimib-mesylate-lymphangioleiomyomatosis-lam 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/imatinib-mesylate-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/imatinib-myeloid-leukemia-chronic-chronic-phase 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/imiquimod-anal-dysplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/imiquimod-cervical-intraepithelial-neoplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/imiquimod-lentigo-maligna 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/imm-bcp-01-sars-cov2-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/immune-enhancing-nutritional-beverage-mitigation-of-immune-function-decrements-in-resp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/immunoglobulins-intravenous-privigen-encephalitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/impedance-threshold-device-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/in-person-cognitive-behavioral-therapy-of-insomn-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/inexin-0-08-act1-dry-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/infant-and-young-child-feeding-growth-stunting-nutritional 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/influenza-a-california-04-09-influenza-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/influenza-a-texas-71-2017-h3n2-influenza-viral-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/inhaled-treprostinil-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/inhaled-treprostinil-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/inhaled-treprostinil-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/inhaled-treprostinil-sarcoidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/inhaled-treprostinil-solution-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/inhaled-treprostinil-tyvaso-nebulizer-copd-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/initiating-daily-oral-prep-during-pregnancy-pre-exposure-prophylaxis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/insulin-acute-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/insulin-aspart-injection-ublin-pharmacokinetics-and-pharmacodynamics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/insulin-burns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/insulin-multiple-sclerosis-relapsing-remitting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intensity-modulated-radiation-therapy-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intervention-a-validated-home-bp-monitor-and-sup-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intranasal-oxytocin-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intravenous-administration-of-ferric-carboxymalt-lung-hypoxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intravenous-artesunate-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intravenous-sedation-lower-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intravenous-subcutaneous-treprostinil-oral-trepr-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intravenous-treprostinil-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/intravenous-vitamin-c-burns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/iodine-124-thyroid-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ipatasertib-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ipilimumab-bclc-stage-b-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ipilimumab-locally-advanced-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/iron-27-mg-folic-acid-600-ug-infant-mortality 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/iron-and-zinc-combined-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/irosustat-breast-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/isoniazid-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/isoniazid-with-ethambutol-human-immunodeficiency-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/isosorbide-mononitrate-kidney-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/itraconazole-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/iv-remodulin-persistent-pulmonary-hypertension-of-the-newborn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/jelly-confectionary-snakes-postop-nausea-vomiting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/kalomin-tab-acute-bronchitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketamine-acute-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketamine-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketamine-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketamine-chronic-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketamine-hydrochloride-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketamine-hydrochloride-traumatic-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketogenic-diet-cns-oxygen-toxicity-ketogenic-diet 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketogenic-diet-heart-failure-with-preserved-ejection-fraction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketogenic-food-products-oxygen-toxicity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketone-ester-ketosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketorolac-injection-orthopaedic-trauma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ketorolac-pain-post-operative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/khalas-dates-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/kras-vaccine-with-poly-iclc-adjuvant-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/l-carnitine-tartrate-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/l-citrulline-post-deployment-related-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/l-leucovorin-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lactobacillus-plantarum-constipation-functional 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lactobacillus-plantarum-is-10506-constipation-functional 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lactose-placebo-elbow-fracture 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lapatinib-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lenalidomide-recurrent-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lenvatinib-columnar-cell-variant-thyroid-gland-papillary-ca 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/letrozole-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/letrozole-lymphangioleiomyomatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/leukocyte-interleukin-injection-200iu-condyloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/leukocyte-poor-platelet-rich-plasma-lp-prp-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/levetiracetam-keppra-alcohol-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/levobupivacaine-arthroplasty-replacement-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/levodopa-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/levoleucovorin-calcium-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/levothyroxine-hypothyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/limonene-containing-massage-oil-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lipid-based-nutrient-supplement-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/liposomal-bupivacaine-blunt-chest-wall-trauma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/liposomal-bupivacaine-femoral-fractures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/liposomal-bupivacaine-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/liposomal-doxorubicin-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/liposomal-irinotecan-oncology 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/local-anesthetics-topical-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lofexidine-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lomustine-brain-and-central-nervous-system-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/losartan-hip-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/losartan-potassium-50mg-emotional-processing 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/losartan-potassium-50mg-social-cognition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/losartan-potassium-emotional-processing 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/losmapimod-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lovaza-omega-3-fatty-acid-ethyl-ester-mood-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/low-dose-radiotherapy-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/low-frequency-right-sided-repetitive-transcrania-tbi-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/low-titer-whole-blood-hemorrhagic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lps-reference-endotoxin-e-coli-o113-h10-k-neg-ma-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lumason-contrast-agent-mitochondrial-myopathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/lumason-contrast-enhanced-ultrasound-kidney-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ly2189265-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mab-3f8-primary-refractory-neuroblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/magellan-acute-burns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/magnesium-sulfate-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mammaglobin-a-dna-vaccine-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/manuka-honey-mgo-1000-post-surgical-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mebeverine-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/medium-quantity-lipid-based-nutrient-supplement-undernutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/melatonin-supplement-intervention-physical-exercise 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/menjugate-meningococcal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mesalazine-irritable-bowel-syndrome-with-diarrhoea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mesenchymal-stromal-cells-corneal-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/metformin-c9orf72-amyotrophic-lateral-sclerosis-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/metformin-hydrochloride-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/metformin-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/metformin-polycystic-kidney-autosomal-dominant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/metformin-standard-of-care-focal-segmental-glomerulosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/metformin-tendinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/methotrexate-psoriatic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/metoprolol-succinate-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mgd020-hiv-human-immunodeficiency-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/micronized-dhacm-40-mg-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/midazolam-stress-disorders-post-traumatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/milatuzumab-lupus-erythematosus-cutaneous 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mind-body-bridging-program-sleep-disturbance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/minocycline-alcohol-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/minocycline-hydrochloride-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mirasol-system-for-whole-blood-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mirasol-treated-fresh-whole-blood-transfusion-transmitted-infectious-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mitomycin-c-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mitomycin-c-corneal-opacity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mitoquinone-mesylate-mitoq-cold-exposure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/modafinil-200mg-cognition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/modified-release-prednisone-chronic-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/morphine-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/moxifloxacin-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mri-prostate-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mri-scan-preterm-birth-complication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/multi-epitope-her2-peptide-vaccine-tpiv100-breast-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/multi-factorial-intervention-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/multistem-trauma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mv-prs-sub-study-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mva85a-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/mycophenolate-mofetil-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/n-acetyl-cysteine-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/n-acetyl-cysteine-neurofibromatosis-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/n-acetylcysteine-capsule-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/n-acetylcysteine-mitochondrial-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/n-acetylcysteine-nac-and-calcitriol-hie-perinatal-hypoxic-ischemic-encephalopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/n-acetylcysteine-posttraumatic-stress-disorder-ptsd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nac-effects-of-high-altitude 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nanodox-1-doxycycline-monohydrate-hydrogel-dehisced-surgical-wounds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nanodox-hydrogel-orthopedic-trauma-wounds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nanosensor-mitochondrial-myopathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nasal-carbon-dioxide-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ndv-3-vaccine-with-alum-im-staphylococcal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nestorone-ethinyl-estradiol-contraceptive-vagina-contraception 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/new-extensively-hydrolysed-formula-protein-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/new-infant-formula-functional-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/new-infant-formula-functional-gastrointestinal-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/new-thickened-formula-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/niclosamide-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nicotinamide-riboside-gulf-war-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nicotine-replacement-therapy-sampling-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nicotinomide-glaucoma-open-angle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nilotinib-mucosal-lentiginous-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nivolumab-metastatic-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nivolumab-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/non-invasive-ventilation-amyotrophic-lateral-sclerosis-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/norovirus-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ntx-001-peripheral-nerve-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nutributter-program-undernutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nutrient-supplement-to-pregnant-women-pns-stunting-in-under-2-children 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/nutritional-supplements-low-birth-weight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/obinutuzumab-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/octreotide-acetate-liver-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/offer-of-voucher-for-cost-free-nicotine-replacem-tobacco-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ogx-011-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/olanzapine-acute-agitation-behavioural-emergency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/olaparib-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/olaparib-bile-duct-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oleoylethanolamide-oea-gulf-war-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/omacor-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/omega-3-atorvastatin-dyslipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ondansetron-ibs-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ondansetron-vomiting-of-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ondansetron-zofran-itching 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/onx-0801-solid-tumours 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-co-trimoxazole-8mg-kg-day-trimithoprim-twic-non-severe-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-nutritional-supplementation-ons-muscle-wasting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-treprostinil-pah 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-treprostinil-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-treprostinil-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-treprostinil-pulmonary-hypertension-associated-with-sickle-ce 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-treprostinil-raynaud-s-phenomenon 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-treprostinil-systemic-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-treprostinil-ut-15c-sustained-release-table-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oral-versus-topical-antibioitics-chronic-rhinosinusitis-diagnosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxandrolone-trauma-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxybutynin-chloride-breast-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxygen-critical-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxymetazoline-fecal-incontinence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxytocin-alcohol-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxytocin-and-misoprostol-postpartum-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxytocin-posttraumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/oxytocin-unit-cohesion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/p3c541b-lipopeptide-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/paclitaxel-clinical-stage-iii-gastric-cancer-ajcc-v8 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/paclitaxel-germ-cell-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/palbociclib-125mg-tab-er-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/palbociclib-taselisib-pictilisib-advanced-solid-tumours 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/palmidrol-chemotherapy-induced-peripheral-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/panitumumab-metastatic-colon-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/paracetamol-blood-pressure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/parenteral-remodulin-treprostinil-injection-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pastured-livestock-diet-omega-3-fatty-acids 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/peanuts-prediabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pegfilgrastim-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-200mg-iv-for-30-minutes-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-25-mg-ml-keytruda-lung-cancer-nonsmall-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-cervix-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-metastatic-small-intestinal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-thoracic-tumours 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pembrolizumab-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pemetrexed-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pentoxifylline-kidney-failure-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/perflutren-lipid-acute-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/perindopril-arginine-abdominal-aortic-aneurysm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/perineural-infusion-continuous-peripheral-nerve-phantom-limb-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pertussis-containing-vaccine-pregnancy-related 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/phenylephrine-spinal-anesthesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/phenytoin-single-dose-300-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/physical-activity-educational-materials-physical-inactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/physiotherapy-sciatica 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/phytic-acid-iron-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pioglitazone-15mg-high-altitude 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pirfenidone-cardiac-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pitavastatin-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-chronic-kidney-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-gulf-war-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-infusion-brain-injuries-traumatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-intravaginal-ring-a-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-oral-capsule-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/placebo-vaginal-film-with-square-corners-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/plain-crystalline-niacin-exercise-sauna-gulf-war-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/radiation-131i-mibg-neuroblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dtx101-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/plasmodium-falciparum-malaria-protein-010-fmp010-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/platelet-rich-plasma-injection-osteoarthritis-of-the-shoulder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/plerixafor-pancreatic-adenocarcinoma-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/plumpy-sup-moderate-acute-malnutrition-mam 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/plx-pad-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pneumococcal-polysaccharide-and-protein-conjugat-pneumococcal-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pnt001-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pramipexole-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prazosin-hydrochloride-alcohol-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prebiotics-prebiotics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prednisolone-adrenal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prednisolone-and-or-aza-mmf-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prednisolone-copd-exacerbation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pregabalin-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prevenar-13-sepsis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prilocaine-hyperbaric-2-cervical-incompetence-in-pregnancy-as-antepartum 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pro-2000-5-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/probiotic-strain-bb-12-infections-respiratory 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/probiotic-stress-physiology 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prochlorperazine-and-benadryl-iv-acute-migraine-headache 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/progesterone-alcohol-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/propranolol-burn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/propranolol-hydrochloride-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prospare-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prostate-alone-imrt-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prostate-biopsy-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/protexia-intervention-for-nerve-agent-exposure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/provision-of-extra-care-coordination-and-managem-hospitalization 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/prunes-perimenopausal-bone-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/psa-il-2-gm-csf-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/psilocybin-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/psilocybin-usona-institute-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pt150-ptsd-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ptvg-hp-with-rhgm-csf-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pul-042-inhalation-solution-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pulmonary-rehabilitation-pr-non-small-cell-lung-cancer-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pumvc3-igfbp2-her2-igf1r-plasmid-dna-vaccine-anatomic-stage-i-breast-cancer-ajcc-v8 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/pvsripo-invasive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/q-griffithsin-3-0-covid-19-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/q-griffithsin-covid-19-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/qutenza-8-capsaicin-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/qutenza-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/radiation-therapy-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/radiation-therapy-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ralinepag-pah 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ralinepag-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/raltegravir-human-immunodeficiency-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ready-to-use-school-food-school-attendance 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ready-to-use-supplementary-food-moderate-acute-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ready-to-use-therapeutic-food-rutf-severe-acute-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/recombinant-factor-viia-burns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/recombinant-fsh-follitropin-alpha-ovulation-induction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/recombinant-human-growth-hormone-gulf-war-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/recombinant-interferon-alfa-melanoma-skin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/recombinant-subunit-b-bacterial-cholera-vaccine-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/reducing-antibiotics-treatment-duration-ventilator-associated-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/regorafenib-adenocarcinoma-of-the-gastroesophageal-junction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/regorafenib-gastro-oesophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/remodulin-congenital-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/remodulin-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/remodulin-treprostinil-sodium-injection-critical-limb-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/remodulin-treprostinil-sodium-injection-peripheral-vascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/removal-of-omentum-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/revumenib-acute-myeloid-leukemia-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rf1v-1018-plague-pneumonic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rf1v-1018-prevention-of-pneumonic-plague-resulting-from-ae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/riboflavin-keratolysis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rice-formula-cow-milk-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rifampicin-severe-acute-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rifaximin-clostridium-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rifaximin-nonalcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rifaximin-travelers-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rifaximin-tropical-enteropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/riluzole-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rituximab-fatigue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rituximab-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rituximab-kidney-transplant-rejection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rituximab-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rivastigmine-transdermal-system-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/roginolisib-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ropivacaine-injection-stress-disorders-post-traumatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sargramostim-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rsv-a-memphis-37-respiratory-syncytial-virus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rts-s-as01b-50mcg-of-rts-s-and-standard-adult-do-plasmodium-falciparum-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/rucaparib-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/s-1-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/s-1-locally-advanced-or-metastatic-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/salbutamol-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/saline-chorioamnionitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sargramostim-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sars-cov-2-convalescent-plasma-sars-cov-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/saturated-fat-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sbrt-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/seasonal-malaria-chemoprevention-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/selenase-selenium-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/self-hypnotic-relaxation-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/selpercatinib-monotherapy-differentiated-thyroid-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/selumetinib-malignant-peripheral-nerve-sheath-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/selumetinib-metastatic-thyroid-gland-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/semaglutide-0-5-mg-ml-cognitive-change 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/semaglutide-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/semaglutide-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sertraline-generalised-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sesame-oil-caloric-restriction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sham-comparator-plasma-ball-phantom-limb-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/shigella-sonnei-53g-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ui15aml055mt-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/shigella-sonnei-53g-shigellosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sildenafil-citrate-edema-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sildenafil-scleroderma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/siltuximab-schwannomatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/silver-sulfadiazine-superficial-partial-thickness-burn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/simvastatin-recurrent-acute-pancreatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sitz-markers-return-of-bowel-function-after-colon-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sodium-iodide-transient-hypothyroxinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/som-230-pasireotide-atypical-ductal-breast-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sorafenib-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sp-chloroquine-amodiaquine-primaquine-artesunate-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/spinalon-buspirone-levodopa-cardidopa-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/splinting-hand-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sr-a-epratuzumab-acute-lymphoblastic-leukemia-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/srx246-ptsd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/standard-care-arm-radiation-proctopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/standard-of-care-plus-epoprostenol-infusion-for-frostbite 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/standard-of-care-po-oral-antibiotics-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/standard-treatment-control-arm-cervical-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/stellate-ganglion-block-injection-with-ropivican-post-traumatic-stress-disorder-ptsd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/stereotactic-radiosurgery-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/steroids-switch-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/subcutaneous-treprostinil-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sublingual-nitroglycerine-colic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/substructure-informed-planning-brain-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sufentanil-30-mcg-sublingual-tablet-traumatic-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sulfadoxine-pyrimethamine-anaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sulfadoxine-pyrimethamine-malaria-uncomplicated 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/super-cereal-plus-sc-moderate-acute-malnutrition-mam 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/supplementary-food-moderate-acute-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/surgery-with-an-external-ring-fixator-severe-open-fractures-of-the-tibia-shin-bone 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sutent-sunitinib-neurofibromatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/sx-682-metastatic-castrate-resistant-prostate-cancer-mc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/synbiotic-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tadalafil-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tadalafil-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/taf-evg-vaginal-insert-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/taf-evg-vaginal-insert-safety-issues 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/targeted-amino-acid-supplement-parkinson-disease-pd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/targeting-normoxemia-spo2-90-96-pao2-60-100-mmhg-critical-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/taxotere-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tecovirimat-smallpox 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/telehealth-intervention-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tenofovir-gel-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tenofovir-gel-hiv-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tepotinib-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/teriparatide-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/teriparatide-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/teriparatide-stress-fracture 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/teriparatide-stress-fracture-of-tibia-or-fibula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tesamorelin-2-milligrams-mg-peripheral-nerve-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/test-formula-cow-s-milk-allergy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tested-formula-with-fiber-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/testosterone-cypionate-castration-resistant-metastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/testosterone-gel-applied-by-a-pump-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/thalidomide-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/therapeutic-progesterone-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/thyroplasty-vocal-cord-paralysis-unilateral 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tibolone-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tice-bcg-for-intravesical-use-bcg-live-strain-of-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tirzepatide-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tki-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tobramycin-injection-wound-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tocilizumab-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tolcapone-impulsive-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tranexamic-acid-spinal-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/topiramate-alcohol-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/topiramate-ptsd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/topiramate-traumatic-brain-injury-tbi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tpoxx-smallpox 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/traditional-fabricated-prosthetic-socket-amputation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tranexamic-acid-1000-mg-10ml-normal-saline-infus-postpartum-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tranexamic-acid-anterior-cruciate-ligament-reconstruction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tranexamic-acid-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/transcon-peg-treprostinil-pah 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trastuzumab-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trastuzumab-metastatic-colon-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trastuzumab-metastatic-colorectal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trazodone-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trc105-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treatment-a-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treatment-glucose-metabolism-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trihexyphenidyl-dystonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treatment-group-post-operative-surgical-site-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-dienthanolmine-sustained-release-critical-limb-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-diethanolamine-hypertension-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-diethanolamine-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-diethanolamine-systemic-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-inhalation-powder-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-inhalation-solution-respiratory-distress-syndrome-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-ischemia-reperfusion-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-sodium-hypertension-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-sodium-liver-transplant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-sodium-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/treprostinil-sodium-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trf-tocotrienol-rich-fraction-end-stage-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/triamcinolone-acetonide-ketorolac-ropivacaine-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trientine-hypertrophic-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/trimebutine-maleate-newbutin-sr-300-mg-tab-nausea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/tumour-biopsy-and-venous-blood-tests-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-221-chronic-idiopathic-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-221-chronic-spontaneous-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-221-urticaria-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-311-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/placebo-nafld 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-421-25-mg-kg-q2w-hiv-1-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-421-hiv-1-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-421-sc-hiv-1-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-612-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-621-genital-herpes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ub-921-breast-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ubt251-injection-2-0-mg-and-ubt251-injection-pla-obesity-amp-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ubt251-injection-2-0-mg-and-ubt251-injection-pla-type-2-diabetes-mellitus-t2dm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ubt251-metabolic-dysfunction-associated-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ubt251-obesity-amp-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ui009-health 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ui022-or-ui023-and-co-administration-of-matching-peripheral-arterial-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ui059-gastro-intestinal-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ui059-gerd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ui05msp015ct-functional-dyspepsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/uic201602-and-co-administration-of-uic201601-and-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ukidney-kidney-failure-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/unex-42-bronchopulmonary-dysplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/urine-culture-urinary-tract-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/usb005-aclerastide-ophthalmic-solution-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ut-15-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ut-15c-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ut-15c-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-110-weekly-mps-iv-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ut-15c-sr-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ut-15c-sr-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/ut-15c-sr-treprostinil-diethanolamine-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/v920-ebola-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vaccine-device-combination-for-prevention-of-hfr-hemorrhagic-fever-with-renal-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/valaciclovir-aciclovir-critical-illness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/valproic-acid-pain-phantom 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/valproic-acid-retinitis-pigmentosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/valproic-acid-solution-acute-kidney-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vancomycin-open-fracture 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vasopressin-traumatic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/venetoclax-400-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/venezuelan-equine-encephalitis-dna-vaccine-vaccine-reaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vestibular-ocular-motor-screening-tool-voms-mild-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vinflunine-locally-advanced-or-metastatic-penile-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitaflow-preload-starvation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamin-a-retinyl-palmitate-vitamin-a-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamin-a-supplementation-15-000-ug-retinol-equi-mortality-through-six-months-of-age 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamin-d-and-calcium-vitamin-d-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamin-d-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamin-d3-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamin-k-calciphylaxis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vitamins-and-minerals-complications-of-other-bariatric-procedure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vla2001-sars-cov-2-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vmp001-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vrc-hivdna016-00-vp-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/vs-6766-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/warfarin-subsegmental-pulmonary-embolism-nos 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/wecareadvisor-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/wheat-soy-blend-plus-plus-wsb-with-nutrition-cou-moderate-acute-malnutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/wheat-soy-blend-wsb-stunting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/whey-protein-high-blood-pressure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/white-wine-unspecified-adult-solid-tumor-protocol-specific 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/whole-body-non-contrast-mri-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/whole-cooked-beans-with-rice-meals-blood-glucose 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/whole-exome-sequencing-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/whole-peanuts-without-skins-peanut-butter-or-no-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/wild-blueberry-containing-foods-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/wx-uk1-in-combination-with-capecitabine-advanced-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/xolair-atopic-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/yogurt-smoothie-with-bb-12-metabolic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zd6474-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zelenirstat-relapsed-adult-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zinc-sulphate-20-mg-bronchiolitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zinc-sulphate-diarrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zinc-sulphate-dietary-supplement-nutrition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zinc-supplementation-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zithromax-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zoledronate-hip-fractures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zoledronate-therapy-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zoledronic-acid-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zonisamide-100mg-cap-hearing-loss-noise-induced 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/united-therapeutics-corp/projects/zonisamide-alcohol-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/amphetamine-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/chronocort-adrenal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/chronocort-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/chronocort-primary-adrenal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/crinecerfont-cah-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/crinecerfont-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/dexamethasone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/ditest-male-hypogonadism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/elagolix-folliculogenesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/hydrocortisone-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/hydrocortisone-granules-adrenal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/hydrocortisone-modified-release-capsules-endocrine-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/indiplon-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/infacort-adrenal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/infacort-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/interleukin-4-pe38kdel-cytotoxin-brain-and-central-nervous-system-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/interleukin-4-pe38kdel-cytotoxin-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/luvadaxistat-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-1065845-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-1065890-tardive-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-1070770-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-1117568-bipolar-i-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-1117568-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-1117570-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-34060-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-5788-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-6024-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-041-stable-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-74788-cah-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux003-mps-7 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-77860-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-827104-epileptic-encephalopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-827104-essential-tremor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-921352-focal-onset-seizure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-921352-scn8a-developmental-and-epileptic-encephalopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-98854-50-mg-capsule-once-daily-effect-of-ketoconazole-on-the-pk-of-nbi-98854-in 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-98854-50-mg-capsule-safety-tolerability-and-pk-of-nbi-98854-in-hepat 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-98854-tardive-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/nbi-98854-tourette-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/opicapone-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/placebo-anhedonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/placebo-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/placebo-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/placebo-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-041-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegph20-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-653-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-653-placebo-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-831-friedreich-ataxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-831-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-831-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-831-oral-suspension-schizophrenia-cerebellar-ataxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-831-oral-tablet-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-831-t2-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/tak-831-tablet-t2-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-chorea-huntington 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-obsessive-compulsive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-oral-capsule-tardive-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-oral-capsule-trichotillomania-hair-pulling-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-tardive-dyskinesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-tardive-dyskinesia-td 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/valbenazine-tourette-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/vy-aadc01-idiopathic-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/vy-aadc01-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/neurocrine-biosciences-inc/projects/vy-aadc02-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/a-benzodiazepine-drug-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/adx-n05-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/asparaginase-erwinia-chrysanthemi-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/asparaginase-erwinia-chrysanthemi-b-acute-lymphoblastic-leukemia-philadelphia-chro 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/atezolizumab-endometrial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/atezolizumab-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/avelumab-pd-l1-inhibitor-immunotherapy-lurbinect-metastatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/bicarbonate-de-sodium-hematologic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/brincidofovir-adenovirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/brincidofovir-adenovirus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/brincidofovir-adenovirus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/brincidofovir-cmv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/brincidofovir-cytomegalovirus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/brincidofovir-cytomegalovirus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/brincidofovir-double-stranded-dna-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cannabidiol-cbd-clinical-high-risk-for-psychosis-chr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cannabidiol-early-life-adversity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cannabidiol-epidiolex-study-the-efficacy-of-epidiolex-for-typical-abse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cannabidiol-lennox-gastaut-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cannabidiol-oral-solution-epidiolex-tuberous-sclerosis-complex-associated-neuropsych 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cannabidiol-sturge-weber-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cannabidivarin-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cbd-400-mg-opiate-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cbd-oral-solution-ecbd-system-target-fragile-x-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cbd-oral-solution-fragile-x-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cbd-os-focal-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/clonazepam-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cmx001-ebola-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cmx001-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cmx001-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cmx157-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-1-irinotecan-hcl-floxuridine-liposome-inject-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-acute-myeloid-leukemia-aml-in-remission 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-cytarabine-daunorubicin-liposome-injecti-hematologic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-hematologic-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-high-risk-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-lymphoid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cpx-351-myeloid-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cx-8998-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cx-8998-essential-tremor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cx-8998-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cytarabine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cytarabine-and-idarubicin-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/cytarabine-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/defibrotide-covid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/defibrotide-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/defibrotide-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/defibrotide-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/defibrotide-hepatic-veno-occlusive-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/actr707-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/defibrotide-severe-hepatic-veno-occlusive-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dordaviprone-onc201-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/defibrotide-transplant-associated-thrombotic-microangiopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dociparstat-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dociparstat-sodium-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dociparstat-sodium-coronavirus-disease-2019-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dordaviprone-onc201-diffuse-intrinsic-pontine-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dordaviprone-onc201-endometrial-cancer-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dordaviprone-onc201-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/dordaviprone-onc201-h3-k27m 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/enasidenib-mesylate-recurrent-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/epidiolex-100-mg-ml-oral-solution-dravet-syndrome-ds 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/epidiolex-100-mg-ml-oral-solution-electrical-status-epilepticus-of-slow-wave-sleep 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/erwinase-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/erwinaze-asparaginase-erwinia-chrysanthemi-erwin-acute-lymphoblastic-leukemia-all-lymphoblastic-l 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/erwinia-chrysanthemi-asparaginase-acute-lymphoblastic-leukemia-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/everolimus-diffuse-intrinsic-pontine-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/experimental-anti-anxiety-drug-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/fludarabine-acute-myeloid-leukemia-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/fludarabine-hematologic-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gemtuzumab-ozogamicin-acute-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gilteritinib-acute-myeloid-leukemia-with-flt3-itd-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/glasdegib-acute-myelogenous-leukemia-aml-due-to-therapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gw-1000-02-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gw-1000-02-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-dyslipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-20-mg-kg-day-dose-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-5-mg-kg-day-dose-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-infantile-spasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-lennox-gastaut-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-rett-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-seizure-in-participants-with-tuberous-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-seizures-associated-with-emas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42003-p-tuberous-sclerosis-complex 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42004-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42006-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/gwp42006-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/im-jzp-458-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp-110-excessive-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp-110-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp-110-obstructive-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp-258-idiopathic-hypersomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp-258-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp-258-narcolepsy-with-cataplexy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp047-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp150-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp258-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp258-xywav-idiopathic-hypersomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp341-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp3507-meningioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp385-essential-tremor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp441-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp441-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp541-irritability-associated-with-autism-spectrum-dis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp815-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/jzp898-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/liposome-encapsulated-daunorubicin-cytarabine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/liposome-encapsulated-daunorubicin-cytarabine-acute-myeloid-leukemia-arising-from-previous-mye 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/liposome-encapsulated-daunorubicin-cytarabine-essential-thrombocythemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-4-mg-injection-zepzelca-gastrointestinal-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-advanced-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-ewing-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-extensive-stage-lung-small-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-extensive-stage-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-locally-advanced-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-refractory-ewing-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/lurbinectedin-small-cell-lung-cancer-sclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/mpeg-r-crisantaspase-hematologic-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nabiximols-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nabiximols-multiple-sclerosis-ms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nabiximols-nmo-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nabiximols-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nabiximols-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nabiximols-spasticity-in-participants-with-multiple-scleros 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nabiximols-spasticity-with-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/nivolumab-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/odsh-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/odsh-at-0-125-mg-kg-h-protein-losing-enteropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/onc201-advanced-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/onc201-diffuse-intrinsic-pontine-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/onc201-meningioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/onc201-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/onc206-advanced-pheochromocytoma-and-paraganglioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/onc206-central-nervous-system-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/onc206-diffuse-midline-glioma-dmg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/open-label-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux701-wilson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/paclitaxel-gastroesophageal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/paclitaxel-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/pegcrisantaspase-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-chronic-fatigue-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-palliative-care 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-spray-and-oral-moxifloxacin-placebo-effects-of-sativex-on-ecg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/placebo-viruria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/rapydan-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-and-rifampicin-evaluation-of-pharmacokinetics-of-sativex-in-the 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-cerebral-palsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/mexiletine-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-detrusor-overactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-evaluation-of-abuse-potential-of-sativex 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-food-effect 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-spasticity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sativex-treatment-a-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sm-edtmp-metastatic-osteosarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/xyrem-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-alternating-hemiplegia-of-childhood 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-essential-tremor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-rem-sleep-behavior-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/sodium-oxybate-sleep 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/solriamfetol-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/st-thomas-coronary-artery-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/supersaturated-calcium-phosphate-oral-complaints 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/tetrahydrocannabinol-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/ultrasound-elastography-bone-marrow-transplant-complications 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/vyxeos-44-mg-100-mg-liposome-injection-relapsed-pediatric-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/vyxeos-acute-myeloid-leukaemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/vyxeos-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/xyrem-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/xyrem-narcolepsy-with-cataplexy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/xyrem-sodium-oxybate-oral-solution-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/xyrem-sodium-oxybate-oral-solution-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/xyrem-x-obstructive-sleep-apnea-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zanidatamab-biliary-tract-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zanidatamab-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zanidatamab-gastroesophageal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zanidatamab-her2-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zanidatamab-metastatic-her2-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zanidatamab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zw25-zanidatamab-her2-expressing-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zw25-zanidatamab-her2-expressing-gastrointestinal-cancers-includi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jazz-pharmaceuticals-plc/projects/zw25-zanidatamab-her2-hr-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/acupuncture-fatigue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ak112-injection-non-squamous-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ak112-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/bottle-pack-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/control-femoral-perineural-local-anesthetic-infu-postoperative-pain-following-knee-arthroplasty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/drug-ivonescimab-injection-metastatic-colorectal-cancer-crc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ezutromid-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/fish-oil-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/hyperbaric-oxygen-therapy-tbi-traumatic-brain-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/infasurf-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-10-mg-kg-extensive-stage-lung-small-cell-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-10-mg-kg-squamous-cell-carcinoma-head-and-neck-cancer-hns 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-advanced-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-biliary-tract-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-cutaneous-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-endometrial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-injection-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-leiomyosarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-metastatic-esophageal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-pleural-mesotheliomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-salivary-gland-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-stomach-cancer-stage-iv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-thymus-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ivonescimab-tnbc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ketamine-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/nebivolol-ophthalmic-suspension-1-percent-open-angle-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/replens-and-coconut-oil-genitourinary-abnormality 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ridinilazole-clostridioides-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/ridinilazole-clostridium-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/smt-c1100-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/smt-c1100-muscular-dystrophy-duchenne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/smt19969-clostridium-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/summit-therapeutics/projects/vendy-harm-reduction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/akcea-angptl3-lrx-familial-chylomicronemia-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/akcea-angptl3-lrx-familial-partial-lipodystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/akcea-angptl3-lrx-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/alicaforsen-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/alicaforsen-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/apoc-iii-l-rx-elevated-triglycerides-tg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/azd9150-advanced-adult-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/biib094-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/donidalorsen-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/donidalorsen-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/eplontersen-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/eplontersen-hereditary-transthyretin-mediated-amyloid-polyne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/eplontersen-transthyretin-mediated-amyloid-cardiomyopathy-at 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/fomivirsen-sodium-cytomegalovirus-retinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ghr-lrx-acromegaly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/inotersen-fap 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/inotersen-hereditary-transthyretin-mediated-amyloid-polyne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion-682884-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion-827359-chronic-bronchitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion224-steatohepatitis-nonalcoholic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion251-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion269-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion337-dravet-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion356-pelizaeus-merzbacher-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion363-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion440-methyl-cpg-binding-protein-2-mecp2-duplication-s 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion464-multiple-system-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion537-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion547-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-120-chondrosarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion582-angelman-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion717-prion-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion775-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion904-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ion904-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-agt-lrx-chronic-heart-failure-with-reduced-ejection-frac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-agt-lrx-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-angptl3-lrx-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-ghr-lrx-acromegaly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-apo-a-lrx-elevated-lipoprotein-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-dgat2rx-hepatic-steatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-dmpkrx-myotonic-dystrophy-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-enacrx-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-fb-lrx-geographic-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-fb-lrx-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-fb-lrx-primary-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-fxi-lrx-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-hbvrx-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-maptrx-mild-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-pkkrx-isis-546254-chronic-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-stat3rx-advanced-cancers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/ionis-tmprss6-lrx-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-104838-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-681257-elevated-lipoprotein-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-113715-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-14803-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-14803-peginterferon-alfa-ribavirin-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-2503-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-301012-hypercholesterolemia-familial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-301012-or-placebo-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-301012-or-placebo-hypercholesterolemia-familial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-325568-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-333611-familial-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-3521-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-353512-inflammatory-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-388626-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-416858-end-stage-renal-disease-esrd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-420915-gsk-299872-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-443139-10-mg-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-678354-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-681257-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-721744-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/cap-1002-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-apo-a-rx-elevated-lipoprotein-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-apoc-iii-rx-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-apociiirx-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-crp-rx-or-placebo-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-crp-rx-paroxysmal-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-eif4e-rx-castrate-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-eif4e-rx-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-fgfr4rx-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-fxirx-dose-2-venous-thromboembolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-gccrrx-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-gcgrrx-dose-level-1-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-gcgrrx-dose-level-1-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-gcgrrx-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/isis-ptp1brx-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-lipid-metabolism-inborn-errors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-metabolic-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-sodium-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-sodium-heterozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-sodium-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/mipomersen-sodium-lipid-metabolism-inborn-errors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/olezarsen-familial-chylomicronemia-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/olezarsen-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/olezarsen-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/placebo-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/placebo-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/placebo-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/placebo-mild-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/sapablursen-beta-thalassemia-intermedia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/sapablursen-phlebotomy-dependent-polycythemia-vera 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/tofersen-als-caused-by-superoxide-dismutase-1-sod1-mutati 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/tofersen-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/volanesorsen-abnormalities-cardiovascular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/volanesorsen-familial-chylomicronemia-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/volanesorsen-familial-partial-lipodystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/volanesorsen-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/warfarin-sodium-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ionis-pharmaceuticals-inc/projects/zilganersen-alexander-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-02-oral-zoledronate-complex-regional-pain-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-02-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-agitation-in-patients-with-dementia-of-the-alzhe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-dextromethorphan-and-bupropion-oral-table-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-dextromethorphan-bupropion-agitation-in-patients-with-dementia-of-the-alzhe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-dextromethorphan-bupropion-treatment-resistant-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-treatment-resistant-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-05-treatment-resistant-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-07-meloxicam-rizatriptan-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-07-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-07-moseic-meloxicam-and-rizatriptan-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-12-reboxetine-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/axs-14-esreboxetine-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/dextromethorphan-bupropion-major-depressive-disorder-mdd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-150-mg-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-150-mg-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-150-mg-excessive-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-150-mg-major-depressive-disorder-with-excessive-daytime 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-150-mg-oral-tablet-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-300-mg-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-75-mg-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-75mg-150-mg-or-300-mg-binge-eating-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-excessive-daytime-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/axsome-therapeutics/projects/solriamfetol-oral-tablet-excessive-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/100-mg-resmetirom-tablet-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/atorvastatin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/mgl-3196-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/mgl-3196-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/mgl-3196-nash-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/mgl-3196-non-alcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/mgl-3196-resmetirom-heterozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/mgl-3196-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/placebo-drug-safety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/placebo-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/resmetirom-mash-metabolic-dysfunction-associated-steatohepa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/resmetirom-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/resmetirom-non-alcoholic-fatty-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/madrigal-pharmaceuticals-inc/projects/simvastatin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/anti-hypertensive-therapy-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-520-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-520-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-520-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-520-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-520-injection-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-520-injection-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-521-injection-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/arc-aat-injection-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-aat-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-aat-injection-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-alk7-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-ang-3-injection-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-ang3-dyslipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-apoc3-dyslipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-apoc3-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-apoc3-mixed-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-apoc3-severe-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-atxn2-injection-spinocerebellar-ataxia-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-cfb-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-dimerpa-hyperlipidemia-mixed 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-110-weekly-mucopolysaccharidosis-iv-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-dm1-intravenous-iv-infusion-myotonic-dystrophy-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-enac-cystic-fibrosis-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-hbv-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-hif2-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-hsd-injection-non-alcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-inhbe-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-mapt-sc-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-mmp7-inhalation-solution-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-muc5ac-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-rage-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-rage-injection-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/aro-sod1-injection-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/azithromycin-pill-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/bevacizumab-pterygium 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/calcium-carbonate-uterine-contraction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-333-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/fazisiran-injection-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/plozasiran-familial-chylomicronemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/plozasiran-familial-chylomicronemia-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/plozasiran-injection-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/plozasiran-severe-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/statins-intracerebral-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/tranexamic-acid-hemorrhagic-shock 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/venofer-200-mg-per-10-ml-injection-iron-deficiency-anemia-of-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/vsa001-injection-healthy-adult-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/zodasiran-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrowhead-pharmaceuticals-inc/projects/zodasiran-injection-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/6r-bh4-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/6r-bh4-isolated-systolic-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/6r-bh4-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/6r-bh4-sapropterin-dihydrochloride-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/active-bmn-111-subcutaneous-injection-of-recomme-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/aldurazyme-mucopolysaccharidosis-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/aldurazyme-recombinant-human-alpha-l-iduronidase-mucopolysaccharidosis-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bh4-pku-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-044-iv-6-mg-kg-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-110-mps-iv-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-110-mucopolysaccharidosis-iva 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-110-mucopolysaccharidosis-iva-morquio-a-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-111-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-111-administration-via-injector-pen-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-165-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-165-ravpal-peg-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-190-jansky-bielschowsky-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-190-recombinant-human-tripeptidyl-peptidase-jansky-bielschowsky-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-255-hyperoxaluria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-307-phenylketonuria-pku 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-349-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-351-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-351-duchenne-muscular-dystrophy-dmd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-701-late-onset-pompe-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn-701-pompe-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/bmn165-20mg-day-phenylketonuria-pku 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/cisplatin-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/dose-1-of-bmn-331-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/drisapersen-muscular-dystrophies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/inz-701-ectonucleotide-pyrophosphatase-phosphodiesterase 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/kuvan-autistic-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/kuvan-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/kuvan-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/kuvan-phenylketonuria-pku 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/laronidase-cognitive-decline 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/laronidase-mucopolysaccharidosis-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/n-acetylgalactosamine-4-sulfatase-mucopolysaccharidosis-vi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/naglazyme-maroteaux-lamy-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/naglazyme-mucopolysaccharidosis-vi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/parp-inhibitor-bmn-673-metastatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/pegvaliase-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/pegvaliase-phenylketonuria-pku 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/phenoptin-tetrahydrobiopterin-deficiencies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/placebo-mucopolysaccharidosis-vi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/pro044-sc-6-mg-kg-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/pro044-sc-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/pro045-0-15-mg-kg-week-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/ravpal-peg-0-001-mg-kg-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/ravpal-peg-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/rdd-to-palynziq-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/regimen-selection-phase-group-2-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/rhidu-recombinant-human-alpha-l-iduronidase-mucopolysaccharidosis-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-autistic-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-behavioral-manifestations-of-lesch-nyhan-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-6r-bh4-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-6r-bh4-tetrahydrobio-phenylketonurias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-endothelial-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-intermittent-claudication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-phenylketonurias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-dihydrochloride-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-gtp-cyclohydrolase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-hyperphenylalaninemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/sapropterin-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/saproterin-dihydrochloride-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/talazoparib-childhood-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/talazoparib-tosylate-advanced-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/tetrahydrobiopterin-10-mg-kg-claudication-intermittent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/valoctocogene-roxaparvovec-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/valoctocogene-roxaparvovec-hemophilia-a-with-inhibitor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/valoctocogene-roxaparvovec-severe-haemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/vosoritide-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/vosoritide-hypochondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/vosoritide-injection-idiopathic-short-stature 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biomarin-pharmaceutical-inc/projects/vosoritide-injection-noonan-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/praxis-precision-medicines/projects/hiv-1-c4-v3-polyvalent-peptide-vaccine-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/praxis-precision-medicines/projects/nimotuzumab-pancreatic-cancer-advanced-or-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/praxis-precision-medicines/projects/pneumococcal-vaccine-polyvalent-23-valent-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/praxis-precision-medicines/projects/prx-p4-003-fcf-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/praxis-precision-medicines/projects/telemedically-guided-oropharyngeal-nasal-op-n-se-telemedicine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/praxis-precision-medicines/projects/transcutaneous-cervical-spinal-cord-stimulation-spinal-cord-injury-cervical 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb105-autosomal-recessive-ichthyosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb105-tgm-1-related-autosomal-recessive-congenital-ich 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb301-skin-roughness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb304-wrinkles-in-decolletage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb407-nebulization-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb408-nebulization-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb707-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb707-lung-cancer-non-small-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb801-neurotrophic-keratitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/kb803-dystrophic-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/ly2456302-anxiety-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/mebendazole-pilomyxoid-astrocytoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/open-label-topical-beremagene-geperpavec-b-vec-dystrophic-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/krystal-biotech/projects/topical-beremagene-geperpavec-dystrophic-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/5-fluorouracil-5-fu-gastric-adenocarcinoma-or-gastroesophageal-junct 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/atezolizumab-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/axumin-pet-ct-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/chemophase-superficial-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/cinryze-with-rhuph20-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/cohort-1-bococizumab-150-mg-rhuph20-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/commercial-hylenex-recombinant-hyaluronidase-hum-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/eribulin-mesylate-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/gemcitabine-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/gemcitabine-stage-iv-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/humalog-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/humalog-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/humalog-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/hyaluronidase-human-recombinant-rehydration-flui-dehydration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/hylenex-facilitated-subcutaneous-lactated-ringer-dehydration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/hylenex-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/hylenex-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/insulin-aspart-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/insulin-lispro-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/insulin-lispro-diabetes-mellitus-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/insulin-lispro-diabetes-mellitus-type-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/isotonic-hydration-fluid-and-recombinant-human-h-dehydration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/large-protein-molecule-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/mitomycin-c-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/ondansetron-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegph20-cholangiocarcinoma-non-resectable 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegph20-metastatic-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegph20-metastatic-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegph20-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegph20-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegvorhyaluronidase-alfa-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/pegylated-recombinant-human-hyaluronidase-ph20-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/placebo-pancreatic-ductal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/rapid-acting-insulin-with-pre-treatment-of-rhuph-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/recombinant-human-hyaluronidase-dehydration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/recombinant-human-hyaluronidase-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/recombinant-human-hyaluronidase-ph20-rhuph20-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/rhuph20-dermatitis-allergic-contact 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/rhuph20-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/rhuph20-risk-factors-for-or-a-diagnosis-of-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/sc-hylenex-and-ceftriaxone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/sham-injection-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/subcutaneous-hylenex-recombinant-human-hyaluroni-dehydration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/halozyme-therapeutics-inc/projects/testosterone-enanthate-hypogonadism-male 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-253-myeloid-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-333-non-hodgkin-lymphoma-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-413-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-474-placebo-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-579-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-621-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-621-eosinophilic-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/kt-621-healthy-participants-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/sar444656-kt-474-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kymera-therapeutics/projects/sar444656-kt-474-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/open-label-rusfertide-polycythemia-vera 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/placebo-polycythemia-vera 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/pn-232-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/pn-235-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/pn-881-oral-solution-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/pn-943-ulcerative-colitis-chronic-moderate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/ptg-100-celiac-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/ptg-100-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/ptg-300-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/ptg-300-hereditary-hemochromatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/ptg-300-polycythemia-vera 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/protagonist-therapeutics-inc/projects/ptg-300-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/14c-cort113176-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/14c-cort125134-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/14c-cort125281-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort113176-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort113176-lipid-capsule-formulation-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort118335-25-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort118335-oral-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort125134-150-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort125134-cushing-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort125134-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort125236-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort125281-40mg-fasted-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/cort125329-lipid-capsule-formulation-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/dabigatran-etexilate-cushing-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/dazucorilant-300-mg-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/dazucorilant-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/dazucorilant-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/enzalutamide-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/enzalutamide-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/exicorilant-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/midazolam-hydrochloride-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-1200-mg-daily-treatment-resistant-ptsd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-300-mg-drug-interaction-potentiation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-300-mg-korlym-hypercortisolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-and-eribulin-in-combination-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-central-adrenal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-cushing-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-cushing-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-fluvastatin-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-psychotic-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/mifepristone-weight-gain-prevention 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-150-mg-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-300-mg-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-antipsychotic-induced-weight-gain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-antipsychotic-induced-weight-gain-aiwg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-cohort-a-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-non-alcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-nonalcoholic-steatohepatitis-nash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorilant-treatment-a-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/miricorlilant-antipsychotic-induced-weight-gain-aiwg 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/nab-paclitaxel-80-mg-m-2-ovarian-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/nenocorilant-200-mg-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/olanzapine-antipsychotic-induced-weight-gain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-100-mg-and-25-mg-metastatic-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-150-mg-once-daily-qd-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-150-mg-once-daily-qd-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-350mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-3x100-mg-softgel-capsules-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-adrenocortical-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-cushing-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-fasted-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-hypercortisolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-recurrent-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-under-fasted-conditions-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/relacorilant-with-nab-paclitaxel-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corcept-therapeutics-inc/projects/risperidone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/spyre-therapeutics/projects/spy001-001-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/spyre-therapeutics/projects/spy001-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/spyre-therapeutics/projects/spy002-072-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/spyre-therapeutics/projects/spy002-091-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/spyre-therapeutics/projects/spy003-207-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/ablation-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/ablation-procedure-and-or-cardioversion-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/access-arm-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/anti-arrhythmics-arrhythmia-cardiac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/arctic-front-advance-cardiac-cryoablation-system-paroxysmal-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/baroreceptor-stimulation-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/bivamelagon-hypothalamic-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/bupivacaine-alone-or-bupivacaine-ketorolac-ketam-pain-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/cardiac-resynchronization-therapy-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/carelink-remote-monitoring-pacemaker 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/cg-future-annuloplasty-ring-band-mitral-valve-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/chronotropic-incompetence-diagnostic-algorithm-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/class-i-or-iii-antiarrhythmic-medications-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/conducted-af-response-algorithm-cafr-on-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/coronary-artery-bypass-grafting-ischemic-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/crt-aop-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/crt-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/crt-p-or-crt-d-device-heart-failure-congestive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/crt-with-triple-site-ventricular-stimulation-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/diuretics-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/doac-ventricular-tachycardia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/dual-chamber-pacemeker-syncope 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/early-standardised-rhythm-control-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/fill-out-questionnaire-bradycardia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/flecainide-or-sotalol-or-propafenone-paroxysmal-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/freezor-cardiac-cryoablation-catheter-cryoconsol-tachycardia-atrioventricular-nodal-reentry 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/icd-ablation-plus-vt-ablation-tachycardia-ventricular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/implantable-cardiac-defibrillator-tachycardia-ventricular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/implantable-cardiac-monitor-chagas-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/implantable-cardioverter-defibrillator-acute-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/implantable-defibrillator-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/intravenous-sotalol-administered-as-a-loading-do-arrhythmias-cardiac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/lb54640-hypothalamic-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/lv-dp-dt-pressure-measurement-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/managed-ventricular-pacing-programmed-on-off-cardiovascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/marvel-algorithm-atrioventricular-conduction-block 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/medtronic-at500-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/medtronic-endeavor-resolute-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/medtronic-primeadvanced-neurostimulator-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/medtronic-talent-stent-graft-system-aortic-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/monthly-review-arm-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/pacemaker-medtronic-enrhythm-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/pacing-lead-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/part-a-rm-718-or-placebo-matched-to-specific-rm-hypothalamic-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/pci-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/placebo-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/programming-crt-d-icd-optivol-and-cardiac-compas-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/reveal-xt-insertable-cardiac-monitor-cryptogenic-symptomatic-transient-ischemic-attac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/rf-ablation-procedure-paroxysmal-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/rm-493-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/search-av-algorithm-arrhythmia-sinus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-2-mg-bardet-biedl-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-bardet-biedl-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-bardet-biedl-syndrome-bbs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-genetic-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-hypertriglyceridemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-hypothalamic-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-leptin-receptor-deficiency-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-obesity-associated-with-defects-in-leptin-melano 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-overweight-and-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-pro-opiomelanocortin-pomc-deficiency-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/setmelanotide-renal-insufficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/single-site-pacing-acute-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/stent-ischemic-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/tideglusib-arrhythmogenic-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/tyrx-absorbable-antibacterial-envelope-cied-related-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/use-of-an-implantable-loop-recorder-syncope 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/vagal-nerve-stimulation-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rhythm-pharmaceuticals-inc/projects/ventricular-assist-device-system-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/cbs001-chronic-inflammatory-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/cleminorexton-narcolepsy-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/imgatuzumab-cutaneous-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/lb101-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/lixivaptan-autosomal-dominant-polycystic-kidney 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/lixivaptan-polycystic-kidney-disease-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/orx142-tablets-excessive-daytime-sleepiness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/orx489-tablets-healthy-adult-male-and-female-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/orx750-narcolepsy-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/serpinpc-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/serpinpc-hemophilia-b-with-inhibitor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/centessa-pharmaceuticals-plc/projects/zf874-alpha1-anti-trypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apogee-therapeutics/projects/abc294640-carcinoma-hepatocellular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apogee-therapeutics/projects/abc294640-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apogee-therapeutics/projects/apg777-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apogee-therapeutics/projects/opaganib-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tg-1801-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/apogee-therapeutics/projects/sphingosine-kinase-2-inhibitor-abc294640-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/acalabrutinib-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/azercabtagene-zapreleucel-azer-cel-b-cell-mediated-autoimmune-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/cosibelimab-b-cell-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/nm1f-injection-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/obinutuzumab-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/pembrolizumab-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tg-1701-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgi-5-crc-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgi-6-injection-advanced-or-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgr-1202-brentuximab-vedotin-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgr-1202-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgr-1202-chronic-lymphocytic-leukemia-small-lymphocytic-l 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgr-1202-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgr-1202-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgr-1202-obinutuzumab-chlorambucil-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/tgr-1202-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-autoimmune-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-follicular-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-multiple-sclerosis-ms-relapsing-remitting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-non-hodgkins-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-relapsing-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-relapsing-multiple-sclerosis-rms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-relapsing-remitting-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/ublituximab-tgr-1202-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/umbralisib-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/umbralisib-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/umbralisib-marginal-zone-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tg-therapeutics-inc/projects/venetoclax-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/blinded-cdca-250-mg-tid-ctx 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/brelovitug-300-mg-chronic-hepatitis-d-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/brelovitug-bjt-778-chronic-hepatitis-d 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/cholic-acid-bile-acid-synthesis-defect 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/cholic-acid-inborn-errors-of-bile-acid-synthesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/cholic-acids-infantile-refsum-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/livmarli-oral-product-alagille-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/low-dose-of-mrm-3379-fragile-x-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/lum001-alagille-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/lum001-maralixibat-alagille-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/lum001-maralixibat-progressive-familial-intrahepatic-cholestasis-pf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/lum001-pbc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/lum001-primary-biliary-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/lum001-primary-sclerosing-cholangitis-psc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/maralixibat-biliary-atresia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/maralixibat-cholestatic-liver-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/maralixibat-cholestatic-liver-disease-except-algs-pfic-pbc-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/maralixibat-intrahepatic-cholestasis-of-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/maralixibat-progressive-familial-intrahepatic-cholestasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/placebo-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/shp626-non-alcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/volixibat-intrahepatic-cholestasis-of-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/volixibat-primary-biliary-cholangitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mirum-pharmaceuticals/projects/volixibat-primary-sclerosing-cholangitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/aav2-haadc-aromatic-amino-acid-decarboxylase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-amino-acid-metabolism-inborn-errors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-aniridia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-muscular-dystrophy-duchenne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-nonsene-mutation-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-pembrolizumab-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ataluren-ptc124-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/cnsa-001-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/deflazacort-and-rifampin-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/deflazacort-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/deflazacort-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/deflazacort-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/deflazacort-limb-girdle-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/deflazacort-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/eladocagene-exuparvovec-aadc-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/epi-589-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/epi-743-leigh-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/gene-therapy-aromatic-l-amino-acid-decarboxylase-aadc-deficie 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/placebo-friedreich-s-ataxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/placebo-leigh-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc124-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc124-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc299-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc299-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc299-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc299-neurofibromatosis-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc299-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc518-huntington-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc596-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc596-high-grade-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc857-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc923-bh4-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/ptc923-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/sepiapterin-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/unesbulin-leiomyosarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/unesbulin-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/vatiquinone-friedreich-ataxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/vatiquinone-inherited-mitochondrial-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/vatiquinone-mitochondrial-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/vegf-inhibitor-ptc299-brain-and-central-nervous-system-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ptc-therapeutics-inc/projects/vegf-inhibitor-ptc299-kaposi-s-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/cg0070-adenovirus-vector-transitional-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/cg0070-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/cg0070-muscle-invasive-bladder-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/cg0070-non-muscle-invasive-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/cretostimogene-grenadenorepvec-high-risk-non-muscle-invasive-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/cretostimogene-grenadenorepvec-non-muscle-invasive-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/ivaltinostat-metastatic-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cg-oncology/projects/oncolytic-adenovirus-expressing-gmcsf-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/actr-t-cell-product-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/actr087-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/actr087-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/bezuclastinib-advanced-systemic-mastocytosis-advsm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/bezuclastinib-in-combination-with-sunitinib-gastrointestinal-stromal-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/bezuclastinib-tablets-formulation-a-ssm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/cgt4255-advanced-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/cgt4859-intrahepatic-cholangiocarcinoma-icc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/cgt6297-pik3ca-mutations 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/cgt9486-gastrointestinal-stromal-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cogent-biosciences/projects/cgt9486-plus-sunitinib-advanced-gastrointestinal-stromal-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/14c-xen1101-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/azetukalner-bipolar-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/azetukalner-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/azetukalner-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xen1101-10-mg-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xen1101-focal-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xen1101-focal-onset-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xen1101-primary-generalized-tonic-clonic-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xen496-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xen901-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-001-dental-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-001-healthy-human-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-001-primary-erythromelalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-002-postherpetic-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-002-primary-erythromelalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-005-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-008-healthy-male-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xenon-pharmaceuticals/projects/xpf-008-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/anti-cd123-car-t-treatment-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/car-t-re-treatment-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/cd19-cd20-dual-target-in-vivo-car-t-lentiviral-p-relapsed-refractory-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/dual-specificity-cd19-and-cd22-car-t-cell-immuno-lymphoma-b-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/dual-specificity-cd19-and-cd22-car-t-cell-immuno-refractory-b-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/efficacy-of-lcar-t2c-car-t-cells-cd4-t-lymphocyte-tumor-t-cell-lymphoma-and-t-cel 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/efficacy-of-lcar-t2c-car-t-cells-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lb1901-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lb1908-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lb2102-small-cell-lung-cancer-extensive-stage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-aio-cells-product-b-cell-lymphoma-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-aio-t-cells-multiple-sclerosis-ms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-aio-t-cells-relapsed-refractory-autoimmune-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-aio-t-cells-systemic-lupus-erythematosus-sle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-amdr-cells-product-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-b38m-car-t-cell-injection-refractory-or-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-b38m-car-t-cell-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-b4822m-car-t-cell-immunotherapy-refractory-or-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-bcdr-cells-product-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-bcx-cells-product-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-c182a-cells-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-c18s-cells-solid-tumors-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-g08-cells-advanced-gastrointestinal-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-hl30-cells-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-m23-cells-epithelial-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lcar-m61s-cells-preparation-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lucar-20s-car-t-cells-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lucar-20sp-cells-relapsed-b-cell-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lucar-b68-cells-product-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lucar-dks1-nk-cells-relapsed-refractory-autoimmune-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lucar-g39d-cells-product-b-cell-non-hodgkin-lymphoma-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lucar-g79-t-cells-relapsed-refractory-autoimmune-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lucar-g79d-t-cells-systemic-lupus-erythematosus-sle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/legend-biotech-corp/projects/lvivo-tavec400-product-relapsed-refractory-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dianthus-therapeutics-inc-de/projects/claseprubart-chronic-inflammatory-demyelinating-polyneuropath 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dianthus-therapeutics-inc-de/projects/claseprubart-multifocal-motor-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dianthus-therapeutics-inc-de/projects/dnth103-myasthenia-gravis-generalized 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx001-beta-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx001-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx110-b-cell-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx112-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx112-sle-systemic-lupus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx112-warm-autoimmune-hemolytic-anemia-waiha 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx120-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx130-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx130-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx131-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx131-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/ctx310-cardiovascular 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/vctx210a-unit-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crispr-therapeutics-ag/projects/vctx211-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/14c-idv184001an-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/2-0mg-buprenorphine-0-5mg-naloxone-hepatic-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/arbaclofen-placarbil-alcohol-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/arbaclofen-placarbil-sr-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-and-low-dose-naloxone-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-extended-release-injection-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-hydrochloride-marketed-sublingual-opioid-dependency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-injectable-solution-part-a-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-naloxone-film-strip-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-naloxone-suboxone-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-opiate-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-soluble-film-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/buprenorphine-subutex-opioid-dependency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/indv-2000-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/indv-2000-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/indv-2000-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/indv-6001-moderate-to-severe-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/indv-6200-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/intranasal-challenge-drug-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/morphine-sulfate-analgesic-response 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/perseris-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/rbp-6000-opioid-related-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/rbp-6000-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/rbp-6300-opioid-related-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/rbp-7000-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/rbp-8000-100-mg-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/risperidone-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/sublocade-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/sublocade-opioid-use-disorder-severe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/suboxone-buprenorphine-hydrochloride-naloxone-sc-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/suboxone-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/suboxone-sublingual-film-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/suboxone-sublingual-film-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/tm-buprenorphine-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/transmucosal-buprenorphine-moderate-to-severe-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/indivior-pharmaceuticals/projects/xp19986-cr-gerd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/alitretinoin-sarcoma-kaposi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/aplindore-early-stage-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/aplindore-restless-legs-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-1-gel-parapsoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-cutaneous-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-nbuvb-vs-placebo-nbuvb-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-sarcoma-kaposi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-targretin-advanced-malignant-aerodigestive-tract-tumor-lun 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/bexarotene-targretin-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/budesonide-azelastine-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/budesonide-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/ce-iohexol-contrast-induced-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/denileukin-diftitox-drug-agent-toxicity-by-tissue-organ 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/erlotinib-and-bexarotene-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/erlotinib-tarceva-and-bexarotene-targretin-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/intravenous-carbamazepine-iv-cbz-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/irbesartan-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/lasofoxifene-bone-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/lasofoxifene-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/lgd-6972-5-mg-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/lgd-6972-solution-type-2-diabetes-mellitus-t2dm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/lgd-6972-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/mb07133-300mg-m2-day-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/mb07803-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/mb07811-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/nco-48-fumarate-4-mg-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/nco-48-fumarate-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/ontak-denileukin-difitox-dab389il-2-lymphoma-t-cell-cutaneous 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/ps433540-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/ramipril-hydrochlorothiazide-tablet-10-mg-25-mg-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/ramipril-tablet-10-mg-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ligand-pharmaceuticals-inc/projects/targretin-gel-1-alopecia-areata 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/abiprubart-sj-grens-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/kpl-387-pericarditis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/kpl-387-recurrent-pericarditis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/kpl-404-arthritis-rheumatoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/kpl-404-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/kpl-716-chronic-idiopathic-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/kpl-914-recurrent-pericarditis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/mavrilimumab-covid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/mavrilimumab-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/mavrilimumab-giant-cell-arteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/rilonacept-recurrent-pericarditis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kiniksa-pharmaceuticals-international-plc/projects/vixarelimab-prurigo-nodularis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/fosmetpantotenate-pantothenate-kinase-associated-neurodegeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/pegtibatinase-homocystinuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/re-021-sparsentan-focal-segmental-glomerulosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/re-021-sparsentan-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/sparsentan-anca-associated-vasculitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/sparsentan-focal-segmental-glomerulosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/sparsentan-immunoglobulin-a-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/sparsentan-proteinuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/travere-therapeutics/projects/sparsentan-proteinuric-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/asenapine-sublingual-tablets-10-mg-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/bimatoprost-ophthalmic-solution-0-01-open-angle-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/crexont-er-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/estradiol-vaginal-tablets-10-mcg-atrophic-vaginitis-due-to-menopause 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/imatinib-mesylate-tablets-400-mg-chronic-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/kshn001126-150mg-healthy-postmenopausal-women 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/methotrexate-amneal-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/mometasone-furoate-nasal-spray-50-mcg-seasonal-allergic-rhinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/phenazopyridine-hydrochloride-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/placebo-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/placebo-of-phenazopyridine-hydrochloride-tables-uncomplicated-urinary-tract-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/test-bimatoprost-0-01-ophthalmic-solution-glaucoma-open-angle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/test-product-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amneal-pharmaceuticals/projects/testosterone-topical-gel-1-62-metered-pump-primary-hypogonadism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/airway-bypass-emphysema-or-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/amifampridine-phosphate-10-mg-oral-tablet-spinal-muscular-atrophy-type-3 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/amifampridine-phosphate-lambert-eaton-myasthenic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/amifampridine-phosphate-muscular-atrophy-spinal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/amifampridine-phosphate-myasthenia-gravis-generalized 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/amifampridine-phosphate-myasthenia-gravis-musk 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/amifampridine-phosphate-myasthenic-syndromes-congenital 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/bumetanide-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/coagulation-factor-ix-variant-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/coagulation-factor-viia-variant-factor-vii-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/coagulation-factor-viia-variant-hemophilia-a-with-inhibitor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/cpp-109-vigabatrin-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/cpp-115-cocaine-dependency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/decitabine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/dupilumab-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/hwk-016-mucin-16-targeted-adc-proc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/isu304-cb2679d-dalcinonacog-alfa-75-150-iu-kg-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/marzaa-marzeptacog-alfa-activated-hemophilia-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/mhs-1031-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/catalyst-pharmaceuticals-inc/projects/vigabatrin-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/14c-crn00808-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/atumelnant-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/atumelnant-crn04894-congenital-adrenal-hyperplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/atumelnant-cushing-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/atumelnant-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/crn00808-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/crn01941-oral-solution-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/crn04894-oral-solution-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/crn09682-sst2-positive-neuroendocrine-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/paltusotine-acromegaly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/paltusotine-carcinoid-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/crinetics-pharmaceuticals/projects/randomized-40-mg-paltusotine-carcinoid-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oruka-therapeutics/projects/orka-001-induction-dose-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oruka-therapeutics/projects/orka-001-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oruka-therapeutics/projects/orka-002-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oruka-therapeutics/projects/orka-002-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-044-dose-a-acute-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-044-dose-a-osteoarthritis-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-103-hallucinations 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-103-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-104-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-204-alzheimer-s-disease-psychosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-204-lewy-body-dementia-psychosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/acp-211-major-depressive-disorder-mdd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/active-drug-pimavanserin-17mg-2-strength-tablets-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/carbetocin-hyperphagia-in-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/l-helveticus-r0052-and-b-longum-r0175-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-34-mg-agitation-and-aggression-in-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-34-mg-intermittent-explosive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-34-milligrams-mg-nuplazid-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-adjunctive-treatment-of-major-depressive-disorde 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-agitation-and-aggression-in-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-insomnia-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-irritability-associated-with-autism-spectrum-dis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-neurodegenerative-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-neuropsychiatric-symptoms-related-to-neurodegene 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-parkinson-disease-psychosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-tartrate-34-mg-oral-capsule-nuplazi-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-tartrate-acp-103-parkinson-s-disease-psychosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-tartrate-alzheimer-s-disease-psychosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-tartrate-parkinson-s-disease-psychosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/pimavanserin-treatment-of-depression-in-adults-with-parkinson 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/placebo-anxiety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/placebo-dementia-related-psychosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/acadia-pharmaceuticals-inc/projects/trofinetide-rett-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/14c-edg-7500-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-15400-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-5506-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-5506-muscular-dystrophies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-5506-tablet-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-7500-healthy-adult-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-7500-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-7500-hepatic-impairment-hi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-7500-hypertrophic-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/edg-7500-renal-impairments 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/sevasemten-10-mg-becker-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/sevasemten-becker-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/sevasemten-dose-1-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/edgewise-therapeutics/projects/sevasemten-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/131i-ipa-neoplastic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/153sm-dotmp-bone-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/177lu-dota-tlx591-metastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/177lu-dota-tlx591-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/177lu-girentuximab-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0187-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/177lu-tlx250-and-peposertib-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/177lu-tlx250-ccrcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/177lu-tlx591-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/4-l-131i-iodo-phenylalanine-131i-ipa-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/64cu-dota-tlx592-metastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/68-ga-psma11-prostate-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/68ga-psma-11-pca 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-dfosq-olaratumab-89zr-tlx300-cdx-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-girentuximab-carcinoma-renal-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-girentuximab-clear-cell-renal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-girentuximab-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-girentuximab-clear-cell-renal-cell-carcinoma-ccrcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-girentuximab-for-pet-ct-imaging-of-caix-pos-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-girentuximab-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/89zr-tlx250-pet-ct-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/fluciclovine-f18-prostate-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/ga-68-psma-11-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/illuccix-68ga-psma-11-total-body-pet-ct-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/psma-pet-mr-gallium-68-labeled-psma-hbed-cc-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/standard-of-care-metastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/tlx-101-tx-lomustine-neoplastic-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/telix-pharmaceuticals-ltd/projects/zirconium-zr-89-girentuximab-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viking-therapeutics/projects/placebo-weight-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viking-therapeutics/projects/vk0214-adrenomyeloneuropathy-form-amn-of-x-linked-adren 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viking-therapeutics/projects/vk2735-weight-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viking-therapeutics/projects/vk2809-hyperlipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viking-therapeutics/projects/vk2809-nash-nonalcoholic-steatohepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viking-therapeutics/projects/vk5211-hip-fractures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tango-therapeutics/projects/s095035-mtap-deleted-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tango-therapeutics/projects/tng260-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tango-therapeutics/projects/tng348-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tango-therapeutics/projects/tng456-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tango-therapeutics/projects/tng462-locally-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tango-therapeutics/projects/tng908-locally-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/14c-biib122-14c-dnl151-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/14c-dnl343-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/biib122-225-mg-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/biib122-dnl151-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/biib122-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl126-mucopolysaccharidosis-type-iiia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl151-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl201-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl201-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl343-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl593-frontotemporal-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl628-alzheimer-disease-early-onset 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl747-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl747-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl919-healthy-participant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/dnl952-late-onset-pompe-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/denali-therapeutics/projects/tividenofusp-alfa-mucopolysaccharidosis-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/14c-etrumadenant-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/ab308-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/ab680-advanced-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/ab680-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/ab680-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/ab801-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/ab801-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/atezolizumab-prostate-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/casdatifan-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/casdatifan-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/casdatifan-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/domvanalimab-advanced-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/domvanalimab-advanced-upper-gastrointestinal-tract-adenocarci 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/domvanalimab-gastrointestinal-tract-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/domvanalimab-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/domvanalimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/domvanalimab-solid-tumor-unspecified-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/durvalumab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/etrumadenant-ab928-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/etrumadenant-gastroesophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/etrumadenant-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/etrumadenant-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/etrumadenant-non-small-cell-lung-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/etrumadenant-prostatic-neoplasms-castration-resistant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/fluorouracil-borderline-resectable-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/gemcitabine-biliary-tract-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/quemliclustat-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/quemliclustat-metastatic-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/quemliclustat-oligometastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/srf617-metastatic-castration-resistant-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/volrustomig-advanced-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zanzalintinib-advanced-clear-cell-renal-cell-carcinoma-or-othe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-adenocarcinoma-stomach 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-hepatobiliary-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcus-biosciences/projects/zimberelimab-zim-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dyne-therapeutics/projects/dyne-101-myotonic-dystrophy-type-1-dm1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dyne-therapeutics/projects/dyne-251-duchenne-muscular-dystrophy-dmd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/dyne-therapeutics/projects/zeleciment-basivarsen-dyne-101-myotonic-dystrophy-type-1-dm1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/100mg-spn-812-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/14c-nv-5138-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/apokyn-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/apomorphine-infusion-idiopathic-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/bis-001-er-epilepsy-complex-partial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/bis-001er-focal-impaired-awareness-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/botulinum-toxin-type-b-cervical-dystonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/botulinum-toxin-type-b-myobloc-drooling 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/brexanolone-post-partum-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/brexanolone-tinnitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/gocovri-extended-release-amantidine-radiation-encephalopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/ir-tpm-topamax-migraine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/ir-viloxazine-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/molindone-impulsive-aggression-comorbid-with-adhd-in-child 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/myobloc-low-dose-sialorrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/myobloc-sialorrhea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/nv-5138-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/nv-5138-treatment-resistant-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/oxcarbazepine-xr-partial-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/phase-2-low-dose-myobloc-15-000-units-spasticity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/phase-2-low-dose-myobloc-spasticity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/placebo-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/placebo-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/placebo-epilepsies-partial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/placebo-postpartum-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-547-postpartum-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-547-severe-postpartum-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-547-super-refractory-status-epilepticus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-718-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-718-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-718-huntington-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-718-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-718-matching-placebo-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-718-mild-cognitive-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-718-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/sage-904-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-538-migraine-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-804o-epilepsies-partial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-810-18-mg-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-810-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-810-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-810-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-810-impulsive-aggression-comorbid-with-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-810m-impulsive-aggression-comorbid-with-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-812-600mg-qd-healthy-lactating-women 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-812-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-812-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-817-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-817-focal-onset-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-817-treatment-b-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/spn-821-2400-mg-major-depressive-disorder-mdd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/topiramate-ir-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/supernus-pharmaceuticals-inc/projects/zulresso-postpartum-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/allogeneic-anti-cd7-car-t-cells-beam-201-t-cell-acute-lymphoblastic-leukemia-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/beam-101-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/beam-103-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/beam-201-lymphoblastic-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/beam-301-single-dose-of-beam-301-administered-by-glycogen-storage-disease-type-ia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/beam-302-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/beam-dream-powder-sleep 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/beam-organics-dream-powder-sleep 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/beam-therapeutics/projects/prdr-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/lotilaner-gel-2-0-papulopustular-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/lotilaner-ocular-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/lotilaner-ophthalmic-solution-0-25-demodex-blepharitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/low-dose-tp-05-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/standart-medical-treatment-high-intensity-interval-training 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/tp-03-0-25-blepharitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/tp-03-blepharitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/tp-03-lotilaner-ophthalmic-solution-0-25-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/tp-03-meibomian-gland-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/tp-05-lotilaner-low-dose-lyme-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/tp-05-lotilaner-oral-capsules-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/tp-05-lotilaner-oral-fasted-group-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/uteratonic-administration-placenta-abruptio 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tarsus-pharmaceuticals/projects/vehicle-of-tp-03-meibomian-gland-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/aleniglipron-obese 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/aleniglipron-or-placebo-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/aleniglipron-or-placebo-obesity-overweight-or-chronic-weight-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/carotid-femoral-pulse-wave-velocity-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/gpc-100-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/gsbr-1290-capsule-tablet-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/gsbr-1290-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/gsbr-1290-overweight-or-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/tg-0054-2-24-mg-kg-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/tg-0054-combined-with-g-csf-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/tg-0054-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/structure-therapeutics/projects/tg-0054-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/darovasertib-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/gsk4418959-neoplasms-colorectal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/ide-161-advanced-or-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/ide034-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/ide397-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/ide574-er-her-2-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/ide849-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ideaya-biosciences/projects/ide892-nsclc-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kailera-therapeutics/projects/kai-7535-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kailera-therapeutics/projects/kai-9531-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kailera-therapeutics/projects/kai-9531-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kailera-therapeutics/projects/kai-9531-obesity-with-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-151-0-3-cream-chronic-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-151-cream-0-05-atopic-dermatitis-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-151-cream-0-15-atopic-dermatitis-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-151-cream-0-15-or-arq-151-cream-0-05-atopic-dermatitis-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-151-cream-0-3-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-151-cream-0-3-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-151-cream-0-5-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-154-foam-0-3-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-154-seborrheic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-234-atopic-dermatitis-ad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-252-cream-0-3-chronic-hand-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/arq-252-cream-0-3-vitiligo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-0-3-cream-chronic-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-cream-0-05-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-foam-seborrheic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/palvella-therapeutics-inc/projects/ptx-022-angiokeratomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-cream-0-05-atopic-dermatitis-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-cream-0-15-atopic-dermatitis-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-cream-0-15-itch 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-cream-0-3-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-cream-atopic-dermatitis-eczema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-foam-0-3-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-foam-0-3-scalp-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-foam-0-3-seborrheic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/roflumilast-topical-0-3-foam-non-segmental-vitiligo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/topical-roflumilast-0-3-foam-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcutis-biotherapeutics/projects/topical-roflumilast-chronic-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/adiposity-and-iron-requirements-in-pregnancy-adi-iron-deficiency-anemia-of-pregnancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/concurrent-chemotherapy-uterine-cervical-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-0974-chronic-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-0974-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-0974-inflammatory-bowel-disease-ibd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-0974-myelofibrosis-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-1459-erythropoietic-protoporphyria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-3405-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-3405-polycythemia-vera-pv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/disc-3405-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/mineral-enriched-powder-iron-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/pioglitazone-and-metformin-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/placebo-erythropoietic-protoporphyria-epp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/disc-medicine/projects/shexiang-baoxin-pill-muskardia-ischemia-with-non-obstructive-coronary-artery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/enliven-therapeutics/projects/elvn-001-chronic-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/enliven-therapeutics/projects/elvn-001-cml-chronic-myelogenous-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/enliven-therapeutics/projects/elvn-002-her2-positive-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relay-therapeutics/projects/rly-2608-pik3ca-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relay-therapeutics/projects/rly-2608-pik3ca-related-overgrowth-spectrum-pros 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relay-therapeutics/projects/rly-5836-pik3ca-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relay-therapeutics/projects/rly-8161-nras-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/analogs-prostaglandin-e1-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/atacicept-150-mg-iga-nephropathy-igan 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/atacicept-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/atacicept-iga-nephropathy-igan 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/atacicept-lupus-nephritis-ln 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/atacicept-pmn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/capecitabine-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/cyp2c19-genotyping-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/experimental-hyperslim-venous-thromboembolism-vte 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/genomically-directed-monotherapy-malignant-neoplasm-of-breast 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/immune-globulin-10-intravenous-solution-chronic-inflammatory-demyelinating-polyneuropath 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/mau868-bk-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/nestacell-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vera-therapeutics/projects/nitazoxanide-tablets-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/145-mg-m2-nktr-102-advanced-or-metastatic-solid-tumors-in-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/aerosolized-vancomycin-or-gentamicin-ventilator-associated-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/amikacin-bay41-6551-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/amikacin-inhalation-solution-bay41-6551-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/amikacin-inhalation-solution-bay41-6551-pneumonia-bacterial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/avelumab-locally-advanced-or-metastatic-urothelial-carcin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/avelumab-squamous-cell-carcinoma-of-the-head-and-neck-scc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/bempegaldesleukin-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/bempegaldesleukin-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/bempegaldesleukin-metastatic-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/bempegaldesleukin-nktr-214-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/bempegaldesleukin-urinary-bladder-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/c-til051-metastatic-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/cyclophosphamide-recurrent-diffuse-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/dose-escalation-doublet-combination-of-nktr-214-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/dronabinol-mdi-migraine-with-aura 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/etirinotecan-pegol-anaplastic-astrocytomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/inhaled-human-insulin-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/ly3471851-colitis-ulcerative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/ly3471851-dermatitis-atopic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/ly3471851-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/ly3471851-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nivolumab-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nivolumab-ependymoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nivolumab-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-100-mg-m2-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-145-mg-m2-malignant-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-locally-recurrent-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-metastasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-q14d-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-102-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-181-bid-tablets-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-181-moderate-to-severe-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-181-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-214-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-214-head-and-neck-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-214-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-214-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-214-unspecified-adult-solid-tumor-protocol-specific 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-255-at-1-5-g-kg-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-255-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-255-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/nktr-255-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/pegylated-irinotecan-recurrent-small-cell-lung-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/pegylated-irinotecan-stage-iv-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/placebo-opioid-induced-constipation-oic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/placebo-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/rezpegaldesleukin-alopecia-areata 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/rezpegaldesleukin-moderate-to-severe-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/tak-659-lymphoma-non-hodgkin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nektar-therapeutics/projects/vb10-neo-locally-advanced-or-metastatic-solid-tumours 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mineralys-therapeutics/projects/lorundrostat-25mg-sglt2i-qd-washout-placebo-sglt-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mineralys-therapeutics/projects/lorundrostat-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mineralys-therapeutics/projects/lorundrostat-obstructive-sleep-apnea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mineralys-therapeutics/projects/mls-101-part-i-hypertension-renal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mineralys-therapeutics/projects/placebo-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/4-diaminopyridine-polyradiculoneuropathy-chronic-inflammatory-demy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/5-mg-prednisone-granulomatosis-with-polyangiitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/6-6-2h2-glucose-glycogen-storage-disease-type-ia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/abatacept-takayasu-s-arteritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/abatacept-wegener-s-granulomatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/aceneuramic-acid-extended-release-ace-er-hereditary-inclusion-body-myopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/aceneuramic-acid-extended-release-hereditary-inclusion-body-myopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/aceneuramic-acid-extended-release-tablets-hereditary-inclusion-body-myopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/acetazolamide-andersen-tawil-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/acyclovir-herpes-simplex 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ad5-cb-cftr-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/adjuvant-immunomodulatory-im-therapy-mucopolysaccharidosis-iiia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/allopurinol-leishmaniasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ambroxol-hydrochloride-30-mg-tablet-9-mg-kg-day-sanfilippo-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/amifostine-fanconi-s-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/aminomidazole-carboxamide-riboside-lesch-nyhan-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/aminosalicylic-acid-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/analatro-latrodectism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anawidow-antivenin-latrodectus-black-widow-equin-latrodectism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-aplastic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-chediak-higashi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-fanconi-s-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-immunologic-deficiency-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-neutropenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-purpura-schoenlein-henoch 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/anti-thymocyte-globulin-systemic-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/antithymocyte-globulin-atg-myelodysplastic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/arginine-butyrate-beta-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/auranofin-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/avtx-801-slc35a2-cdg-solute-carrier-family-35-member-a2-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/betaine-angelman-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/betamethasone-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/bisphosphonate-osteogenesis-imperfecta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/blood-sample-amelogenesis-imperfecta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/botulinum-toxin-type-a-hyperhidrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/bps804-osteogenesis-imperfecta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/bromocriptine-stereotyped-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/burosumab-cutaneous-skeletal-hypophosphatemia-syndrome-csh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/burosumab-hypophosphatemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/calcitriol-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/carbamazepine-spasms-infantile 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cidofovir-cytomegalovirus-retinitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cisplatin-squamous-cell-carcinoma-of-the-anus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cladribine-cholangitis-sclerosing 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/clomiphene-citrate-hyperinsulinism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/colchicine-cirrhosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/colchicine-liver-cirrhosis-biliary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/colchicine-primary-cutaneous-vasculitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/conjugated-estrogens-osteoporosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/copolymer-1-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/crd-tmh-001-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/crysvita-burosumab-twza-treatment-epidermal-nevus-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cyclophosphamide-anemia-hemolytic-autoimmune 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cyclophosphamide-fanconi-s-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cyclophosphamide-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cyclophosphamide-pemphigus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cyclophosphamide-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cyclosporine-metabolism-inborn-errors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cyclosporine-sickle-cell-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/cytarabine-lupus-erythematosus-systemic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dehydroepiandrosterone-addison-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dehydroepiandrosterone-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/desipramine-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dexamethasone-bronchopulmonary-dysplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dextromethorphan-rett-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/diazepam-status-epilepticus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dichlorphenamide-paralysis-hyperkalemic-periodic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/diphtheria-tetanus-pertussis-vaccine-containing-pertussis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/droxidopa-shy-drager-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dtx301-otc-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dtx401-glycogen-storage-disease-type-ia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/dtx401-gsd1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/enalapril-iga-glomerulonephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/enalapril-pseudohypoaldosteronism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/epoprostenol-hypertension-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/estrogen-turner-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/evinacumab-homozygous-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/exercise-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/fetal-nigral-transplantation-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/filgrastim-fanconi-s-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/filgrastim-shwachman-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/fluconazole-histoplasmosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/fluconazole-sporotrichosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/fluticasone-propionate-880-mcg-twice-daily-after-eosinophilic-gastrointestinal-disorders-egids 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/fructose-sickle-cell-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ganciclovir-cytomegalovirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/gene-therapy-familial-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/glut1-ds-glut1-deficiency-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/growth-hormone-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/growth-hormone-turner-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/growth-hormone-werner-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/gtx-102-angelman-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/interferon-alfa-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/guanfacine-tourette-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/h5-001cbcftr-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/heme-arginate-porphyria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/hydrocortisone-bronchopulmonary-dysplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/hydroxyproline-and-leucine-hyperoxaluria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/iloprost-systemic-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/immune-globulin-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/immune-globulin-polyradiculoneuropathy-chronic-inflammatory-demy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/intrathecal-recombinant-human-alpha-iduronidase-mucopolysaccharidosis-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/irradiation-brain-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/itraconazole-histoplasmosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/lactulose-portal-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/leucovorin-calcium-toxoplasmosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/leuprolide-acetate-acanthosis-nigricans 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/leuprolide-hyperandrogenism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/leuprolide-spinal-muscular-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/losartan-potassium-eosinophilic-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/lymphocyte-gene-therapy-mucopolysaccharidosis-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/mannac-hereditary-inclusion-body-myopathy-hibm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/megestrol-acquired-immunodeficiency-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/melphalan-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/methotrexate-liver-cirrhosis-biliary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/methoxsalen-epidermolysis-bullosa-acquisita 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/methylprednisolone-spinal-cord-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/miglustat-gm1-gangliosidoses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/monoclonal-antibody-m-t412-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/monoclonal-factor-ix-replacement-therapy-hemophilia-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/mucoid-exopolysaccharide-p-aeruginosa-immune-glo-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/multistrain-probiotic-cystic-fibrosis-in-children 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/n-acetylcysteine-gaucher-disease-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/n-acetylcysteine-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/neo-asa-argininosuccinate-lyase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ntbc-tyrosinemia-type-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/octreotide-hereditary-hemorrhagic-telangiectasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/olsalazine-ankylosing-spondylitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/osilodrostat-isturisa-mild-autonomous-cortisol-secretion-macs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/pallidotomy-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/pancrelipase-with-bicarbonate-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/phenytoin-post-traumatic-seizure-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/phosphatidylcholine-methionine-adenosyltransferase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/pimozide-tourette-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/plasma-exchange-acute-disseminated-encephalomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/post-triheptanoin-frontal-lobe-hypometabolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/potassium-citrate-hypercalciuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/prednisone-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/protein-intake-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/rad001-pten-gene-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/recombinant-adenovirus-containing-the-ornithine-ornithine-transcarbamylase-deficiency-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/relaxin-systemic-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ribose-5-nucleotidase-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/rifampicin-multiple-system-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/risperidone-tourette-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/rituximab-purpura-thrombocytopenic-idiopathic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sa-er-500-mg-gne-myopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sargramostim-autoimmune-pulmonary-alveolar-proteinosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/scaav8otc-ornithine-transcarbamylase-otc-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/scaav9-aga-aspartylglucosaminuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sdz-msl-109-cytomegalovirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/setrusumab-osteogenesis-imperfecta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sialic-acid-extended-release-sa-er-gne-myopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sialic-acid-extended-release-sa-er-tablets-hereditary-inclusion-body-myopathy-hibm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sirolimus-0-5-mg-beta-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sirolimus-anemia-aplastic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sirolimus-lymphangioleiomyomatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sodium-benzoate-amino-acid-metabolism-inborn-errors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/sodium-phenylbutyrate-argininosuccinic-aciduria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/soy-protein-isolate-hereditary-hemorrhagic-telangiectasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/succimer-lead-poisoning 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/surgery-spastic-diplegia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/thalidomide-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/thioctic-acid-mitochondrial-myopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/thyrotropin-releasing-hormone-respiratory-distress-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/tin-mesoporphyrin-glucosephosphate-dehydrogenase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/tin-mesoporphyrin-hyperbilirubinemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/tiratricol-allan-herndon-dudley-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/tiratricol-monocarboxylate-transporter-8-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/topiramate-lennox-gastaut-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/tridecanoic-acid-rett-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-adult-polyglucosan-body-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-glucose-transporter-type-1-deficiency-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-glucose-transporter-type-1-deficiency-syndrome-g 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-glycogen-storage-disease-type-i 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-glycogen-storage-disease-type-v 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-long-chain-fatty-acid-oxidation-disorders-lc-fao 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-medium-chain-acyl-coa-dehydrogenase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-oil-huntington-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-pyruvate-dehydrogenase-complex-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-rett-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/triheptanoin-tarui-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux003-mucopolysaccharidosis-type-7 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux003-sly-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux007-carnitine-palmitoyltransferase-cpt-i-or-cpt-ii-d 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux007-glucose-transporter-type-1-deficiency-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux007-glucose-transporter-type-1-deficiency-syndrome-g 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux007-long-chain-fatty-acid-oxidation-disorders-lc-fao 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux016-gne-myopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/ux053-glycogen-storage-disease-type-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/von-willebrand-factor-von-willebrand-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ultragenyx-pharmaceutical/projects/whole-cell-pertussis-vaccine-pertussis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/avoralstat-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx-1777-leukemia-lymphocytic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx17725-netherton-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-hydrochloride-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx4161-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx4430-filovirus-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx7353-and-probes-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx7353-capsules-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx7353-capsules-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx7353-hereditary-angioedema-hae 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/bcx9930-complement-3-glomerulopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/berotralstat-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/eculizumab-paroxysmal-nocturnal-hemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-200-mg-cutaneous-t-cell-lymphoma-ctcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-hcl-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-hydrochloride-bcx-1777-b-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-hydrochloride-bcx-1777-leukemia-lymphocytic-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-hydrochloride-bcx-1777-leukemia-t-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-hydrochloride-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/forodesine-hydrochloride-sterile-solution-5-mg-m-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/galidesivir-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/galidesivir-marburg-virus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peldesine-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peramivir-150-mg-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peramivir-150mg-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peramivir-200-mg-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peramivir-acute-uncomplicated-human-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peramivir-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peramivir-seasonal-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/peramivir-soc-cough 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/placebo-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/placebo-paroxysmal-nocturnal-hemoglobinuria-pnh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/biocryst-pharmaceuticals-inc/projects/ulodesine-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/acoustic-cr-stimulator-anm-technology-acoustic-c-chronic-tonal-tinnitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/anm-t30-cr-system-tinnitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/bamlanivimab-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/bacteriophage-prosthetic-joint-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/bacteriophage-therapy-osteomyelitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/bacteriophage-therapy-urinary-tract-infection-bacterial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/bendamustine-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/ceftriaxone-community-acquired-pneumonia-influenza-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/intervention-a-fluoxetine-hydrochloride-hcl-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/intervention-b-vilazodone-hydrochloride-hcl-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/intervention-c-daridorexant-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/intervention-d-sls-002-post-traumatic-stress-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/mosunetuzumab-diffuse-large-b-cell-lymphoma-dlbcl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/nivolumab-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/obinutuzumab-mantle-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/phage-therapy-prosthetic-joint-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/radiation-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/temozolomide-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/adaptive-biotechnologies-corp/projects/venetoclax-monotherapy-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/0-05-voclosporin-ophthalmic-solution-vos-dry-eye-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/aritinercept-myasthenia-gravis-generalized 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/simvastatin-drug-drug-interaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-adolescent-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-focal-segmental-glomerulosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-kidney-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-ophthalmic-solution-dry-eye 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-renal-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aurinia-pharmaceuticals/projects/voclosporin-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tyra-biosciences/projects/dabogratinib-tyra-300-60mg-low-grade-upper-tract-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tyra-biosciences/projects/phase-1-part-a-dose-escalation-tyra-200-taken-on-locally-advanced-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tyra-biosciences/projects/tyra-300-0-125-mg-kg-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tyra-biosciences/projects/tyra-300-60mg-low-grade-nmibc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tyra-biosciences/projects/tyra-300-b01-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tyra-biosciences/projects/tyra-300-locally-advanced-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/tyra-biosciences/projects/tyra-430-metastatic-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nal-er-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nal-er-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nal-er-refractory-chronic-cough 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nalbuphine-er-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nalbuphine-er-tablets-prurigo-nodularis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nalbuphine-hcl-er-prurigo-nodularis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nalbuphine-hcl-er-tablets-60-mg-bid-uremic-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nalbuphine-hcl-er-tablets-90-mg-bid-prurigo-nodularis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nalbuphine-hcl-er-uremic-pruritus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/trevi-therapeutics/projects/nalbuphine-hcl-solution-nalbuphine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viridian-therapeutics-inc-de/projects/veligrotug-thyroid-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viridian-therapeutics-inc-de/projects/vrdn-001-10-mg-kg-thyroid-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viridian-therapeutics-inc-de/projects/vrdn-001-phase-3-cohort-thrive-thyroid-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viridian-therapeutics-inc-de/projects/vrdn-003-thyroid-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/viridian-therapeutics-inc-de/projects/vrdn-003-thyroid-eye-disease-ted 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/stoke-therapeutics/projects/milrinone-valvular-stenosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/stoke-therapeutics/projects/pethidine-pain-relief-in-labour 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/stoke-therapeutics/projects/stk-001-single-ascending-doses-dravet-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/stoke-therapeutics/projects/transanal-irrigation-with-peristeen-anal-irrigat-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/stoke-therapeutics/projects/zorevunersen-dravet-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/stoke-therapeutics/projects/zorevunersen-stk-001-dravet-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/fluocinolone-acetonide-190-micrograms-non-infectious-uveitis-affecting-the-posterior-s 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/fluocinolone-acetonide-age-related-macular-degeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/fluocinolone-acetonide-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/fluocinolone-acetonide-intravitreal-implant-0-18-uveitis-posterior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/fluocinolone-acetonide-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/iluvien-0-19-mg-diabetic-macular-edema-dme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/iluvien-0-19-mg-drug-implant-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/iluvien-chronic-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/misoprostol-25-g-vaginal-cervical-ripening 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/purified-cortophin-gel-40-u-gout-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ani-pharmaceuticals-inc/projects/yutiq-0-18-mg-drug-implant-uveitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/clemizole-hcl-dravet-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/clemizole-hcl-lennox-gastaut-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/complex-with-biotin-5-000-mcg-collagen-keratin-a-hair-thinning 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/complex-with-biotin-collagen-keratin-hyaluronic-hair-thinning 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/hbs-201-narcolepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/hbs-301-tablet-idiopathic-hypersomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/mv-lasv-lassa-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag120-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/open-label-pitolisant-idiopathic-hypersomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/ovx836-480-g-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/ovx836-shot-vaccine-preventable-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/part-1-drug-interaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/pitolisant-idiopathic-hypersomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/pitolisant-oral-tablet-myotonic-dystrophy-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/pitolisant-oral-tablets-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/pitolisant-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/pitolisant-restless-legs-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/pitolisant-tablet-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/harmony-biosciences-holdings/projects/zyn002-22q11-2-deletion-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/amondys-45-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4020-injection-west-nile-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4020-injection-west-nile-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4065-injection-encephalitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4065-injection-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4126-injection-resten-ng-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4658-eteplirsen-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4658-eteplirsen-duchenne-muscular-dystrophy-dmd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4658-for-injection-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-4658-pmo-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-5126-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-6003-marburg-hemorrhagic-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-7100-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-7288-marburg-hemorrhagic-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/avi-7537-ebola-hemorrhagic-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/casimersen-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/delandistrogene-moxeparvovec-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/delandistrogene-moxeparvovec-muscular-dystrophy-duchenne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/elevidys-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/eteplirsen-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/eteplirsen-duchenne-muscular-dystrophy-dmd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/eteplirsen-muscular-dystrophy-duchenne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/golodirsen-50-mg-1-ml-intravenous-solution-vyond-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/placebo-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/placebo-ebola-hemorrhagic-fever 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/raavrh74-mhck7-dysf-dv-dysferlinopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/resten-mp-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-1005-huntington-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-4045-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-5051-muscular-dystrophy-duchenne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-6004-limb-girdle-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-9003-limb-girdle-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-9003-limb-girdle-muscular-dystrophy-type-2e 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-9004-limb-girdle-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-9004-limb-girdle-muscular-dystrophy-type-2d 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/srp-9005-muscular-dystrophies-limb-girdle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sarepta-therapeutics/projects/vesleteplirsen-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/100-mg-dose-of-14c-glpg0634-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/100-mg-glpg1205-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/200-mg-glpg0634-as-capsules-fasted-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/500-mg-glpg1837-as-oral-suspension-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/atorvastatin-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-ankylosing-spondylitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-bioavailability 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/generate-biomedicines/projects/gb-0895-sc-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-fistulizing-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-inflammatory-bowel-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/janux-therapeutics/projects/janx014-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-noninfectious-uveitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-psoriatic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-small-bowel-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/filgotinib-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg-car-t-cell-therapy-hematological-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0187-prodrug-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0187-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0259-fumarate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0259-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0259-oral-capsule-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0259-solution-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0492-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0555-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0555-solid-dispersion-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0634-100mg-capsule-once-a-day-for-10-days-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0634-50-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0634-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0634-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0634-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0634-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0778-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0974-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg0974-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1205-50mg-q-d-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1205-film-coated-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1205-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1205-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1205-single-ascending-doses-oral-suspension-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1205-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1690-600-mg-qd-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1690-film-coated-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/sotrovimab-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1690-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2451-multiple-dose-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1690-single-ascending-doses-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1690-systemic-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1837-500-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1837-single-ascending-doses-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1972-600-mg-oral-solution-fasted-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1972-a-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3312-ir-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1972-cohort-1-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1972-film-coated-tablets-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1972-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1972-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg1972-single-ascending-doses-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2222-150-mg-q-d-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2222-50-mg-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2222-single-dose-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2451-dose-regimen-a-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2451-single-dose-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2737-autosomal-dominant-polycystic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2737-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2737-single-dose-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg2737-single-dose-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3067-single-dose-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3067-single-dose-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3121-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3121-sad-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3667-capsule-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3667-dermatomyositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3667-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3667-oral-suspension-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3667-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3667-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3970-film-coated-tablet-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3970-film-coated-tablet-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3970-oral-solution-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3970-primary-sj-gren-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3970-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg3970-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg4059-oral-suspension-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg4399-oral-suspension-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg4716-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/pirfenidone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/glpg5101-relapsed-refractory-b-cell-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/lanraplenib-cutaneous-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/lanraplenib-sjogren-s-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/mor-106-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/mor106-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/mor106-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/mor106-single-ascending-doses-intravenous-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/peg-liposomal-prednisolone-sodium-phosphate-acute-exacerbation-of-remitting-relapsing-multip 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/sulfasalazine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lakefront-biotherapeutics-nv/projects/synovial-biopsy-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/atezolizumab-metastatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/axatilimab-idiopathic-pulmonary-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/axatilimab-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/azacitidine-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/durvalumab-unresectable-intrahepatic-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-drug-interaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-epithelial-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-er-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-estrogen-receptor-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-fallopian-tube-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-metastatic-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-non-small-cell-lung-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-pancreas-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/maze-therapeutics/projects/mze001-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/entinostat-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/fulvestrant-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/pembrolizumab-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/pembrolizumab-metastatic-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-acute-myeloid-leukemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-blinatumomab 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-refractory-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-relapsed-adult-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/revumenib-relapsed-refractory-leukemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/sndx-275-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/sndx-5613-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/sndx-5613-acute-myeloid-leukemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/sndx-6352-coronavirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/syndax-pharmaceuticals-inc/projects/venetoclax-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag221-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/14c-tebapivat-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sionna-therapeutics/projects/blood-draw-from-three-different-vessels-accidental-hypothermia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sionna-therapeutics/projects/pad-gauze-with-tranexamic-acid-hemostopan-bleeding 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sionna-therapeutics/projects/polyamide-hd-membrane-end-stage-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sionna-therapeutics/projects/sion-451-cystic-fibrosis-cf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sionna-therapeutics/projects/sion-719-cystic-fibrosis-cf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rapport-therapeutics/projects/rap-219-bipolar-1-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rapport-therapeutics/projects/rap-219-focal-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rapport-therapeutics/projects/rap-219-focal-onset-seizures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/rapport-therapeutics/projects/rap-219-focal-seizure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nurix-therapeutics/projects/drug-product-de-til-0255-platinum-resistant-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nurix-therapeutics/projects/ip-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nurix-therapeutics/projects/nx-1607-ovarian-cancer-epithelial 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nurix-therapeutics/projects/nx-2127-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nurix-therapeutics/projects/nx-5948-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nurix-therapeutics/projects/nx-5948-chronic-lymphocytic-leukemia-cll 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/nurix-therapeutics/projects/nx-5948-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/14c-ag-120-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-120-ivosidenib-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-181-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-181-phenylketonuria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-236-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-348-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-348-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-348-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-348-pyruvate-kinase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-348-sequence-a-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-348-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-348-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-519-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-636-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-881-healthy-male-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-881-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag-946-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag881-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag881-formulation-1-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ag881-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/enasidenib-hematologic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/itraconazole-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ivosidenib-ag-120-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ivosidenib-and-nivolumab-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/ivosidenib-idh1-mutation-myeloid-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-matched-placebo-transfusion-dependent-alpha-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-moderate-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-non-transfusion-dependent-alpha-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-pediatric-pyruvate-kinase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-pyruvate-kinase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-tablet-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/mitapivat-tablets-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/placebo-for-treatment-a-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/placebo-matching-mitapivat-non-transfusion-dependent-alpha-thalassemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/placebo-pyruvate-kinase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/tebapivat-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/agios-pharmaceuticals-inc/projects/tebapivat-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/allogeneic-cardiosphere-derived-cells-cap-1002-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/allogeneic-cardiosphere-derived-cells-cdcs-dilated-cardiomyopathy-dcm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/cap-1002-allogeneic-cardiosphere-derived-cells-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/cap-1002-muscular-dystrophies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/cenderitide-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/deramiocel-cap-1002-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/capricor-therapeutics-inc/projects/deramiocel-cap-1002-muscular-dystrophies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/generate-biomedicines/projects/gb-0669-sars-cov-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/generate-biomedicines/projects/gb-0895-severe-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/generate-biomedicines/projects/gb-4362-advanced-urothelial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/generate-biomedicines/projects/gb-5267-iv-only-platinum-resistant-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/generate-biomedicines/projects/gb-7624-atopic-dermatitis-ad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/palvella-therapeutics-inc/projects/ptx-022-bccs-in-gorlin-syndrome-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/palvella-therapeutics-inc/projects/ptx-022-microcystic-lymphatic-malformation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/palvella-therapeutics-inc/projects/ptx-022-pachyonychia-congenita 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/palvella-therapeutics-inc/projects/qtorin-3-9-rapamycin-anhydrous-gel-cutaneous-venous-malformations 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/palvella-therapeutics-inc/projects/qtorin-3-9-rapamycin-anhydrous-gel-microcystic-lymphatic-malformation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/palvella-therapeutics-inc/projects/qtorin-3-9-rapamycin-anhydrous-gel-pachyonychia-congenita 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibrx-biosciences/projects/inbrx-101-rhaat-fc-alpha-1-antitrypsin-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibrx-biosciences/projects/inbrx-105-pdl1x41bb-antibody-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibrx-biosciences/projects/inbrx-106-head-and-neck-squamous-cell-carcinoma-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibrx-biosciences/projects/inbrx-106-hexavalent-ox40-agonist-antibody-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibrx-biosciences/projects/inbrx-109-conventional-chondrosarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibrx-biosciences/projects/inbrx-109-ewing-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/inhibrx-biosciences/projects/pembrolizumab-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/aldesleukin-bone-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/autologous-tumor-infiltrating-lymphocytes-mda-ti-malignant-solid-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/cyclophosphamide-clinical-stage-iv-cutaneous-melanoma-ajcc-v8 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/cyclophosphamide-locally-advanced-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/cyclophosphamide-metastatic-bladder-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/e7-tcr-t-cells-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/e7-tcr-t-cells-hpv-associated-cervical-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/interleukin-2-chronic-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/iov-2001-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/iov-3001-unresectable-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/iov-4001-unresectable-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ipilimumab-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/kk-lc-1-tcr-t-cells-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/lifileucel-endometrial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/lifileucel-ln-144-ln-145-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/lifileucel-ln-144-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/lifileucel-melanoma-skin-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/lifileucel-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/lifileucel-plus-pembrolizumab-metastatic-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ln-144-stage-iiib-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ln-145-cervical-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ln-145-cutaneous-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ln-145-ln-144-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ln-145-metastatic-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ln-145-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/ln-145-squamous-cell-carcinoma-of-the-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/locally-manufactured-adoptive-cellular-therapy-a-malignant-pleural-effusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/nivolumab-melanoma-skin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/nivolumab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/til-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/iovance-biotherapeutics-inc/projects/tumor-infiltrating-lymphocytes-til-ln-145-metastatic-triple-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/monte-rosa-therapeutics/projects/cabergoline-1-mg-lactation-suppressed 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/monte-rosa-therapeutics/projects/mrt-6160-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/monte-rosa-therapeutics/projects/mrt-8102-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/monte-rosa-therapeutics/projects/oral-mrt-2359-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/monte-rosa-therapeutics/projects/temozolomide-brain-neoplasms-malignant-primary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/exs73565-relapsed-or-refractory-b-cell-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/exs74539-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/gtaexs617-head-and-neck-squamous-cell-carcinoma-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/rec-1245-unresectable 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrivent-biopharma/projects/firmonertinib-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/rec-2282-neurofibromatosis-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/rec-3964-recurrent-clostridioides-difficile-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/rec-4881-axin1-gene-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/rec-4881-familial-adenomatous-polyposis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/recursion-pharmaceuticals-inc/projects/rec-994-cerebral-cavernous-malformation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amylyx-pharmaceuticals/projects/amx0035-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amylyx-pharmaceuticals/projects/amx0035-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amylyx-pharmaceuticals/projects/amx0035-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amylyx-pharmaceuticals/projects/amx0035-progressive-supranuclear-palsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amylyx-pharmaceuticals/projects/amx0035-wolfram-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amylyx-pharmaceuticals/projects/amx0114-als 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amylyx-pharmaceuticals/projects/avexitide-post-bariatric-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/brii-179-for-treatment-of-chronic-hepatitis-b-virus-infec 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/brii-835-vir-2218-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/ly3819253-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/peg-ifn-chronic-hepatitis-b-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/sotrovimab-covid-19-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/sotrovimab-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/sotrovimab-gen1-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/tenofovir-alafenamide-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-3434-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/tobevibart-viral-hepatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-1111-hiv-i-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-2218-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-2218-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-2218-hepatitis-d-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-2218-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-2482-450-mg-influenza-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-2482-influenza-a 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-3434-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-5500-hormone-refractory-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-5525-solid-tumor-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-5818-locally-advanced-or-metastatic-her2-expressing-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-7831-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vir-7831-sotrovimab-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vir-biotechnology/projects/vron-0200-adc6-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mbx-biosciences/projects/400-g-of-mbx-2109-once-weekly-by-subcutaneous-in-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mbx-biosciences/projects/mbx-1416-inn-imapextide-postbariatric-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mbx-biosciences/projects/mbx-1416-part-a-postbariatric-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mbx-biosciences/projects/mbx-2109-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mbx-biosciences/projects/mbx-2109-part-a-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mbx-biosciences/projects/mbx-2109-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mbx-biosciences/projects/mbx-4291-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/kvd001-injection-diabetic-macular-edema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/kvd824-angioedema-hereditary-types-i-and-ii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/kvd824-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hemab-therapeutics-holdings/projects/hmb-001-glanzmann-thrombasthenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/kvd824-prototype-1-modified-release-tablet-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/kvd900-150-mg-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/kvd900-600-mg-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/kvd900-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kalvista-pharmaceuticals/projects/placebo-hereditary-angioedema 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/maze-therapeutics/projects/mze829-proteinuric-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/semnur-pharmaceuticals/projects/sp-102-lumbosacral-radicular-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bicara-therapeutics/projects/bca101-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bicara-therapeutics/projects/ficerafusp-alfa-head-and-neck-squamous-cell-carcinoma-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bicara-therapeutics/projects/ficerafusp-alfa-squamous-cell-carcinoma-of-head-and-neck-scchn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bicara-therapeutics/projects/pembrolizumab-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrivent-biopharma/projects/firmonertinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrivent-biopharma/projects/furmonertinib-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arrivent-biopharma/projects/mrg007-locally-advanced-or-metastatic-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/maplight-therapeutics/projects/ml-004-ir-er-tablet-autism-spectrum-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/maplight-therapeutics/projects/ml-007c-ma-psychosis-associated-with-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/maplight-therapeutics/projects/ml-007c-ma-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/maplight-therapeutics/projects/placebo-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moonlake-immunotherapeutics/projects/sonelokimab-arthritis-psoriatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moonlake-immunotherapeutics/projects/sonelokimab-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moonlake-immunotherapeutics/projects/sonelokimab-m1095-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/moonlake-immunotherapeutics/projects/sonelokimab-relative-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hemab-therapeutics-holdings/projects/hmb-002-part-a-von-willebrand-disease-vwd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/hemab-therapeutics-holdings/projects/sutacimig-congenital-factor-vii-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/obexelimab-igg4-related-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/obexelimab-relapsing-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/obexelimab-systemic-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/obexelimab-warm-autoimmune-hemolytic-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/orelabrutinib-multiple-sclerosis-ms-primary-progressive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/orelabrutinib-secondary-progressive-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/zb001-for-injection-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/zb001-for-injection-thyroid-eye-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/zb002-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zenas-biopharma/projects/zb004-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/olema-pharmaceuticals/projects/op-3136-advanced-or-metastatic-er-her2-breast-cancer-mbc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/olema-pharmaceuticals/projects/palazestrant-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/olema-pharmaceuticals/projects/palazestrant-metastatic-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jade-biosciences/projects/jade101-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jade-biosciences/projects/jade101-healthy-volunteers-hv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jade-biosciences/projects/jade101-iga-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/jade-biosciences/projects/jade201-rhematoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/crushed-ticagrelor-followed-by-morphine-unstable-angina-pectoris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/de-escalation-to-ticagrelor-60-mg-at-day-30-non-st-segment-elevation-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/empagliflozin-10-mg-acute-decompensated-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/empagliflozin-20-mg-metabolic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/evolocumab-sars-cov-2-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/gold-omega-3-chronic-kidney-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/hld200-methylphenidate-hydrochloride-capsules-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/immunological-factors-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/levosimendan-systolic-heart-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/methoxyflurane-penthrox-st-elevation-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/morphine-st-segment-elevation-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/oral-chondroitin-sulfate-flextrum-meniscus-lesion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/oxycodone-deterx-chronic-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/platelet-rich-plasma-acl-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/pulverized-ticagrelor-sublingually-unstable-angina-pectoris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/rifaximin-acs-acute-coronary-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/rosuvastatin-and-ezetimibe-morning-or-evening-ad-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/ticagrelor-90-mg-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/ticagrelor-90mg-stemi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/ticagrelor-followed-with-methoxyflurane-unstable-angina 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/collegium-pharmaceutical-inc/projects/xtampza-er-oxycodone-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/g-pen-glucagon-injection-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/g-pen-insulin-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/g-pen-mini-glucagon-injection-diabetes-mellitus-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/g-pen-mini-glucagon-injection-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/g-pen-tm-1-mg-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/g-pump-glucagon-infusion-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/glucagon-congenital-hyperinsulinism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/glucagon-diabetes-mellitus-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/glucagon-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/glucagon-post-bariatric-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/glucagon-rtu-hyperinsulinemic-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/glucagon-rtu-injection-with-insulin-pump-reducti-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/levothyroxine-sodium-hypothyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/novo-nordisk-glucagen-hypoglycemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/pram9-diabetes-mellitus-type-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/xeris-biopharma-holdings/projects/xerisol-glucagon-type1diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aktis-oncology/projects/225ac-ac-aky-1189-therapeutic-urothelial-carcinoma-bladder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aktis-oncology/projects/225ac-ac-aky-2519-therapeutic-castration-resistant-metastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/ciforadenant-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/ciforadenant-renal-cell-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/cpi-006-2-mg-kg-soc-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/cpi-006-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/cpi-006-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/cpi-444-capsules-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/cpi-818-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/soquelitinib-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/corvus-pharmaceuticals/projects/soquelitinib-peripheral-t-cell-lymphoma-not-otherwise-specifi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/14c-lx4211-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/250-mg-capsule-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/250-mg-lx1033-tablets-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/300-mg-lx4211-150-mg-tablets-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/400-mg-lx4211-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/50-mg-lx3305-qd-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/500-mg-14c-lx1606-carcinoid-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/75-mg-lx4211-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/fexofenadine-drug-interactions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/gemcitabine-locally-advanced-unresectable-pancreatic-adenoca 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx1031-high-dose-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx3305-low-dose-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx3305-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx4211-400-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx4211-400-mg-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx4211-800-mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx4211-low-dose-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx4211-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx6171-high-dose-age-related-memory-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx7101-0-125-primary-open-angle-glaucoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/lx9211-diabetic-peripheral-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/omeprazole-40-mg-drug-drug-interaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/placebo-blinded-diabetic-peripheral-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/placebo-postherpetic-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/placebo-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/placebo-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/schedule-a-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-cardiac-failure-aggravated 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-diabetic-nephropathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-low-dose-type-1-diabetes-t1d 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-obstructive-cardiomyopathy-hypertrophic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-sar439954-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-sota-followed-by-3-drugs-in-a-rand-platelet-function-and-reactivity-tests 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-type-1-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-type-1-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-type-1-diabetes-mellitus-t1dm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/sotagliflozin-type-2-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/telotristat-ethyl-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/telotristat-etiprate-carcinoid-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/telotristat-etiprate-drug-interactions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/telotristat-etiprate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/telotristat-etiprate-qt-interval 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/telotristat-etiprate-ulcerative-colitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/treatment-a-digoxin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexicon-pharmaceuticals-inc/projects/treatment-a-rosuvastatin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/pytest-14c-urea-breath-test-h-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/pytest-14c-urea-capsule-breath-test-at-home-h-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-eosinophilic-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-erosive-esophagitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-helicobacter-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-non-erosive-gastro-esophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/phathom-pharmaceuticals/projects/vonoprazan-odt-1-or-odt-2-without-water-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/cytarabine-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/darlifarnib-solid-tumors-with-hras-alterations 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/dexamethasone-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ko-947-advanced-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-hnscc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-hras-gene-mutation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-leukemia-myelomonocytic-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-myelodysplastic-syndromes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-relapsed-or-refractory-peripheral-t-cell-lymphom 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/tipifarnib-thyroid-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/venetoclax-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-advanced-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-gastrointestinal-stromal-tumor-gist 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-kmt2a-rearranged 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-refractory-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/kura-oncology/projects/ziftomenib-relapsed-refractory-kmt2a-r-acute-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/50-mcg-duramorph-exparel-multi-modal-pain-regime-elective-cesarean-section 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-fnb-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-hcl-hemorrhoids 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-hcl-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-liposome-dental-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-liposome-injectable-suspension-266-m-bunionectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-liposome-injectable-suspension-ipsa-total-knee-arthroplasty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-liposome-injectable-suspension-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-liposome-injectable-suspension-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-liposome-injectable-suspension-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-malignant-neoplasms-of-female-genital-organs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/bupivacaine-snb-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/cryo-touch-ii-facial-wrinkles 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/cryo-touch-iii-facial-wrinkles 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/depodur-extended-release-epidural-morphine-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/depofoam-bupivacaine-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/depotxa-total-knee-arthroplasty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/duloxetine-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/enekinragene-inzadenovec-pcrx-201-osteoarthritis-oa-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-1-3-in-20-ml-injection-rotator-cuff-tear 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-13-3mg-ml-suspension-for-injection-bunion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-20-ml-postsurgical-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-266-mg-per-20-ml-injection-post-operative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-266-mg-posterolateral-thoracotomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-analgesia-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-and-bupivacaine-hcl-postoperative-pain-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-and-bupivacaine-postoperative-pain-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-ankle-arthrodesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-block-in-arthroscopic-shoulder-surgery-injury-of-shoulder-region 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-bupivacaine-c-section 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-chronic-shoulder-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-forearm-block-hand-injuries 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-hernia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-hip-fractures 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-injectable-product-breast-augmentation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-injectable-product-bunion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-injectable-product-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-laparotomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-lower-extremity-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-mammaplasty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-postoperative-pain-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-rotator-cuff-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-spinal-fusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx301-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/exparel-total-ankle-arthroplasty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/formoterol-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/formoterol-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx005-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-10-mg-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-32-mg-bilateral-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-32-mg-osteoarthritis-hip 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-32-mg-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-32-mg-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-32-mg-osteoarthritis-of-the-shoulder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-32-mg-post-traumatic-osteoarthritis-of-the-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-osteoarthritis-hip 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-osteoarthritis-of-the-shoulder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx006-trochanteric-bursitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/fx201-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/group-1-standard-of-care-retraction-of-colostomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/instillation-exparel-mammoplasty 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/intrathecal-injected-into-the-spinal-fluid-depoc-meningeal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/intrathecal-morphine-injection-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/iv-morphine-sulfate-bowel-obstruction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/iv-morphine-sulfate-or-sponsor-approved-equivale-bowel-obstruction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/iv-morphine-sulfate-or-sponsor-approved-equivale-retraction-of-colostomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposomal-bupivacaine-13-3-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposomal-bupivacaine-infiltration-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposomal-bupivacaine-male-infertility 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposomal-bupivacaine-rotator-cuff-tear 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposomal-bupivacaine-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposomal-bupivacaine-vaginal-hysterectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposomal-cytarabine-brain-and-central-nervous-system-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposome-bupivacaine-bupivacaine-dupuytren-s-contracture-of-the-hand-viking-s-dis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/liposome-bupivacaine-hallux-valgus-bunions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/low-dose-sky0402-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/methadone-adolescent-idiopathic-scoliosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/morphine-sulfate-bowel-obstruction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/myoscience-tissue-remodeling-device-facial-rhytides 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/placebo-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/popliteal-nerve-block-including-liposomal-bupiva-moderate-to-severely-painful-ankle-surgery 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-300mg-in-healthy-patients-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-bunion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-bupivacaine-hcl-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-hemorrhoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-inguinal-hernia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/janux-therapeutics/projects/janx011-autoimmune 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/sky0402-postoperative-pain-management 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/triamcinolone-acetonide-extended-release-injecta-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/zilretta-glenohumeral-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/pacira-biosciences/projects/zilretta-osteoarthritis-of-hip 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-049-relapsed-refractory-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-081-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-617-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-619-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-619-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-978-nhl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-978-rheumatoid-arthritis-ra 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-978-sj-gren 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/cln-978-sle 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cullinan-therapeutics/projects/vk-2019-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/janux-therapeutics/projects/janx007-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/janux-therapeutics/projects/janx008-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-101-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-101-prostatic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-101-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-114-dose-1-amivantamab-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-114-food-effect-in-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-114-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-533-relapsed-or-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/oric-pharmaceuticals/projects/oric-944-metastatic-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sagimet-biosciences/projects/denifanstat-mash 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/dexmedetomidine-injection-post-spinal-shivering 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/dexmedetomidine-laparoscopic-cholecystectomy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/hcq01-2019-novel-coronavirus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/hydroxyurea-thalassemia-beta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/liraglutide-morbid-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/methotrexate-chronic-plaque-psoriasis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/myocet-non-pegylated-liposomal-doxorubicin-npld-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/sana-device-control-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/sc262-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/sc291-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/sc291-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sana-biotechnology/projects/up421-type1diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/ab-101-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/ab-729-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/arb-001467-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/imdusiran-ab-729-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/imdusiran-hepatitis-b-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/pro-040201-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/tkm-080301-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/tkm-080301-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/tkm-100201-ebola-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arbutus-biopharma-corp/projects/tkm-100802-for-injection-ebola-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/aevi-001-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/aevi-007-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/sagimet-biosciences/projects/denifanstat-masld 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/avtx-002-non-eosinophilic-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/avtx-009-regimen-1-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/cerc-002-covid-19-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/cerc-006-lymphatic-malformation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/cerc-301-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/fp01-acute-cough 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/fp01-chronic-refractory-cough 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/fp01-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/mdgn-002-crohn-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/mdgn201-targtepo-anemia-of-end-stage-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/nfc-1-100-mg-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-0714-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/nfc-1-22q11-2-deletion-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/nfc-1-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/avalo-therapeutics/projects/nfc-1-attention-deficit-hyperactivity-disorder-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/14c-gsk961081-solution-for-iv-infusion-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/400-microgrammes-gsk961081-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/ampreloxetine-dose-a-symptomatic-neurogenic-orthostatic-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/ampreloxetine-symptomatic-neurogenic-orthostatic-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/ampreloxetine-symptomatic-neurogenic-orthostatic-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/gsk961081-15mcg-sd-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/gsk961081-pulmonary-disease-chronic-obstructive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/nezulcitinib-td-0903-dose-a-acute-lung-injury-ali-due-to-coronavirus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/placebo-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/placebo-crohn-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/revefenacin-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/revefenacin-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/revefenacin-inhalation-solution-yupelri-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-0714-healthy-adults-elderly-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-0903-acute-lung-injury-ali-associated-with-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1058-idiopathic-pulmonary-fibrosis-ipf 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1211-dose-1-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1211-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1211-opioid-induced-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1211-opioid-induced-constipation-oic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1439-healthy-adults-elderly-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1439-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1473-dose-a-inflammatory-bowel-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1473-dose-a-ulcerative-colitis-uc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1473-for-sad-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1473-inflammatory-bowel-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lexeo-therapeutics/projects/lx1001-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1473-oral-capsule-intestinal-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1473-tablet-a-intestinal-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1473-ulcerative-colitis-active-moderate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1607-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1607-serious-infections-due-to-known-or-suspected-gra 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-1792-staphylococcal-skin-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-3504-active-mild-ulcerative-colitis-active-moderate-u 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-4208-175-mcg-cardiac-repolarization-in-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-4208-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-4208-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-4208-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-4208-hepatic-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-4208-renal-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-5108-chronic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-5202-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-6450-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-8236-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-8954-gastrointestinal-motility-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-9855-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-9855-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-9855-drug-drug-interaction-ddi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-9855-group-1-fibromyalgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/td-9855-neurogenic-orthostatic-hypotension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/telavancin-end-stage-renal-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/telavancin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/telavancin-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/umeclidinium-62-5-g-and-vilanterol-25-g-copd-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/velusetrag-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/velusetrag-dose-1-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cet-pt-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/theravance-biopharma/projects/velusetrag-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vor-biopharma/projects/telitacicept-generalized-myasthenia-gravis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vor-biopharma/projects/telitacicept-primary-sjogren-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vor-biopharma/projects/vcar33-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vor-biopharma/projects/vor33-leukemia-myeloid-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/seaport-therapeutics/projects/spt-300-major-depressive-disorder-mdd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/0-n2o-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/99mtc-macro-albumin-aggregate-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/1-nalmefene-implant-opioid-abuse-and-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/1-tenofovir-gel-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/10-n2o-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/10-week-smoking-cessation-group-therapy-combined-tobacco-use-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/11c-app311-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/11c-omar-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/11c-omar-healthy-control 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/11ucb-j-pet-scan-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/epidiolex-cbd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/124i-labeled-monoclonal-antibody-mu-11-1f4-al-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/15-valent-pneumococcal-conjugate-vaccine-pneumonia-pneumococcal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/18f-fluoro-peg-folate-pet-ct-scan-epithelial-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/400-mg-cannabidiol-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/2-4-of-the-drugs-listed-below-drug-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/2-4-of-the-drugs-listed-below-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/2-mg-hydromorphone-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/20-n2o-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/3-4-methoxybenzyloxy-pregn-5-en-20-one-cannabis-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/3-4-methoxybenzyloxy-pregn-5-en-20-one-in-fed-co-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/30-nitrous-oxide-alcohol-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/30-nitrous-oxide-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/400iu-cholecalciferol-and-500mg-of-elemental-cal-benign-paroxysmal-positional-vertigo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/413abm-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/42-mg-transdermal-nicotine-replacement-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/5-a-tobacco-use-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aav8-hcoch-cocaine-dependence-in-remission 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/active-cannabis-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/active-cannabis-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/active-delta-9-thc-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/active-nicotine-gum-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/active-referral-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/active-rtms-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/acyclovir-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/adderall-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/adderall-xr-and-topiramate-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/adderall-xr-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/adolescent-methamphetamine-treament-amt-behavior-and-mental-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aef0117-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aerobic-exercise-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/affect-regulation-training-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/afq056-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/agitated-saline-soc-right-to-left-shunt 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/alcohol-alcohol-drinking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/alcohol-caffeine-beverage-alcohol-or-other-drugs-effects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/alcohol-opioid-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aprepitant-0mg-narcotic-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/alcohol-oral-and-placebo-alcohol-drinking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/algorithm-treatment-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/alks-33-bup-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/alprazolam-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/alprazolam-drug-interactions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/arise-with-ar-pediatric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/amantadine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/antiretroviral-therapy-art-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/apr002-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aprepitant-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aripiprazole-cocaine-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aripiprazole-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/aripiprazole-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/arm-1-il13ra2-specific-car-tcm-cells-recurrent-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/art-i02-arthritis-rheumatoid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/art-initiation-at-time-of-hiv-diagnosis-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/asp8062-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/asp8082-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/assets-getting-to-outcomes-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/atafenovir-200-mg-kapsul-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/athena-strategy-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/av-101-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ati-1013-0-2-g-thromboangiitis-obliterans-buerger-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/atm-dual-diagnosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/atomoxetine-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/armata-pharmaceuticals/projects/ap-pa02-cystic-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/atomoxetine-hydrochloride-attention-deficit-disorder-with-hyperactivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/atomoxetine-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/atomoxetine-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/atomoxetine-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/automated-contingency-management-acm-software-opiate-replacement-therapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/avicod-200-mg-film-tablet-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/b007-generalized-myasthenia-gravis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/b007-primary-membranous-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/b013-nab-paclitaxel-triple-negative-breast-cancer-tnbc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/b013-platinum-resistant-recurrent-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/baclofen-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/baclofen-marijuana-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bc-101-nasolabial-fold-wrinkles 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bedaquiline-multi-drug-resistant-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-behavior-therapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-hcv-negative-status 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-rise-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-the-study-was-designed-to-develop-a-cognitive-be 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavior-therapy-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavioral-buprenorphine-naloxone-maintenance-mt-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavioral-couples-therapy-drug-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavioral-drug-and-hiv-risk-reduction-counselin-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavioral-drug-and-risk-counseling-bdrc-hiv-risk-behaviors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/behavioral-intervention-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/belsomra-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/benznidazole-trypanosoma-cruzi-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bevacizumab-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bevacizumab-colorectal-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bf-amlodipine-tablet-10mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bf-gliclazide-tablet-80mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bf-lisinopril-tablets-20mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bf-metoprolol-tablet-100mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bias-retraining-alcohol-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bmb-101-prader-willi-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bicx104-naltrexone-implantable-pellet-healthy-adult-male-and-female-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bicx104-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bicyclol-25mg-tablet-drug-induced-acute-liver-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/biopin-6-active-implant-with-naltrexone-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bleomycin-keloid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/blinded-study-medication-knee-osteoarthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bmb-101-absence-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bmb-101-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/booster-sessions-skill-development-of-staff 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bpt567-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/arcturus-therapeutics-holdings/projects/arct-2303-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brand-lamotrigine-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brand-name-metoprolol-er-blood-pressure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brief-advice-drug-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brief-computer-delivered-intervention-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brief-motivational-intervention-drug-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brief-motivational-intervention-substance-abuse-detection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brief-motivational-intervention-substance-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brief-strategic-family-therapy-bsft-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bright-changyou-probiotic-flavored-yogurt-intestinal-health 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bright-momchilovtsi-yogurt-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brincidofovir-ebola-virus-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/brixadi-injectable-buprenorphine-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buccal-buprenorphine-300-mcg-analgesia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buffergel-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bup-microdose-induction-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-and-outpatient-parenteral-antibiot-drug-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-injection-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-human-immunodeficiency-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-maternal-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-opiate-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naloxone-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-naltrexone-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-neonatal-abstinence-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-opiate-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-otp-heroin-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-sl-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buprenorphine-taper-followed-by-naltrexone-maint-prescription-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-amphetamine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-and-nrt-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-extended-release-oral-tablet-postpartum-smoking-relapse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-methamphetamine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-schizophrenia-and-disorders-with-psychotic-featu 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-sr-150mg-tabs-adolescent-methamphetamine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-sr-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-sr-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-tobacco-use-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bupropion-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buspirone-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buspirone-cocaine-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/buspirone-marijuana-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bvrs-gamvac-combi-mers-middle-east-respiratory-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bxcl501-180-micrograms-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/bzd-discontinuation-protocol-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/caffeine-150-mg-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/caffeine-citrate-retinopathy-of-prematurity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/caffeine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cam2038-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/candesartan-with-cbt-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabidiol-cbd-600-mg-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabidiol-fscbd-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabidiol-medium-dose-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabidiol-opioid-use-disorder-oud 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ceremony-substance-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabidiol-radiculopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabis-30-thc-concentrate-thc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabis-behavioral-pharmacology-of-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabis-cannabis-intoxication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabis-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabis-cigarette-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabis-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cannabis-sativa-extract-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/capsaicin-diabetic-polyneuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/carbamazepine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/carbon-monoxide-inhalation-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cariprazine-oral-capsule-vraylar-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/carvedilol-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cbd-day-1-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cdd-2101-constipation-functional 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cefepime-meropenem-or-piperacillin-tazobactam-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cerc-501-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cetirizine-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clozapine-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/chantix-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/chantix-varenicline-and-the-blunting-of-cocaine-cues 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/chatbot-opiate-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/chestnut-bloomington-outpatient-cbop-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ci-581a-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ci-581a-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ci-581aa-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cigarette-cigarette-smoker 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/precision-biosciences-inc/projects/pdi-320-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cigarette-cigarette-smoking-related-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cigarettes-with-varying-nicotine-content-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cimetidine-or-acyclovir-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ciprofloxacin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cisplatin-squamous-cell-carcinoma-of-head-and-neck 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/citalopram-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/citicoline-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clarithromycin-drug-induced-qt-prolongation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clarithromycin-relapse-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clavulanic-acid-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clavulanic-acid-cocaine-dependence-in-remission 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clonazepam-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clonazepam-rem-sleep-behavior-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clonidine-hcl-neonatal-abstinence-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clonidine-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/clopidogrel-metabolism-of-clopidogrel 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-cocaine-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-hydrochloride-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-hydrochloride-cocaine-induced-sympathoexciation-and-vasoconstr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-iv-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-related-disorders-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cocaine-self-adminstration-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/coformulated-emtricitabine-ftc-and-tenofovir-dis-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cognitive-behavioral-intervention-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cognitive-behavioral-therapy-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cognitive-behavioral-therapy-cbt-stress-disorders-post-traumatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cognitive-behavioral-therapy-for-anxiety-plus-be-anxiety-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cognitive-behavioral-therapy-stress-disorders-post-traumatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cognitive-behavioral-therapy-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cognitive-behavioral-withdrawal-regulation-strat-tobacco-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cohort-1-tmp-301-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/combination-nrt-nicotine-patch-nicotine-lozenge-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/combination-nrt-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/combined-intervention-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/community-reinforcement-approach-cra-hiv-prevent-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/computer-based-motivational-interviewing-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/computer-delivered-brief-intervention-5as-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/computerized-cognitively-stimulating-activities-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/computerized-tasks-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/contingency-management-family-engagement-cm-fam-adolescent-substance-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/controlled-release-carvedilol-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/coreg-anxiety 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cotinine-fumarate-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/counseling-amphetamine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/counseling-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/counseling-transfer-heroin-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/craft-t-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cs-1103-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cvl-354-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cvl-354-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cyb003-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cycloserine-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cycloserine-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/cypep-1-cutaneous-warts 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-amphetamine-30mg-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-amphetamine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-amphetamine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-amphetamine-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-cycloserine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-cycloserine-dcs-cocaine-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-cycloserine-panic-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-cycloserine-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/d-cycloserine-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dabigatran-mild-cognitive-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/danhong-injection-acute-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/danhong-injection-unstable-angina-pectoris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/decoy20-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/deferiprone-oral-solution-pantothenate-kinase-associated-neurodegeneration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/delamanid-bedaquiline-opc-167832-and-sutezolid-d-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/delta-9-tetrahydrocannabinol-comt-gene-polymorphism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/delta-9-thc-low-dose-age-related-cognitive-decline 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/depot-naltrexone-opiate-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/depot-naltrexone-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/descovy-or-truvada-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/desipramine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/desipramine-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dextro-amphetamine-sulfate-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dextroamphetamine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/df-003-rosah 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/diflunisal-familial-amyloid-polyneuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dihydrexidine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/directly-administered-antiretroviral-therapy-daa-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/disulfiram-alcohol-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/disulfiram-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/disulfiram-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/divalproex-sodium-attention-deficit-and-disruptive-behavior-disord 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/divalproex-sodium-depakote-mood-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/divalproex-sodium-extended-release-250mg-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/docetaxel-prostatic-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dociparstat-sodium-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dofetilide-drug-induced-qt-prolongation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/double-blind-varenicline-vaping 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/double-trouble-in-recovery-dual-diagnosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/doxazosin-4mg-day-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/doxazosin-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/doxazosin-extended-release-methamphetamine-or-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-120mg-day-marijuana-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-30mg-day-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-capsules-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-capsules-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-marijuana-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-pregnancy-related 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dronabinol-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/drug-a-blinded-drug-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/drug-cimetidine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/drug-condition-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/drug-use-prevention-intervention-adolescent-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/drug-will-be-recommended-based-on-ihc-fish-cgh-a-previously-treated-metastatic-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/duragesic-reference-fentanyl-tds-peer-review-research 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/dynorphin-1-13-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/e-cigarette-nontherapeutic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/e-cigarettes-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ebc-129-advanced-solid-tumours 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/echo-empowering-our-community-health-outcomes-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ecig-liquid-vehicles-nicotine-exposure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/egg-based-influenza-vaccines-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/either-normal-nicotine-content-cigarettes-15-8mg-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/electroencephalography-eeg-magnetoencephalograph-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/electronic-cigarette-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/emb-001-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/emixustat-stargardt-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/empagliflozin-10-mg-oral-tablet-jardiance-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/employment-based-reinforcement-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/empowered-relief-on-demand-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/empowerment-theory-based-small-group-discussion-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ena-001-respiratory-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/engerix-b-20-mcg-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/enhanced-care-drug-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/enzalutamide-prostate-cancer-metastatic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/erythromycin-4-topical-gel-formulation-acne-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/erythromycin-4-topical-gel-formulation-inflammation-skin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/erythromycin-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/escitalopram-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/escitalopram-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/eszopiclone-marijuana-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/etc-159-with-mss-pmmr-advanced-platinum-resistant-ovaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/etc-1907206-ph-acute-lymphoblastic-leukemia-ph-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/etc-1922159-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/etr028-etr029-etr028-etr029-or-hcbt-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/evaluate-the-effects-of-environmental-enrichment-alcohol-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/everolimus-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/evolocumab-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/evolution-young-women-taking-charge-and-growing-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/evp-6124-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/experimental-1-dbs-of-bilateral-nac-6-months-of-methamphetamine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-release-buprenorphine-bxr-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-release-buprenorphine-substance-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-release-buprenorphine-xrb-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-release-naltrexone-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-release-naltrexone-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-release-naltrexone-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-release-naltrexone-xr-ntx-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/extended-treatment-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/f18-asem-3-1-4-diazabicyclo-3-2-2-nonan-4-yl-6-1-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/f2f-prescription-stimulant-misuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/family-therapy-based-on-structural-family-therap-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/favicovir-200-mg-film-tablet-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/favir-200-mg-ft-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fenfluramine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fentanyl-injection-respiratory-function-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fexofenadine-hydrochloride-without-sodium-lauryl-the-impact-of-excipients-on-drug-absorption 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fibre-mixture-health-status 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fimasartan-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/finger-2-0-multidomain-lifestyle-based-intervent-cognitive-decline 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/florbetapir-f-18-18f-av-45-postoperative-cognitive-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/flumazenil-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fluorodopa-f-18-malignant-brain-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fluoxetine-body-dysmorphic-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fluoxetine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fluoxetine-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fluoxetine-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fluoxetine-outpatient-cognitive-behavioral-thera-alcohol-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/flupenthixol-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/flupenthixol-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/fmri-substance-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/four-naloxone-nasal-spray-doses-1-every-2-5-min-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/g-202-glioblastoma-multiforme 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/g207-supratentorial-neoplasms-malignant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gabapentin-300mg-alcohol-drinking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gabapentin-benzodiazepine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gabapentin-drug-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gabapentin-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/galantamine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/galantamine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/galantamine-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gamma-hydroxybutyric-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gts-21-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gbr-12909-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gemcitabine-cisplatin-upper-tract-urothelial-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gemcitabine-treatment-refusal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gentamicin-plague 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gepirone-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/goal2quit-nrt-sampling-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gonadorelin-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gsk598809-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/guanfacine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/guanfacine-er-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/guanfacine-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/guanfacine-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/guanfacine-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/guselkumab-psoriasis-vulgaris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gw468816-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/gz17-6-02-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/h-pylori-vaccine-h-pylori-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/harvoni-fixed-dose-combination-ledipasvir-sofosb-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hcv-pwid-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/health-promotion-and-education-cigarette-smoking-related-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/healthwise-south-africa-curriculum-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/heart-rate-variability-biofeedback-tobacco-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/heart-to-haart-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hepatitis-b-vaccine-made-by-recombinant-dna-tech-hepatitis-b-vaccines 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/heroin-dependence-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/high-dose-donepezil-cocaine-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hla-b-5801-test-stevens-johnson-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hrg80-red-ginseng-gamma-cyclodextrin-drug-absorption 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hw071021-tablets-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hw201877-capsules-healthy-participants 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hws116-injection-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hydrocodone-bitartrate-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hydrocortisone-acetate-1-ointment-postoperative-sore-throat-cough-hoarseness 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hydrocortisone-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hydroxycarbamid-central-retinal-vein-occlusion-non-ischemic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hydroxychloroquine-sulfate-200-mg-plaquenil-coronavirus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/hypnotic-medication-open-label-taper-hypnotic-dependence-among-those-with-insomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ibudilast-20mg-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ibudilast-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/iiv4-and-ppv23-influenza-human 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/imiquimod-cream-50mg-g-cutaneous-lupus-erythematosus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/immune-globulin-intravenous-ivig-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/immunization-with-p-vivax-irradiated-sporozoites-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/inactive-marijuana-0-thc-marijuana-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/inactive-marijuana-0-thc-marijuana-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/incentives-for-being-tobacco-free-tobacco-prevention-and-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/individualized-caffeine-cessation-instructions-self-identified-problematic-caffeine-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/indv-2000-healthy-volunteer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/injectable-buprenorphine-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/injectable-naltrexone-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/interactive-injection-and-sexual-risk-interventi-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/interferon-beta-1a-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/intermittent-oral-naltrexone-methamphetamine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/internet-based-smoking-treatment-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/intervention-condition-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/intravenous-fentanyl-citrate-peer-review-research 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/intravenous-nicotine-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/isoniazid-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/isradipine-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/isradipine-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/itbs-to-the-left-dlpfc-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/iti-333-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ivpt-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/jdtic-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ketamine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ketamine-hydrochloride-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/kindolor-tosylate-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/knx100-healthy-volunteer-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/l-dopa-carbidopa-entacapone-lce-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/l-glutamine-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/l-tetrahydropalmatine-l-thp-cocaine-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/l-thp-l-tetrahydropalmatine-cocaine-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/laam-behavior-therapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tmc207-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/laam-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/labetalol-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lamotrigine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lamotrigine-extended-release-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lbh581-small-cell-lung-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/learning-session-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lemborexant-drug-interaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lenalidomide-cc-5013-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ymsm-behavior 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/levetiracetam-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/levodopa-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/levodopa-cyclops-parkinson 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lidocaine-hcl-postherpetic-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lidocaine-patch-heat-effect 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lifestyle-counseling-adherence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/linezolid-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/linezolid-tuberculosis-meningeal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/placebo-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/liraglutide-pen-injector-opiate-substitution-treatment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lisdexamfetamine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lithium-carbonate-frontotemporal-dementia-ftd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/live-attenuated-influenza-vaccine-laiv-influenza 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lobeline-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-granules-for-reconstitution-normal-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-hcl-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-hcl-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-hcl-renally-impaired-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-hydrochloride-normal-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-hydrochloride-normal-healthy-volunteers-will-be-treated-with-l 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-marijuana-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-opiate-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lofexidine-opioid-withdrawal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lopinavir-ritonavir-200-mg-50-mg-film-tablet-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lorazepam-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lorcaserin-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lorcaserin-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lorcaserin-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lorcaserin-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lorcaserin-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/losartan-glomerulonephritis-iga 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/low-dose-modafinil-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/low-fat-milk-group-metabolic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/low-strength-nicotine-e-liquid-electronic-cigarette-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/lx1001-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/m-cpp-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mailed-nicotine-replacement-therapy-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mango-overweight-or-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/marijuana-blunt-marijuana-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/marijuana-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/marijuana-check-ins-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/marijuana-via-vape-device-cigarette-smoking-related-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/marinol-10mg-capsule-tms-sham-neurosciences 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/matching-placebo-familial-dysautonomia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mazindol-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mcam-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mda-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mdma-mdma-ecstasy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mdma-metabolism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/medication-for-opioid-use-disorder-moud-for-opio-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/medication-for-opioid-use-disorder-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/medium-thc-marijuana-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/memantine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/memantine-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/meningococcal-acyw135-polysaccharide-conjugate-v-meningitis-meningococcal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/meningococcal-groups-a-and-c-and-haemophilus-b-c-meningitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mepolizumab-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/metformin-systemic-inflammation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/metformin-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-100-dose-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-opiate-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-opioid-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methadone-treatment-as-usual-opioid-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methamphetamine-desoxyn-methamphetamine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methamphetamine-methamphetamine-intoxication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methamphetamine-methamphetamine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methamphetamine-stimulant-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methylphenidate-carboxylesterase-1-ces1-genotype 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methylphenidate-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methylphenidate-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methylphenidate-hcl-er-tablets-1-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/methylphenidate-substance-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/metronidazole-gel-1-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/metyrapone-oxazepam-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mhealth-application-custom-cognitive-function-abnormal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mi-cbt-alcohol-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mi-cbt-alcoholic-marijuana-misuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/micronized-progesterone-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mindful-awareness-in-body-oriented-therapy-substance-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mindfulness-based-relapse-prevention-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mindfulness-oriented-recovery-enhancement-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mindfulness-training-for-smokers-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/minnelide-capsules-advanced-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/minocycline-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mirtazapine-15-mg-oral-tablet-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mirtazapine-amphetamine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mirtazapine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mirtazapine-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mitragynine-safety-and-tolerability-in-healthy-subjects 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mixed-amphetamine-salts-extended-release-mas-er-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mn-166-50-mg-first-opioid-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/modafinil-0-mg-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/modafinil-200mg-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/modafinil-and-escitalopram-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/modafinil-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/modafinil-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/modafinil-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mometasone-furoate-drug-formulation-mff-1-hypersensitivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/monitoring-and-feedback-intervention-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mood-management-phone-counseling-for-smoking-ces-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/more-and-mi-and-nrt-polysubstance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/more-opioid-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/morphine-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/morphine-sleep-deprivation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/morphine-sulfate-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/motivational-enhancement-therapy-cannabis-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/motivational-interviewing-adherence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/motivational-interviewing-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/motivational-interviewing-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/motivational-network-intervention-substance-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/moxifloxacin-ethambutol-isoniazid-pyrazinamide-r-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/moxifloxacin-m-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/moxifloxacin-tuberculosis-pulmonary-drug-sensitive 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/moxifloxacin-with-rifampin-pyrazinamide-and-etha-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/multi-media-wings-intimate-partner-violence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/multimedia-worth-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/multivitamins-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/mycophenolate-mofetil-hematopoietic-stem-cell-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/n-acetyl-cysteine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/n-acetyl-cysteine-gambling 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/n-acetylcysteine-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/n-acetylcysteine-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sipv-dtap-mmr-vaccine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/n-acetylcysteine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/n-acetylcysteine-nac-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nab-paclitaxel-metastatic-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nabilone-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nabilone-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nabilone-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nabilone-frontotemporal-dementia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nafamostat-mesilate-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nalmefene-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naloxone-drug-overdose 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naloxone-hydrochloride-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naloxone-nasal-spray-kit-drug-overdose 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naloxone-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-alcohol-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-alcohol-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-alcoholism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-and-2-butanol-healthy-adults 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-and-bupropion-sr-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-drug-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-for-extended-release-injectable-suspe-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-hydrochloride-obesity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-implant-14-4-grams-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-implant-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-implant-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/naltrexone-stable-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nap-naptumomab-estafenatox-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/narcan-40-mg-ml-nasal-spray-opioid-induced-respiratory-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/navigating-my-journey-program-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nd-003-40mg-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ndx-1017-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nefazodone-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nepicastat-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-0-mg-ml-nicotine 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-gum-and-lozenge-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-marijuana-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-nasal-spray-0-5-mg-adverse-childhood-experiences 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-nasal-spray-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-tobacco-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-tobacco-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-patch-transdermal-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-pharmaceutical-productions-inc-nicotine-pharmacokinetic-study 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-pod-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-polacrilex-bupropion-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-polacrilex-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-pouches-nicotine-pouch-self-administration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-replacement-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-replacement-cigarette-smoking-related-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-replacement-therapy-habitrol-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-replacement-therapy-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-replacement-treatment-nrt-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-saline-infusion-0-00mcg-kg-s-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-smoking-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-transdermal-system-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotine-transdermal-system-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicotrol-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicvax-conjugate-vaccine-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nicvax-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nifedipine-60-mg-extended-release-oral-tablet-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nimodipine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nitrous-oxide-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/np-g2-044-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nrs-033-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nt-301-1-mg-tolerability-of-nt-301-nasal-spray 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nut-group-metabolic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/nx210c-healthy-elderly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/omalizumab-xolair-chronic-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/omnitram-oral-tablet-diabetic-neuropathies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/omnitram-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/on-site-bundled-rapid-hiv-hcv-testing-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ond-pr002-and-mph-ir-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ondansetron-amphetamine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ondansetron-opioid-withdrawal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/one4all-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oopen-bbcc-opioid-overdose 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/open-placebo-acute-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/opiates-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/opioid-agonist-opioid-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/opioid-related-disorders-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oral-consumption-growth-acceleration 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oral-methamphetamine-hiv-1-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oral-methylphenidate-and-oral-haloperidol-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oral-micronized-progesterone-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oral-naltrexone-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oral-naltrexone-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/original-formulation-emb-001-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oros-mph-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ory-2001-low-dose-mild-to-moderate-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oshadi-icp-diabetes-mellitus-insulin-dependent-1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oshadi-oral-insulin-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/outpatient-mst-option-a-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxcarbazepine-brand-name-vs-generic-drugs-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxycodone-15-mg-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxycodone-5-mg-oral-tablet-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxycodone-and-midazolam-hypercapnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxycodone-chronic-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxycodone-in-physiologically-based-pharmacokinetic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxycodone-medication-first-prescription-drug-abuse-not-dependent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxycodone-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxygen-15-o-water-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxytocin-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/oxytocin-social-cognition 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pa-824-1000-mg-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pa-824-200mg-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pa-824-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pa-824-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/paclitaxel-dosing-according-to-smpc-carcinoma-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/panitumumab-advanced-head-and-neck-squamous-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/panobinostat-lbh589-carboplatin-and-paclitaxel-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/parenting-in-2-worlds-p2w-parenting 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/parotid-gland-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/paroxetine-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/part-1-cream-systemic-exposure-to-sunscreen-ingredients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/peer-hiv-education-program-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/peer-mentoring-intervention-for-hcv-infected-idu-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pegylated-interferon-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pemoline-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pepinemab-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/peptides-n-r-c-formulated-in-montanide-isa-720-malaria-vivax 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pergolide-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/perindopril-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/perindopril-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pf-04457845-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pf-05190457-alcoholism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pf614-solution-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pfizer-biontech-mrna-covid-19-vaccine-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pharmacist-practice-change-to-dispense-appropria-opioid-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pharmacogenomics-testing-for-clopidogrel-respons-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pharmacotherapy-for-opioid-use-disorder-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pharmacotherapy-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pharmacy-based-methadone-administration-and-disp-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/phase-1-web-based-intervention-mywebquit-with-1-social-anxiety-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/phenytoin-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pio-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pioglitazone-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/piracetam-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-adult-attention-deficit-hyperactivity-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-and-oxycodone-hypercapnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-aprepitant-nicotine-withdrawal 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-bipolar-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-capsules-pain-threshold 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-chronic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-cocaine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-cocaine-related-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-d-limonene-and-thc-pharmacodynamics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-inactive-marijuana-0-thc-marijuana-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-magnetic-resonance-imaging 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-memory 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-methamphetamine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-methamphetamine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-mouthwash-dentinal-hypersensitivity 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-pills-for-14-day-intervention-healthy-controls 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aura-biosciences/projects/au-011-eye-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-session-1-aprepitant-session-2-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ti-0010-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebo-thc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/placebos-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/policosanol-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pomaglumetad-methionil-methamphetamine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pprs-drug-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pramipexole-cocaine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/prazosin-continuous-methamphetamine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pre-quit-nicotine-lozenges-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pregabalin-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/preoperative-genotyping-ppap 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pretomanid-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pretomanid-tuberculosis-pulmonary 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pro-2000-5-gel-p-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/probiotics-hiv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/probuphine-buprenorphine-implant-opioid-dependency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/progesterone-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/progesterone-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/progesterone-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/progesterone-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/progesterone-tobacco-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/progesterone-tobacco-use-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/progesterone-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/prograf-renal-transplant-rejection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/proleukin-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbp-711-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/propranolol-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/propranolol-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/propranolol-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/propranolol-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/psilocybin-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/psilocybin-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/psilocybin-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/pvcs-montanide-isa-51-vg-vaccine-plasmodium-vivax-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/qrl-101-dose-a-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/quercetin-dietary-supplement-fanconi-anemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/quetiapine-and-placebo-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/quetiapine-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/quitadvisormd-software-algorithm-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/quitstart-mobile-application-nicotine-vaping 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/rad-001-in-combination-with-caelyx-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/radioactive-substance-amphetamine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/radiolabelled-diclofenac-tablet-a-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/radiolabelled-t4-tablet-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ramelteon-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ranolazine-drug-induced-qt-prolongation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/rdc-0313-buprenorphine-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/real-ctbs-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/recombinant-nonavalent-types-6-11-16-18-31-33-45-human-papilloma-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/recombinant-nonavalent-types-6-11-16-18-31-33-45-human-papillomavirus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/recombivax-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/recovery-by-choice-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/recovery-line-support-system-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/recovery-management-checkups-rmc-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/reduced-nicotine-content-cigarettes-tobacco-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/reference-patch-location-thigh-batch-1-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/regional-anesthesia-inguinal-hernia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/rehabilitation-therapy-as-part-of-standard-of-ca-acute-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/reinforcement-based-treatment-drug-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/repetitive-transcranial-magnetic-stimulation-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/repetitive-transcranial-magnetic-stimulation-rtm-amphetamine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/research-ends-s-ta-u001-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/reserpine-amphetamine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/reserpine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/residential-usual-aftercare 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/rimonabant-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/risperidone-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ritanserin-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/rotigotine-transdermal-system-neupro-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/routine-hiv-testing-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/rt-pcr-test-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/rti-336-methamphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/safemedwaste-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/saline-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/salmeterol-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sarcosine-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sativex-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sativex-registered-trademark-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/satraplatin-in-combo-with-vinorelbine-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sau-signs-and-symptoms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sbp-9330-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/scaling-and-root-planing-and-septilin-for-7-days-chronic-periodontitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/scheduled-gradual-reduction-varenicline-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sd-101-dermal-cream-6-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/selegiline-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/selegiline-hydrochloride-marijuana-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/selegiline-tobacco-use-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/selegiline-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/selegiline-transdermal-patch-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/selg1-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/semaglutide-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/semaglutide-extended-release-for-injectable-susp-diabetes-mellitus-type-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/semaglutide-pen-injector-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/senicapoc-mild-cognitive-impairment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/seromycin-d-cycloserine-dcs-cocaine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sertraline-alcoholism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sertraline-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sgm-101-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/short-cycle-antiretroviral-therapy-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sildenafil-50-mg-oral-tablet-erectile-dysfunction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/single-dose-of-ibuprofen-800-mg-tablet-human-gastrointestinal-physiology-data 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sl-bup-opioid-use-disorder-oud 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/smoking-research-cigarettes-with-e-cigarette-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sofosbuvir-hepatitis-c-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sofosbuvir-velpatasvir-epclusa-hepatitis-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sofosbuvir-velpatasvir-oral-tablet-epclusa-hepatitis-c-hcv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/spironolactone-alcohol-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sporozoite-challenge-model-for-plasmodium-vivax-malaria-vivax 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/spt-07a-injection-stroke-acute 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/st-2427-acute-post-operative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/st1968-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/stage-12-drug-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-brief-intervention-drug-usage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-care-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-care-intervention-sci-tobacco-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-care-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-clinical-care-first-followed-by-standar-cannabis-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/karyopharm-therapeutics/projects/selinexor-thymoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-cognitive-behavioral-treatment-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-drug-counseling-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-intervention-counseling-self-help-writt-tobacco-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-of-care-and-prep-choice-at-enrollment-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-of-care-medication-for-early-alzheimer-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-of-care-with-lofexidine-opioid-withdrawal-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standard-treatment-as-usual-tau-substance-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/standardized-research-e-cigarette-srec-smoking-cigarette 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/stimulant-or-sedative-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/stp7-mavoglurant-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/stp705-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/strengths-based-case-management-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/study-3-chronic-care-management-smoking-tobacco 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sublingual-nicotine-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/suboxone-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/suboxone-remote-observed-dosing-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sugammadex-injection-2mg-kg-anesthesia-general 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sugar-pill-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sunitinib-added-to-folfiri-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sutezolid-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/sxc-2023-cocaine-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/syn115-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tacrolimus-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tacrolimus-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/target-controlled-naloxone-infusion-central-nervous-system-sensitization 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tba-354-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tba-7371-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tbaj-587-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tbaj-876-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/telacebec-buruli-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tmc207-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/telephone-based-skills-training-intervention-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/vtv-therapeutics/projects/ttp889-coagulation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/test-drug-heroin-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/test-favipiravir-200-mg-loqular-bioequivalence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/thc-30mg-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/thc-cannabis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/thc-high-dose-cannabis-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/thc-thc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/theory-based-counseling-program-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/therapeutic-workplace-intervention-drug-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/thoracic-epidural-ropivicaine-fentanyl-pectus-excavatum 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tiagabine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tiered-titrated-vitamin-d-dosing-hiv-associated-co-morbidities 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tiotropium-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tirzepatide-cannabis-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tirzepatide-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tmc207-j-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tms-magventure-magpro-100-with-magoption-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tnx-1300-injection-cocaine-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tobacco-abstinent-contingent-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tobacco-free-snuff-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tobacco-use-cessation-tobacco-use-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tobacco-use-disorder-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tolcapone-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tolcapone-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/topiramate-cannabis-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/topiramate-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cumberland-pharmaceuticals-inc/projects/caldolor-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/topiramate-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/topiramate-cognitive-behavioral-therapy-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tramadol-opioid-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tramadol-opioid-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tramadol-substance-withdrawal-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-patch-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-patch-e-cigarette-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-patch-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-patch-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-patch-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-patch-tobacco-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-patches-tobacco-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transdermal-nicotine-replacement-therapy-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/transitional-case-management-study-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/trazodone-poor-quality-sleep 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/treatment-as-usual-tau-cocaine-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/treatment-as-usual-tau-drug-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/trin2755-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/truvada-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/trv734-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/tyrosine-amphetamine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/ub-312-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/usual-care-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vaccination-to-prevent-hepatitis-b-virus-infecti-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vaccine-pvcs-n-c-r-150-mcg-malaria-vivax 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vaccine-pvcs-n-c-r-malaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/valproate-bipolar-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vaporized-marijuana-marijuana-usage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-adaptive-protocol-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-alcohol-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-alcoholism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-drug-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-parkinson-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-tartrate-nicotine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-then-placebo-methamphetamine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-tobacco-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/varenicline-vaping 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/veliparib-small-cell-lung-cancer-sclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/venlafaxine-cocaine-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/venlafaxine-depression 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/very-low-nicotine-cigarette-tobacco-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/bdb001-tumor-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/very-low-nicotine-cigarettes-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vitamin-d-supplement-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/very-low-nicotine-content-cigarettes-nicotine-dependence-cigarettes-uncomplicated 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/very-low-nicotine-content-cigarettes-tobacco-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/very-low-nicotine-content-cigarettes-tobacco-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vicks-vapoinhaler-opiates 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/video-directly-observed-therapy-with-contingency-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/viewing-e-cigarette-ads-e-cig-use 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vigabatrin-cocaine-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/virtual-reality-based-distraction-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vivitrol-injection-and-vivitrol-placebo-injectio-amphetamine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vivitrol-naltrexone-extended-release-injectable-cocaine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vivitrol-opiate-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vivitrol-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vivitrol-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/vk4-116-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/voucher-based-reinforcement-therapy-substance-related-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/web-based-smoking-cessation-program-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/widow-spider-antivenom-arachnidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/widus-computer-delivered-indirect-brief-interven-drug-abuse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/within-subject-test-of-blinded-study-medication-low-back-pain-recurrent 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/within-subject-test-of-blinded-study-medications-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/within-subjects-mdma-drug-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/woebot-substance-use-disorder-substance-use-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/woman-focused-intervention-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/workshop-hiv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/zinc-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/x-82-age-related-macular-degeneration-amd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/xinnaoning-capsule-chronic-stable-angina-pectoris 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/xr-b-sublocadetm-opioid-use-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/xr-ntx-community-location-opioid-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/xr-ntx-opiate-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/xue-fu-zhu-yu-capsule-qi-stagnation-and-blood-stasis-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/yb-1113-poi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/yohimbine-hydrochloride-cigarette-smoking 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/zolmitriptan-intranasal-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/zolpidem-extended-release-drug-addiction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/zonisamide-nicotine-dependence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bright-minds-biosciences-inc/projects/zyban-smoking-cessation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-072-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-188-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-2009-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-2009-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-2029-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-2051-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-801-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cytomx-therapeutics/projects/cx-904-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/14c-etc-1002-hyperlipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/bempedoic-acid-180-mg-oral-tablet-healthy-lactating-women 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/bempedoic-acid-180-mg-tablet-cardiovascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/etc-1002-hyperlipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/bempedoic-acid-180mg-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/mereo-biopharma-group-plc/projects/omp-18r5-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/bempedoic-acid-ezetimibe-fdc-oral-tablet-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/bempedoic-acid-ezetimibe-fixed-dose-combination-hyperlipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/bempedoic-acid-ezetimibe-oral-tablet-cardiovascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/bempedoic-acid-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/cardiopulmonary-exercise-testing-intrauterine-growth-restriction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/etc-1002-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/etc-1002-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/etc-1002-or-placebo-mild-dyslipidemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/esperion-therapeutics/projects/etc-1002-safety-evaluation-of-escalating-doses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lb-pharmaceuticals-inc/projects/lb-102-50-mg-tablet-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lb-pharmaceuticals-inc/projects/lb-102-bipolar-i-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/lb-pharmaceuticals-inc/projects/lb-102-schizophrenia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/odyssey-therapeutics/projects/od-07656-inflammatory-bowel-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/odyssey-therapeutics/projects/od-07656-ulcerative-colitis-uc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/odyssey-therapeutics/projects/prv-002-traumatic-brain-injury-tbi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/a006-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/a006-dpi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/albuterol-armstrong-albuterol-hfa-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/albuterol-dpi-25-mcg-inh-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/albuterol-hfa-armstrong-s-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/albuterol-inhalation-powder-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/arm-t-epinephrine-inhalation-aerosol-hfa-125-mcg-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/arm-t1-primatene-mist-hfa-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/armstrong-albuterol-sulfate-inhalation-aerosol-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/e004-epinephrine-inhalation-aerosol-90-mcg-actua-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/e004-epinephrine-inhalation-aerosol-hfa-mdi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/epinephrine-0-125-mg-inhalation-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/epinephrine-hfa-mdi-e004-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/epinephrine-inhalation-aerosol-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/epinephrine-inhalation-aerosol-hfa-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/hyaluronidase-allergic-skin-reaction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/amphastar-pharmaceuticals/projects/i004-pharmacokinetics 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aura-biosciences/projects/au-011-non-muscle-invasive-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aura-biosciences/projects/au-011-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aura-biosciences/projects/light-activated-au-011-uveal-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ars-pharmaceuticals/projects/ars-1-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ars-pharmaceuticals/projects/ars-1-urticaria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ars-pharmaceuticals/projects/ars-1-with-urti-upper-respiratory-tract-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ars-pharmaceuticals/projects/ixchiq-chikungunya-virus-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ars-pharmaceuticals/projects/neffy-allergic-reactions 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ars-pharmaceuticals/projects/placebo-urticaria-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ars-pharmaceuticals/projects/spect-123-i-fp-cit-datscan-and-123i-adam-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relmada-therapeutics-inc/projects/ndv-01-sustained-release-gemcitabine-docetaxel-bladder-urothelial-transitional-cell-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relmada-therapeutics-inc/projects/ndv-01-sustained-release-gemcitabine-docetaxel-bladder-urothelial-transitional-cell-cancer-supe 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relmada-therapeutics-inc/projects/ndv01-intravesical-controlled-release-formulatio-non-muscle-invasive-bladder-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relmada-therapeutics-inc/projects/rel-1017-depressive-disorder-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relmada-therapeutics-inc/projects/rel-1017-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/relmada-therapeutics-inc/projects/rel-1017-neuropathic-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/acoramidis-ag10-amyloid-cardiomyopathy-transthyretin-related 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/acoramidis-ag10-amyloidosis-in-transthyretin-ttr 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/acoramidis-amyloidosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/acoramidis-transthyretin-related-attr-familial-amyloid-poly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/ag10-amyloid-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/ag10-familial-attr-cm-attrm-cm-or-fac 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/ag10-oral-tablet-amyloid-cardiomyopathy-transthyretin-related 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/ag10-transthyretin-related-attr-familial-amyloid-poly 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/alxn2060-symptomatic-transthyretin-amyloid-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbo-10203-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbo-11818-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbo-8520-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbp-398-formerly-known-as-iacs-15509-tumor-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbp-398-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbp-398-with-nivolumab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bbp-671-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bgj398-advanced-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/cellectar-biosciences/projects/nov-002-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/bgj398-infigratinib-advanced-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/encaleret-autosomal-dominant-hypocalcemia-adh 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/encaleret-autosomal-dominant-hypocalcemia-type-1-adh1 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/encaleret-post-surgical-hypoparathyroidism 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-0-016-mg-kg-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-0-128-mg-kg-day-hypochondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-0-25-mg-kg-day-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-bladder-transitional-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-hypochondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-is-provided-as-a-single-dose-of-min-achondroplasia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/infigratinib-upper-tract-urothelial-carcinomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/ptr-01-recessive-dystrophic-epidermolysis-bullosa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/bridgebio-oncology-therapeutics/projects/vt30-venous-malformation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/9vhpv-vaccine-plus-bcg-vaccine-mix-for-percutane-hpv-infection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/abiraterone-usual-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/adult-allogeneic-mesenchymal-cells-from-adipose-acute-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/alectinib-usual-alk-positive-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/allo-depleted-lymphocyte-infusion-transplant-related-hematologic-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/allogeneic-and-expanded-adipose-tissue-derived-m-sars-cov2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/amchafibrin-osteoarthritis-knee 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/anterior-lamellar-nanostructured-artificial-huma-severe-trophic-corneal-ulcers-refractory-to-conv 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/autologous-adipose-derived-mesenchymal-stem-cell-critical-limb-ischemia-cli 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/autologous-bone-marrow-mononuclear-cells-peripheral-vascular-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/autologous-mesenchymal-stem-cells-from-adipose-t-autoimmune-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/bioengineered-artificial-mesenchimal-sheet-bams-venous-ulcer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/bone-marrow-mesenchymal-stem-cells-autologous-multiple-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/bone-marrow-mononuclear-cells-chronic-myocardial-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/carfilzomib-acute-lymphoblastic-leukemia-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/cea-protein-antigen-plus-bcg-vaccine-mix-for-per-rectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/cell-infusion-intraportal-mononuclear-bone-marro-liver-transplant-rejection 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/cloxacilin-staphylococcus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/cmb305-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/combination-of-mk3475-with-metronomic-cp-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/conventional-medical-treatment-coronary-atherosclerosis-and-other-heart-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/conventional-treatment-plus-intravenous-infusion-graft-versus-host-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/covid-19-therapeutic-biologic-mix-novavax-covid-covid19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/discontinuation-antipsychotic-treatment-psychosis-nos-other 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/dt-168-fuchs-endothelial-corneal-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/dt-216-friedreich-ataxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/dt-216p2-friedreich-ataxia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/etoposide-usual-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/farxiga-dapagliflozin-onglyza-saxagliptin-metfor-type-2-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/g100-follicular-low-grade-non-hodgkin-s-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/gabapentin-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/gla-af-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/gla-se-merkel-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/hiv-therapeutic-biologic-mix-hiv-gp160-plus-bcg-hiv-infections 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/hsv-2-formulation-1-genital-herpes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/hyperbaric-bupivacaine-sufentanil-anesthesia-functional 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/hyperimmune-plasma-sars-cov-2 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/id-lv305-melanoma-currently-enrolling 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/idc-g305-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/bdb018-tumor-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-1777-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/imd-1041-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/implantation-with-an-autologous-human-palatal-mu-cleft-lip-and-palate 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/influenza-vaccine-infection-in-solid-organ-transplant-recipients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/infudopa-i-v-parkinson-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/infusion-of-autologous-mononuclear-bone-marrow-c-idiopathic-dilated-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/infusion-of-mesenchymal-stem-cells-from-adipose-faecal-incontinence 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/infusion-of-msc-discordant-immunological-response-in-hiv-infecte 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/injectable-suspension-of-allogeneic-adult-mesenc-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/intraarterial-infusion-of-autologous-bone-marrow-critical-limb-ischemia-cli 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/intracoronary-infusion-of-autologous-bone-marrow-dilated-cardiomyopathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/intravenous-administration-of-1-million-of-msc-amyotrophic-lateral-sclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/levodopa-ischaemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/low-intensity-laser-for-oral-mucositis-oral-mucositis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/lv305-synovial-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/mesenchymal-stem-cells-from-adipose-tissue-critical-limb-ischemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/msd-001-mental-health-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/novel-restraint-acute-respiratory-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/paclitaxel-releasing-pta-balloon-catheter-arteriovenous-fistula-renal-dialysis-devices-obs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/phitah-basal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/platelet-rich-plasma-coxarthrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/pre-dilation-side-branch-coronary-angiography 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/raloxifene-usual-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/rex-001-peripheral-arterial-disease-pad 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/rituximab-lupus-nephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/roflumilast-alternated-days-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/stem-cell-infusion-critical-limb-ischemia-cli 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/subcutaneous-glargine-insulin-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/switch-active-lifestyles-brought-to-you-by-media-overweight 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/design-therapeutics/projects/topotecan-usual-sclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/allo-316-advanced-metastatic-clear-cell-renal-cell-carcin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/allo-329-systemic-lupus-erythematosus-with-and-without-ne 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/allo-501-relapsed-refractory-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/allo-501a-relapsed-or-refractory-large-b-cell-lymphoma-rel 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/allo-605-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/allo-647-relapsed-refractory-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/allo-715-relapsed-refractory-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/allogene-therapeutics/projects/cemacabtagene-ansegedleucel-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/7-g-ispaghula-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/irritable-bowel-syndrome-with-constipation-ibs-c-irritable-bowel-syndrome-with-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/ispaghula-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-3300-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-3300-rectal-foam-interstitial-cystitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-3718-gastroesophageal-reflux 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-3718-gastroesophageal-reflux-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-3718-gastroesophageal-reflux-disease-gerd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-6118-healthy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-9179-diabetic-gastroparesis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/iw-9179-dyspepsia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/lesinurad-gout 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-145-micrograms-opioid-induced-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-290-micrograms-chronic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-290-micrograms-irritable-bowel-syndrome-characterized-by-consti 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-acetate-chronic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-acetate-irritable-bowel-syndrome-with-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-chronic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-chronic-idiopathic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-dose-a-irritable-bowel-syndrome-with-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-functional-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-irritable-bowel-syndrome-characterized-by-consti 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-irritable-bowel-syndrome-with-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/linaclotide-or-matching-placebo-irritable-bowel-syndrome-with-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/matching-placebo-chronic-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/md-0727-hypercholesterolemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/md-1100-acetate-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/md-1100-acetate-irritable-bowel-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/md-7246-irritable-bowel-syndrome-with-diarrhea-ibs-d 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/microgestin-healthy-volunteers 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/placebo-for-linaclotide-functional-constipation-fc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/placebo-functional-constipation-in-children-ages-6-17-ye 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/ironwood-pharmaceuticals-inc/projects/placebo-irritable-bowel-syndrome-with-constipation-ibs-c 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/bevacizumab-irinotecan-glioblastoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/cetuximab-head-and-neck-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/dactinomycin-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/docetaxel-cddp-head-and-neck-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/erlotinib-leptomeningeal-carcinomatosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/filgrastim-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/filgrastim-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/filgrastim-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/genexolpm-cisplatin-locally-advanced-head-and-neck-squamous-cell-car 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/ip-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/sgt-001-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/sgt-003-duchenne-muscular-dystrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/sgt-212-friedreich-s-ataxia-fa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/sgt-501-catecholaminergic-polymorphic-ventricular-tachyc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/solid-biosciences/projects/trofosfamide-idarubicin-etoposide-soft-tissue-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-25-seborrheic-keratosis-sk 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-common-wart 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-seborrheic-keratosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-solution-40-common-warts 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-solution-seborrheic-keratosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-topical-solution-40-dermatosis-papulosa-nigra 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-topical-solution-common-wart 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-topical-solution-seborrheic-keratosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/a-101-vehicle-seborrheic-keratosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/active-common-wart 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-045-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-1777-2-0-w-w-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-2138-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-2231-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-450-50-mg-oral-tablet-bid-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-450-cryopyrin-associated-periodic-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-450-hidradenitis-suppurativa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-450-psoriatic-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-450-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ct0594cp-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-50002-alopecia-areata 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-50002-androgenetic-alopecia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-50002-high-dose-alopecia-areata 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-50002-topical-solution-vitiligo 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-501-400mg-bid-low-dose-alopecia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-502-0-46-topical-solution-alopecia-areata 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/ati-502-atopic-dermatitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/oxymetazoline-hcl-1-0-cream-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/bdb001-eik1001-tumor-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/epcs-plus-pta-diabetic-foot 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/vehicle-alopecia-universalis-au 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/zumsemetinib-hormone-receptor-positive-her-2-negative-metasta 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/aclaris-therapeutics/projects/zunsemetinib-metastatic-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zevra-therapeutics-inc/projects/kp415-oral-capsule-adhd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zevra-therapeutics-inc/projects/serdexmethylphenidate-idiopathic-hypersomnia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zevra-therapeutics-inc/projects/sodium-phenylbutyrate-combined-d-l-2-hydroxyglutaric-aciduria 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/zevra-therapeutics-inc/projects/sodium-phenylbutyrate-medium-chain-acyl-coa-dehydrogenase-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/association-atezolizumab-bdb001-rt-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/eik1001-advanced-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/eik1001-non-small-cell-lung-cancer-squamous-or-non-squam 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/eik1001-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/eik1004-001-imp1707-001-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/eik1005-advanced-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/eikon-therapeutics/projects/imp1734-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/adv-tk-glioma-malignant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/adv-tk-malignant-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/adv-tk-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/adv-tk-valacyclovir-malignant-pleural-effusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/aglatimagene-besadenovec-borderline-resectable-pancreatic-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/aglatimagene-besadenovec-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/aglatimagene-besadenovec-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/aglatimagene-besadenovec-valacyclovir-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/aglatimagene-besadenovec-valacyclovir-prostate-cancer-patients-treated-by-radiotherapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/can-2409-malignant-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/can-2409-valacyclovir-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/candel-therapeutics/projects/rqnestin-malignant-glioma-of-brain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/0-9-sodium-chloride-kidney-disease-chronic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/14c-hsk7653-type-ii-diabetes 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/14c-tgrx-326-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/177lu-dota-eb-fapi-radionuclide-therapy-refractory-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/177lu-lu-xt117-advanced-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/18f-92-alzheimer-s-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/18f-apn-1607-alzheimer-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/18f-fapibiotin-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/18f-fdg-multiple-myeloma-and-malignant-plasma-cell-neopl 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/18f-fdg-tumor-solid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/2-cycles-induction-chemotherapy-locally-advanced-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/2-cycles-of-combined-drug-induction-therapy-ever-cervical-cancer-stage-iva 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/20-mg-sildenafil-citrate-by-mouth-pulmonary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/20mg-febuxostat-hyperuricemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/225ac-lnc1011-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/3-n-butylphthalide-multiple-system-atrophy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/37-5mg-pregabalin-75mg-pregabalin-pain-postoperative 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/3d-hypoxia-preconditioned-uc-msc-group-severe-aplastic-anemia-saa 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/6-month-course-of-antiandrogen-drugs-metastatic-hormone-sensitive-prostate-cancer-mhs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-aazta-ni-093-prostate-cancer-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-bnu-psma-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-dota-fapi-177lu-dota-fapi-177lu-dota-fapi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-dota-nota-fapi-04-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-dota-nt-20-3-pancreatic-ductal-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-dotatate-and-68ga-fapi-tumor-positron-emission-tomography 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-fap-chx-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-fapi-04-liver-fibrosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-fapi-biotin-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-g21-prostate-cancer-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-ga-sa-dabi-4-stimulator-of-interferon-gene 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-her2-affibody-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-jh04-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-jh12-malignant-neoplasm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-mgs5-medullary-thyroid-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-nodaga-sna006-solid-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-nota-mal-cys39-exendin-4-insulinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-ny104-pet-ct-clear-cell-renal-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-p3-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-pentixafor-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/68ga-psma-11-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/89zr-kn035-solid-tumor-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/99mtc-h7nd-spect-ct-imaging-performed-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/99mtc-qulic-5-p1-prostate-cancer-stage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/a-car028-acute-myeloid-leukemia-aml 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/a-continuous-intravenous-infusion-of-0-5-0-6-mg-neuromuscular-blockade 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/a-control-group-disorder-of-stomach-function-and-feeding-problem 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/a-single-dose-of-liposomal-bupivacaine-is-admini-anal-fistula 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/abatacept-s-c-abatacept 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/absorbable-and-moldable-skull-base-support-plate-sellar-tumor 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/acalabrutinib-chronic-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/accurate-prediction-artificial-intelligence-mode-prostate-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/acetazolamide-levamisole-hcc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ad-hgf-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/adebellizumab-resectable-lung-non-small-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/adebrelimab-albumin-paclitaxel-cisplatin-locally-advanced-hypopharyngeal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/adebrelimab-biliary-tract-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/adebrelimab-combined-with-irinotecan-liposomal-i-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/adebrelimab-paclitaxel-carboplatin-bevacizumab-f-platinum-sensitive-relapsed-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/adjustment-of-antiplatelet-drugs-intracranial-aneurysm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aerobic-exercise-primary-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aerosol-inhaled-amikacin-chronic-obstructive-pulmonary-disease-copd 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aerosolized-13-cis-retinoic-acid-plus-vitamin-d-post-covid-19-anosmia-loss-of-smell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/afn50-injection-autoimmune-diseases 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ak104-nab-paclitaxel-carboplatin-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ak105-and-anlotinib-cervical-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/akk-gut-bacteria-supplement-premature-ovarian-failure-pof 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ala-actinic-keratoses 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/albuterol-chronic-obstructive-pulmonary-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/alirocumab-intracranial-atherosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/all-trans-retinoic-acid-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/all-trans-retinoic-acid-in-combination-with-the-multiple-myeloma-in-relapse 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/almonertinib-egfr-positive-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/almonertinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/alprostadil-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/amberen-climacteric-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ambrisentan-pulmonary-arterial-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ametinib-combined-with-bevacizumab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/amitriptyline-hydrochloride-25mg-tablet-hunan-do-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/amlodipine-besylate-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/amlodipine-sleep-apnea-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/an69st-hemofilter-critical-ill-patients 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-and-sintilimab-injection-advanced-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-combined-with-penpulimab-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-hydrochloride-effect-of-drugs 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-hydrochloride-non-small-cell-lung 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-hydrochloride-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-hydrochloride-penpulimab-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-liposomal-doxorubicin-sarcoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-tqb2450-nab-paclitaxel-cisplatin-advanced-biliary-tract-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anlotinib-tqb2450-oxaliplatin-s-1-advanced-gastric-or-gastroesophageal-junction-g 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-bcma-car-t-cells-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd19-bcma-ucar-t-cells-rheumatoid-arthritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd19-car-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd19-car-nk-cells-antisynthetase-syndrome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd19-car-t-acute-lymphoblastic-leukemia-lymphomas 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd19-car-t-b-cell-adult-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd19-car-t-cells-or-anti-cd30-car-t-cells-o-relapsed-refractory-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd20-monoclonal-antibody-and-the-btk-inhibi-anti-cd20-monoclonal-antibody 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-cd7-car-pnk-cells-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-flt3-car-t-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-her2-car-t-cells-her2-positive-advanced-malignant-solid-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-muc1-car-pnk-cells-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-pd-1-antibody-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/anti-peristaltic-ileosigmoid-anastomosis-constipation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/antiplatelet-therapy-coronary-artery-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-advanced-esophageal-squamous-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-combined-with-shr-1210-injection-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-intrahepatic-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-malignant-ascites 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-mesylate-tablets-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-non-small-cell-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-shr-1210-camrelizumab-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-systematic-review-of-the-pcr-rate-of-apatinib-co 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apatinib-thyroid 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/apheresis-and-bridging-therapy-large-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ara-c-group-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/arm-1-standard-synchronous-group-advanced-non-small-cell-lung-cancer-nsclc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/arm-a-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/artificial-intelligence-enabled-transvaginal-ult-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/asc09-ritonavir-group-2019-ncov 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/asc22-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aspirin-100mg-d-therapy-coronary-atherosclerosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aspirin-and-clopidogrel-atrial-fibrillation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aspirin-anterior-ischemic-optic-neuropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aspirin-g6pd-deficiency 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aspirin-recurrent-pregnancy-loss 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/athena-car-t-lupus-erythematosus-systemic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/atorvastatin-20-mg-oral-tablet-atherosclerotic-cardiovascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/atorvastatin-calcium-20mg-tab-hyperlipidemias 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/atorvastatin-contrast-induced-acute-kidney-injury 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/atorvastatin-myocardial-infarction 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/atra-venetoclax-azacitidine-aml-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/aumolertinib-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/autologous-anti-bcma-chimeric-antigen-receptor-t-itp 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/autologous-cd5-car-t-cells-t-cell-acute-lymphocytic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azacitidine-aza-with-ruxolitinib-mds-mpn 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azacitidine-combined-with-venetoclax-and-atra-gr-acute-myeloid-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azacitidine-in-combination-with-venetoclax-hematologic-malignancy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azacitidine-injection-b-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azacitidine-philadelphia-chromosome 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azathioprine-myasthenia-gravis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azvudine-chronic-hepatitis-b 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/azvudine-covid-19 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/babaodan-oral-capsule-hepatocellular-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bactoblis-oral-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bao-g-thoracoabdominal-aortic-aneurysm 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/baritinib-intracerebral-hemorrhage 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/basic-treatment-major-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/basiliximab-beta-thalassemia-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/basiliximab-safety-and-efficacy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bcl-regimen-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bcma-cart-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/becotatug-vedotin-nasopharyngeal-carcinoma-npc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bedaquiline-b-pulmonary-tuberculosis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/berberine-diabetes-mellitus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/berberine-hydrochloride-hypertension 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/best-medical-management-stroke-ischemic 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-cd19-t-cell-b-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bevacizumab-biosimilar-ibi305-post-orthotopic-liver-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bevacizumab-brain-glioma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bevacizumab-combined-with-oxaliplatin-and-tas-10-advanced-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bevacizumab-lung-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bevacizumab-malignant-pleural-effusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bevacizumab-ovarian-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bevacizumab-toripalimab-gemcitabine-adjuvant-wit-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bgb-a317-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bicycle-ergometry-test-with-spiroergometry-community-acquired-pneumonia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bifidobacterium-depressive-disorder 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bind19-relapsed-b-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/biological-lv009-injection-cd19-relapse-refractory-b-all 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bivalirudin-st-segment-elevation-myocardial-infarction-stemi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/blinatumomab-acute-b-cell-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/blinatumomab-and-auto-hsct-sandwich-strategy-b-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/blinatumomab-b-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/blinatumomab-plus-reduced-dose-chemotherapy-precursor-b-cell-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bm-mscs-kidney-transplantation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/botulinum-toxin-type-a-injection-botox-rosacea 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/botulinum-toxin-type-a-intradermal-submucosal-in-trigeminal-neuralgia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/breast-mri-interpretation-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/breztri-aerosphere-lung-cancer-nonsmall-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/brl-101-sickle-cell-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bronchial-basal-cells-chronic-respiratory-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/budesonide-200-microgram-puff-hfa-mdi-asthma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/budesonide-formoterol-copd-exacerbation 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/bupivacaine-hydrochloride-pulmonary-nodule 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/buspirone-anxiety-disorders 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/busulfan-bu-primary-central-nervous-system-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/busulfan-thalassemia-major 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/butylphthalide-focal-epilepsy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/butylphthalide-nbp-acute-ischemic-stroke 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/c225-cetuximab-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cadonilimab-immunotherapy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cadonilimab-locally-advanced-esophageal-squamous-cell-carcin 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cadonilimab-lung-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cadonilimab-recurrent-or-metastatic-esophageal-squamous-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cadonilizumab-combined-with-neoadjuvant-radioche-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/calcitriol-glomerulonephritis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-esophageal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-gastric-cancer-stage-iii 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-locally-advanced-or-metastatic-gastric-adenocarc 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-lung-cancer-nonsmall-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-lung-neoplasms 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-melanoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/camrelizumab-with-vinorelbine-and-cisplatin-her2-negative-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/canagliflozin-type-2-diabetes-mellitus-with-complication 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cangpo-liujun-prescription-cancer-related-fatigue 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/capecitabine-aibin-stage-iii-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/capecitabine-biliary-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/capecitabine-monotherapy-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/capecitabine-oxaliplatin-irinotecan-combination-unresectable-metastatic-colorectal-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-bcma-t-cells-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-bcma-t-cells-refractory-or-relapsed-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-t-cell-infusion-hematolymphoid-malignancies 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-t-cell-therapy-acute-lymphoblastic-leukemia-with-failed-remissi 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-t-cells-infusion-chimeric-antigen-receptor-t-relapsed-refractory-plasma-cell-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-t-cells-lung-neoplasm-malignant 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-t-leukemia-lymphocytic-chronic-b-cell 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/car-t-treatment-multiple-myeloma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cardonilizumab-combined-with-renvastinib-resectable-clear-cell-carcinoma-of-the-kidney 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/carrelizumab-cholangiocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/carrelizumab-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cartmeso-cart19-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cbg131-car-t-cell-infusion-advanced-gastric-and-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ccta-ct-mpi-dsa-ffr-coronary-microvascular-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cd19-and-bcma-targeted-allogeneic-car-t-cells-refractory-immune-mediated-platelet-transfusion 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cd19-bcma-targeted-universal-chimeric-antigen-re-refractory-idiopathic-membranous-nephropathy 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cd19-car-t-cells-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cd19-car-t-cells-and-cd19-positive-feeder-t-cell-acute-lymphoblastic-leukemia-in-remission 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cd19-car-t-cells-infusion-non-hodgkin-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cefotiam-gastric-varices 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/celecoxib-low-back-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cfnb-group-postoperative-pain 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chemoembolization-and-response-dependent-resecti-resectable-hepatocellular-carcinoma-beyond-milan 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chemotherapy-acute-lymphoblastic-leukemia 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chemotherapy-drug-hepatocellular-carcinoma-adult 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chemotherapy-endometrial-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chi-gvm-relapsed-refractory-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chidamide-camrelizumab-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chidamide-combined-with-duvillisib-peripheral-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chidamide-combined-with-nkg2d-car-nk-cell-therap-hiv-human-immunodeficiency-virus 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chidamide-fulvestrant-hormone-receptor-positive-advanced-breast-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chidamide-neuroendocrine-tumors 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chimeric-antigen-receptor-t-cell-pancreatic-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chinese-herbal-compound-ointment-atrophic-vaginitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/chinese-herbal-medicine-acute-on-chronic-liver-failure 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cholecalciferol-peritoneal-dialysis-associated-peritonitis 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cik-lung-adenocarcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cilostazol-cerebral-small-vessel-disease 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cinobufacini-injection-liver-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ciprofol-ecmo-treatment 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/ciprofol-postoperative-delirium-pod 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/circulate-free-methylated-ebv-dna-extranodal-natural-killer-t-cell-lymphoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cisplatin-and-5-fu-combined-with-nimotuzumab-stage-iv-nasopharyngeal-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cisplatin-capecitabine-sintilimab-esophageal-squamous-cell-carcinoma 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/cisplatin-oxaliplatin-tegafur-gastric-cancer 2026-05-23 monthly 0.6 https://novapharmanews.com/companies/first-tracks-biotherapeutics/projects/clamp-crushing-technique-hepatobiliary-disease 2026-05-23 monthly 0.6